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Abbreviations
APC  Antigen-presenting cells
cccDNA  Covalently closed circular DNA
DC  Dendritic cells
GM-CSF	 	 Granulocyte	macrophage	colony-stimulating	factor
GZMB	 	 Granzyme	B
HBcAg  Hepatitis B core antigen
HBeAg  Hepatitis B early or pre-core antigen
HBpAg  Hepatitis B polymerase
HBsAg  Hepatitis B surface or envelope antigen
HBV	 	 Hepatitis	B	virus
HBxAg  Hepatitis B x antigen
HCC  Hepatocellular carcinoma
HCV	 	 Hepatitis	C	virus
HSPG  Heparan sulfate proteoglycan
IFN	 	 Interferon
IFNλR1  Interferon-λ receptor 1
IFNAR	 	 Interferon-α/β receptor
IL(-6)	 	 Interleukin(-6)
IMPDH  Inosine-5′-monophosphate dehydrogenase
ISG  Interferon-stimulated gene
ISGF3	 	 IFN-stimulated	gene	factor	3
ISRE	 	 IFN-stimulated	response	elements
KC  Kupffer cells
LBP  LPS-binding protein
LCMV	 	 Lymphocytic	choriomeningitis	virus
LDL  Low-density lipoprotein
LPS  Lipopolysaccharide
MCMV	 	 Murine	cytomegalovirus
mDC  Myeloid DC
MFI	 	 Mean	fluorescence	intensity
MHC  Major histocompatibility complex
MHV	 	 Mouse	hepatitis	virus
MoMΦ  Monocyte-derived macrophages
NA	 	 Nucleos(t)ide	analogues
NK cells  Natural killer cells
NLR  NOD-like receptors
NPC  Non-parenchymal cells
NTCP	 	 Na+-taurocholate cotransporting polypeptide
ORF	 	 Open-reading	frame
PBMC  Peripheral blood mononuclear cells
pDC  Plasmacytoid DC
Peginterferon Pegylated interferon
pgRNA  Pregenome RNA
pHBsAg	 	 HBV	patient’s	plasma-derived	HBsAg
PKR  Protein kinase R
PRR  Pattern recognition receptor
rHBsAg  Recombinant HBsAg
RLR  RIG-like receptor
ROS  Reactive oxygen species
sCD14  Soluble CD14
SR  Scavenger receptor
SVR	 	 Sustained	viral	response
TH1/2/17	 	 T	helper	cell	type	1,	2	or	17
TLR	 	 Toll-like	receptor
TNF	 	 Tumor	necrosis	factor
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Antigen-presenting cells and interferons
Antigen-presenting cells in antiviral immunity
When	the	body	is	exposed	to	a	virus	the	innate	immune	system	forms	the	so-called	
first	 line	 of	 defense	 against	 invading	 pathogens.	 Innate	 immunity	 encompasses	
physical and chemical barriers like epithelial surfaces; blood proteins like the 
complement	 system;	 and	 immune	 cells	 including	 natural	 killer	 (NK)	 cells,	 and	
phagocytes	like	monocytes,	macrophages	and	dendritic	cells	(DC)	[1].	Monocytes,	
macrophages	and	DC	(Figure	1)	sample	their	environments,	binding	and	taking	up	
viral pathogens to be destroyed or further processed, thereby limiting the spread 
of	the	pathogen.	Furthermore,	these	cells	are	able	to	recognize	viral	pathogens	by	
means	of	their	pattern	recognition	receptors,	like	Toll-like	receptors	(TLR)	and	c-type	
lectins.	Virus	 recognition	will	 lead	 to	 the	activation	of	phagocytes	 that	will	 induce	
them to produce chemokines and cytokines, small proteins that not only attract and 
activate other immune cells, but also have direct antiviral capacities like interferon 
alpha	(IFNα),	interleukin	(IL)-6,	and	TNF.	Other	immune	cells	will,	upon	activation,	
also	 secrete	 cytokines	 like	 IFNγ,	 reciprocally	 further	 activating	 innate	 cells	 [2,	 3].	
Additionally, monocytes, macrophages and DC are professional antigen-presenting 
cells	(APC).	Professional	APC	are	capable	of	presenting	pathogen-derived	antigens	
to	T	cells.	DC	have	the	unique	property	to	take	up	antigen	from	the	periphery,	migrate	
to	a	local	lymph	node	and	prime	naïve	T	cells	into	T	effector	cells	via	an	interaction	
between	 the	T-cell	 receptors	and	DC-expressed	MHC	molecules	 (1st	 signal),	 via	
co-stimulatory	signals	(2nd	signal)	and	via	cytokines	(3rd	signal).	DC	and	other	APC	
can	induce	further	T	effector	cell,	but	also	B	cell,	activation	and	differentiation	at	the	
site	of	inflammation,	ultimately	leading	to	the	induction	of	virus-specific	T	and	B	cell	
responses	[1].
Dendritic cells
Among	professional	APC,	particularly	efficient	antigen-presenting	cells	are	DC	–	cells	
that are investigated in chapter 3. As mentioned above, in contrast to macrophages 
they	are	able	to	migrate	from	the	periphery	to	lymph	nodes	to	activate	naive	T	cells.	
In peripheral blood, within the HLA-DR+ lineage-negative fraction, human DC can be 
divided	into	three	main	subsets:	plasmacytoid	DC	(pDC)	and	two	types	of	myeloid	
DC	(mDC);	BDCA-1/CD1c+ and BDCA-3/CD141+ mDC. BDCA-3+ mDC only make 
up 5-10% of the total peripheral blood DC population, while the remainder is divided 
into	equal	parts	pDC	and	BDCA-1+	mDC.	While	both	mDC	subsets	highly	express	
CD11c,	pDC	are	defined	by	 the	expression	of	CD123,	BDCA-2	and	BDCA-4	and	
expression	of	CD11c	is	low	or	even	absent	[4,	5].	mDC	are	especially	well	known	for	
their	efficient	induction	of	T-cell	proliferation	in	general,	and	IL-12-induced	antiviral	
TH1	responses	in	particular	[6,	7].	Furthermore,	BDCA-3	mDC	are	able	to	produce	
IFNλ	and	are	especially	well-known	for	their	cross-presenting	capacity	[6,	8,	9].	pDC,	
on	 the	other	hand,	are	best	known	 for	 their	high	 level	 type	 I	 IFN	production,	and	
to	a	lesser	extent	for	their	type	III	IFN	production,	in	response	to	TLR7	and	TLR9	
triggering,	while	 their	T-cell-inductive	capacities	are	poor	 [10-12].	Single-stranded	
RNA	and	CpG	motifs	found	in	DNA	that	trigger	TLR7	and	TLR9,	respectively,	are	
commonly	 found	 in	 viruses	 or	 bacteria.	 The	 induction	 of	 IFNα, but also of other 
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Figure 1. The role of APC in antiviral immunity during virus infection. Exposure of APC to a virus 
will lead to direct activation of APC that, together with infected hepatocytes, release cytokines and 
chemokines,	which	are	responsible	for	the	attraction	of	other	leukocytes.	Activation	of	infiltrating	immune	
cells	 leads	to	 further	production	of	cytokines	that	 indirectly	activate	APC.	The	secreted	cytokines	may	
inhibit viral replication. Additionally, activated KC, NK cells and CD8+	T	cells	are	able	to	induce	apoptosis	
of	infected	hepatocytes.	Activated	B	cells	produce	virus-specific	neutralizing	antibodies.	*	HBsAg	induces	
IL-23 in vitro in monocyte-derived DC and monocyte-derived macrophages; possibly in vivo in liver 
macrophages and DC.
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cytokines	like	TNF	and	IL-6,	has	strong	direct	antiviral	effects	in	addition	to	affecting	
surrounding	 immune	 and	 non-immune	 cells	 [13].	 By	 presenting	 antigens	 and	
producing	pro-inflammatory	cytokines	but	also	IL-10,	DC	play	a	central	role	bridging	
the innate and adaptive immunity, thereby not only initiating but also regulating the 
adaptive	immune	response	in	a	quantitative	and	qualitative	way	[14-17].
Monocytes
Human blood monocytes are far more abundant than blood DC, representing about 
10%	of	total	peripheral	blood	mononuclear	cells	(PBMC),	and	like	DC	they	can	be	
subdivided	into	different	subsets	based	on	phenotype	and	cytokine	production.	The	
main subset in peripheral blood is CD14hi CD16- monocytes, making up 80-90% 
of	blood	monocytes.	These	often	called	“classical	monocytes”	further	express	high	
levels	of	CCR2,	low	levels	of	CX3CR1,	and	rather	produce	IL-10	than	TNF	and	IL-1	
upon LPS triggering. A second subset is made up of CD16+ monocytes, that can be 
further subdivided into a CD14hi CD16+ subset and a CD14dim CD16+ subset, that 
represent	the	main	producers	of	inflammatory	cytokines	like	TNF	[18,	19].
The	traditional	view	that	monocytes	are	simply	precursors	of	macrophages	and	DC	
has slowly been extended by the observation that also monocytes themselves can 
play	 an	 important	 role	 as	 an	 innate	 immune	 cell	 in	 the	 first-line	 defense	 against	
pathogens,	driving	inflammation	complementary	to	DC	[20].	However,	despite	being	
called a professional APC, expressing high levels of MHC class II and being able to 
retain and present antigen-derived peptides, monocytes are poor antigen presenters 
[18,	21].	Alternative	 functions	 like	cytokine	production	may	however	contribute	 to	
supporting antiviral immunity.
Macrophages
Macrophages	can	roughly	be	divided	into	two	types:	tissue-resident	and	infiltrating	
macrophages.	Tissue	resident	macrophages	are,	as	opposed	to	DC	and	monocytes,	
long-lived non-migratory cells that are specialized in taking up and processing dead 
cells	and	debris.	They	possess	high	proteolytic	activity	and	are	often	poor	antigen	
presenters.	They	play	an	essential	role	in	maintaining	tissue	homeostasis	by	clearing	
cell	debris	and	promote	resolution	of	inflammation	and	wound	healing	[22].	However,	
tissue	resident	macrophages	can	also	promote	antiviral	immunity	and	inflammation	
by	the	production	of	chemokines	like	CCL2,	CXCL1	and	MIF,	and	cytokines	like	IL-6	
and	TNF,	attracting	and	activating	other	immune	cells,	as	discussed	for	Kupffer	cells	
(KC)	–	the	macrophages	of	the	liver	–	in	chapter	2	[13].
The	second	type	of	macrophages,	the	infiltrating	macrophages,	derive	from	monocytes	
that	are	recruited	to	tissues	in	inflammatory	conditions.	In	the	human	setting,	there	
is	still	no	marker	to	distinguish	infiltrating	macrophages	from	resident	macrophages	
which	 makes	 it	 hard	 to	 study	 subpopulations.	 Infiltrating	 macrophages	 can	 be	
divided into three main populations, with a spectrum of macrophage subpopulations 
in	between,	based	on	function,	displaying	either	a	pro-inflammatory	profile	(originally	
coined	“classically	activated”	or	“M1”	macrophages),	a	regulatory	profile,	or	a	wound-
healing	profile	 (both	originally	 grouped	under	 the	 term	 “alternatively	 activated”	 or	
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“M2”	macrophages)	depending	on	the	tissue	context	and	environmental	stimuli	[23,	
24].	In	this	respect,	the	monocyte-derived	macrophages	that	were	used	in	chapter	
4 demonstrate an M1-like activity, while the monocyte-derived macrophages from 
chapter 6 show an M2-like activity.
Interferons
Key	molecules	in	the	induction/regulation	of	an	antiviral	response	are	the	IFN.	They	
not	only	have	direct	antiviral	effect,	 inducing	 IFN	response	genes	 in	 infected	and	
non-infected cells, but also execute their antiviral functions indirectly by modulating 
immune	cells	[25].	IFN	are	subdivided	into	three	groups:	type	I	IFN,	the	largest	group	
encompassing	IFNα,	IFNβ	and	other	less-defined	members;	type	II	IFN	with	only	a	
single	member,	IFNγ;	and	type	III	IFN,	comprising	IFNλ1	(IL-29),	IFNλ2	(IL-28A)	and	
IFNλ3	(IL-28B)	[2,	25,	26].	Although	IFNγ is an important cytokine, and we show its 
production	in	several	experiments	in	the	various	chapters,	our	focus	is	on	IFNα and 
IFNλ in chapters 3 and 4, respectively.
Of	type	I	IFN,	IFNα	and	IFNβ are induced in response to viral infection. Almost all 
nucleated	 cells	 respond	 to	 viral	 infection	 by	 producing	 type	 I	 IFN,	 but	 especially	
pDC	are	very	potent	type	I	IFN	producers	[27].	There	are	14	subtypes	of	IFNα, and 
although	exact	expression	profiles	and	specific	roles	for	 IFN	subtypes	need	to	be	
elucidated	it	seems	that	IFN	types	are	expressed	in	a	cell-	and	ligand-specific	fashion	
and	have	effects	that	are	functionally	specialized	and	subtly	unique	[28-30].	All	type	
I	 IFN	bind	 to	 the	 same	 receptor	 known	as	 the	 IFNAR,	a	heterodimer	 of	 IFNAR1	
and	 IFNAR2;	a	 receptor	ubiquitously	expressed.	Binding	of	 the	 receptor	 leads	 to	
JAK1/TYK1-regulated	phosphorylation	of	IFNAR1,	STAT1	and	STAT2,	which	leads	
to	 dimerization	 of	STAT1	and	STAT2.	Consecutive	 transport	 of	 this	 dimer	 to	 the	
nucleus	enables	association	with	 IRF9,	 forming	 the	 IFN-stimulated	gene	 factor	 3	
(ISGF3)	 complex.	 This	 heterotrimer	 binds	 to	 IFN-stimulated	 response	 elements	
(ISRE),	 present	 in	 the	 promotor	 regions	 of	 most	 ISG,	 to	 induce	 transcription	 of	
hundreds	of	ISG	[31]	for	which	the	function	in	antiviral	immunity	often	remains	to	be	
elucidated.	Some	well-known	ISG	that	have	antiviral	effects	are	2’,5’-oligoadenylate	
synthetase	(OAS)	that	modifies	and	degrades	viral	RNA;	protein	kinase	R	(PKR)	that	
limits	 cellular	 translation;	myxovirus	 resistance	 (Mx),	 a	 guanosine	 triphosphatase	
that	alters	cellular	vesicle	trafficking.	Ultimately,	type	I	IFN	have	been	shown	to	be	
able	 to	 inhibit	 replication	of	various	viruses,	 including	HBV	[32].	Besides	 inducing	
ISG	with	direct	antiviral	effect,	IFNα also has indirect antiviral effects like stimulating 
the proliferation and accumulation of NK cells and modulating the activation of CD8+ 
T	cells	leading	to	increased	IFNγ	[25,	32].
Type	III	IFN,	like	type	I	IFN,	are	induced	following	viral	infection.	Both	non-immune	
cells	 among	 which	 are	 hepatocytes	 and	 immune	 cells	 can	 produce	 type	 III	 IFN	
[9,	12,	33,	34].	Especially	pDC	and	BDCA-3+	mDC	are	potent	 IFNλ	producers	 [9,	
12].	All	 three	 IFNλ	members	bind	 to	 the	 IFNλ receptor, a heterodimer of IL-10R2 
and	IFNλR1.	 In	contrast	 to	 IFNAR	expression,	 the	 IFNλ receptor displays a more 
restricted	expression,	mostly	caused	by	the	limited	expression	pattern	of	the	IFNλR1 
subunit.	Despite	this	difference	in	receptors,	and	although	IFNλ shows little homology 
with	IFNα,	binding	of	IFNλ to its receptor induces a signalling similar to that induced 
by	IFNα/β	binding	to	its	receptor,	involving	JAK1/TYK1,	STAT1,	STAT2	and	IRF9,	
the	latter	three	again	forming	ISGF3.	Consequently,	type	III	IFN	signalling	induces	a	
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gene	expression	profile	in	human	liver	cell	lines	and	other	cell	lines	nearly	identical	
to	that	induced	by	type	I	IFN	[35].	Additionally,	IFNλ is able to inhibit a wide variety 
of	viruses	including	HBV	in	murine	liver	cell	lines,	most	likely	caused	by	the	same	
antiviral	mechanism	utilized	by	type	I	IFN	[35,	36].
However	important	the	role	of	IFN	may	be	in	antiviral	immunity,	in	contrast	to	HCV	
and	other	viruses,	HBV	does	not	seem	to	induce	any	ISG	in	the	livers	of	chimpanzees	
during	the	early	stages	of	infection	[37],	nor	in vitro in primary human hepatocytes 
[38].	And	although	it	is	difficult	to	assess	such	early	events	in	acute	HBV	infection	
in	humans	it	was	recently	shown	that	type	I	IFN	responses	are	also	absent	in	acute	
HBV	patients	[39].	Since	the	IFN	response	induced	by	IFNλ largely overlaps with that 
induced	by	IFNα/β,	it	seems	unlikely	that	IFNα/β	or	IFNλ play a big role in antiviral 
immunity	in	HBV	infection.	However,	since	IFN	are	able	to	inhibit	HBV	infection,	their	
use	as	antiviral	agents	 in	HBV	 therapy	provides	 them	a	 role	 in	antiviral	 immunity	
against	HBV	after	all.
Hepatitis B virus
Hepatitis	 B	 virus	 (HBV)	 is	 a	 hepatotropic	 virus	 causing	 both	 acute	 and	 chronic	
disease. Although the majority of infected adults spontaneously clear the virus, a 
small part of patients is unable to do so, developing a chronic form of hepatitis. 
Currently	over	240	million	people	are	chronically	infected	by	HBV,	which	can	lead	
to	 progressive	 liver	 damage	 that	 increases	 the	 patient’s	 risk	 of	 developing	 liver	
cirrhosis,	liver	failure	and	liver	cancer.	These	consequences	of	HBV	infection	pose	
a serious global health problem, culminating in the death of about 600,000 people 
every	year	[40,	41].
HBV course
HBV	is	transmitted	via	perinatal,	percutaneous	and	sexual	exposure	[42].	Infection	
will lead to an initial acute hepatitis during which symptomatic patients are presented 
with jaundice, dark urine, extreme fatigue, nausea, vomiting and/or abdominal pain, 
but	in	most	patients	the	infection	is	asymptomatic	[41,	43,	44],	especially	in	children	
[45].	After	the	initial	phase,	the	risk	of	developing	chronic	HBV	infection	depends	on	
age, infection route and dose, ranging from 90% in neonates to less than 10% in 
adults.	Accordingly,	most	adults	spontaneously	clear	the	virus,	and	therewith	acquire	
lifelong	protective	immunity	[40].	If	spontaneous	clearance	does	not	take	place	and	
chronic infection ensues, uncontrolled infection may lead to chronic hepatitis, liver 
fibrosis	and	cirrhosis,	which	may	result	in	hepatic	failure,	hepatocellular	carcinoma	
(HCC)	and	ultimately	death	[40].	
Clearance	 of	 the	 infection	 is	 likely	 due	 to	 the	 combination	 of	 an	 efficient	 innate	
immune	 response	 and	 a	 strong,	 sustained,	 and	 multi-specific	 T	 cell-mediated	
immune	response	[2,	46].	Indeed,	in	order	to	control	HBV,	sustained,	vigorous	and	
multi-epitope-specific	CD4+, CD8+	T	cell	responses	are	essential	[46],	and	following	
clearance	of	the	virus	in	the	acute	phase,	long-term	memory	T	cell	responses	are	
detected	[47,	48].	Also	B	cell	antibody	production	is	important,	neutralizing	free	viral	
particles	and	preventing	(re)infection	[49].	Moreover,	in	chronic	HBV,	virus-specific	
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T	and	B	cell	 responses	are	weak,	 transient	and	 targeting	only	 few	epitopes	 [46].	
It is generally believed that this weak adaptive immunity results, in part, from an 
ineffective	hepatic	innate	immune	response	in	which	APC	play	a	prominent	role	[2,	
13,	17,	46].
HBV virology
HBV,	member	of	the	family	Hepadnaviridae,	is	a	DNA	virus	containing	a	genome	of	
3.2	kb	partially	double-stranded	DNA.	Its	four	open	reading	frames	encode	for	the	five	
HBV	proteins:	polymerase	(HBpAg),	envelope	or	surface	(HBsAg),	core	(HBcAg),	
early	or	pre-core	(HBeAg),	and	X	(HBxAg)	protein.	In	infected	cells,	core	particles,	
made up of HBcAg capsids containing the genomic DNA and viral polymerase, are 
transported into the nucleus where the genomic DNA forms covalently closed circular 
DNA	(cccDNA).	This	cccDNA	serves	as	a	template	for	viral	mRNA	transcription	by	
host	RNA	polymerase	 II.	Viral	RNA	subsequently	 is	 transported	 to	 the	cytoplasm	
where it is translated into viral protein, except for the 3.5 kb pre-genomic RNA, 
which	 is	 encapsulated	 by	 HBcAg	 for	 replication	 purposes.	 Viral	 polymerase	
reverse transcribes pre-genomic RNA into the negative genomic DNA strand, 
which is followed by positive DNA strand synthesis. Ultimately, genomic DNA- and 
polymerase-containing core particles bud off into the endoplasmatic reticulum to be 
enveloped	by	HBsAg,	 forming	a	complete	viral	or	Dane	particle	 (Figure	2)	 that	 is	
secreted from the cell. Besides serving as envelope, HBsAg is secreted as empty 
spheres	and	filaments.	HBV	particles,	HBsAg	and	secreted	HBeAg	can	be	detected	
in	HBV	patients’	serum,	where	HBsAg	can	outnumber	HBV	particles	(measured	as	
HBV	DNA)	>10,000	to	1	[40,	50].
Small (S)
Large (S + preS2 + preS1)
Medium (S + preS2)
Nucleocapsid
(made up of Core)
Viral DNA
Polymerase
Viral envelope
(made up of Surface)
Figure 2. Schematic representation of HBV virion. The	viral	DNA	and	 the	polymerase	are	packed	
within	the	nucleocapsid,	which	is	made	up	of	the	core	protein	(HBcAg).	Surrounding	this	capsid	is	the	
viral	envelope,	made	up	of	the	surface	protein	(HBsAg)	in	three	different	sizes	of	which	the	small	HBsAg	
is the most abundant.
Viral proteins
Of	 the	 five	 viral	 proteins,	HBeAg	and	HBsAg	are	 assessed	 in	 chapters	 5	 and	6.	
Being	a	truncated	form	of	HBcAg,	HBeAg,	after	transcription	of	the	HBV	core	gene,	
is N- and C-terminally processed and secreted as a 159 amino acids-long protein. 
The	function	of	HBeAg	remains	unclear:	it	is	not	a	structural	protein	and	dispensable	
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for viral replication. However, since HBeAg is conserved in all hepadnaviruses, it 
is	 likely	that	this	protein	has	a	yet	undefined	function	[51].	HBeAg	seems	to	have	
some	modulatory	capabilities	(Figure	3).	Pretreatment	of	hepatocytes	or	liver	non-
parenchymal	 cells,	 including	KC,	with	HBeAg	 almost	 completely	 abrogated	TLR-
induced	antiviral	activity	 like	IFNβ	production	and	ISG	induction	[52].	Accordingly,	
incubating	human	monocytes	with	HBeAg	inhibited	TLR2-induced	phosphorylation	
of	p38	MAPK,	and	subsequent	production	of	TNF	[53,	54].	In vivo,	TLR2	expression	
by	 KC	 and	 peripheral	 blood	 monocytes	 in	 HBeAg-positive	 chronic	 HBV-infected	
individuals was lower than that in HBeAg-negative patients and controls. Moreover, 
TLR2	 ligation	 induced	 less	 IL-6	 and	 TNF	 in	 those	 HBeAg-positive	 patients	 [54].	
These	alterations	may	be	related	to	the	inhibitory	effect	of	HBeAg	on	TLR2	signaling	
demonstrated in vitro.	HBeAg	also	slightly	inhibits	TLR9-mediated	cytokine	production	
by	pDC	[55].	Interestingly,	exposure	to	HBeAg	in utero	establishes	T	cell	tolerance	
to HBeAg in a murine transgenic model perhaps representing a viral strategy to 
predispose	neonates	born	to	HBV-infected	mothers	to	persistent	infection	[56].
HBsAg is a heavily glycosylated lipoprotein that is produced in three different 
sizes	all	transcribed	from	the	same	ORF.	Which	size	is	produced	upon	translation	
depends	on	the	start	codon	used.	The	small	(S)	HBsAg	is	made	up	of	the	226	amino	
acids	(aa)-long	common	S	domain,	the	middle	(M)	HBsAg	is	the	S	domain	plus	an	
additional	preS2	domain	(55	aa),	while	the	large	(L)	HBsAg	contains	also	a	preS1	
domain	(108-119	aa)	besides	S+preS2.	The	S	form	is	the	major	constituent	of	both	
the	viral	particle	envelope	and	subviral	particles.	The	M	and	L	forms	are	mostly	found	
as	parts	of	the	viral	envelope	[57-59].	Besides	its	major	function	as	viral	envelope,	
HBsAg also seems to play a part in the modulation of the immune system, although 
some	effects	seem	to	be	complementary	(Figure	3).	Like	with	HBeAg,	pretreatment	
of	 hepatocytes	 or	 liver	 non-parenchymal	 cells	 with	 HBsAg	 nearly	 nullified	 TLR-
induced	 antiviral	 activity	 [52].	 Also,	 incubating	 human	 monocytes	 with	 HBsAg	
inhibited	TLR2-	and	TLR4-induced	production	of	IL-1β,	IL-12	and	TNF,	although	this	
could	only	be	shown	for	recombinant	HBsAg,	not	patient-derived	HBsAg	[59,	60].	
HBsAg	was	also	shown	to	 inhibit	TLR4-induced	IL-12	and	IL-18	production	 in	the	
monocytic	cell	line	THP-1	[61],	while	in	pDC	TLR9-induced,	but	not	TLR7-induced,	
cytokine	production	and	co-stimulatory	molecule	expression	was	 reduced	 [55].	 In	
mDC,	maturation	was	inhibited,	but	–	in	contrast	to	other	cell	types	mentioned	above	
–	not	cytokine	production	[62].	The	inhibition	of	both	monocyte	cytokine	production	
and	 DC	 maturation	 may	 impair	 subsequent	 activation	 of	 the	 adaptive	 immunity	
and	NK	cells	and	 its	production	of	 IFNγ. However, in contrast to HBeAg, HBsAg 
as	well	as	HBV	not	only	seem	to	inhibit	 immune	cell	 function,	but	also	to	activate	
immune	cells,	possibly	initiating	the	antiviral	immune	response	to	HBV.	While	pDC	
have	 been	 shown	 not	 to	 be	 activated	 by	 HBV	 and	 its	 components	 [55],	 and	 for	
mDC this needs to be further examined, liver macrophages (CD68+)	and	a	CD11c+ 
intrahepatic	population	produce	 IL-23	during	HBV	 infection	 [63].	HBsAg	 turns	out	
to be able to induce this IL-23 production, but also IL-12 production, in monocyte-
derived	DC	[63,	64].	Furthermore,	Hösel	et al. showed that non-parenchymal cells, 
presumably	KC,	react	to	HBV	by	secreting	pro-inflammatory	cytokines	IL-1β, IL-6, 
TNF	and	CXCL8	[38].	Finally,	HBsAg	also	induced	IL-23	expression	in	monocyte-
derived	macrophages	[63],	while	monocytes	produced	TNF	and	IL-10	upon	HBsAg	
exposure	[65].
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Treatment
First-line	treatment	of	chronic	HBV	infection	comprises	two	different	types	of	drugs:	
IFNα,	mostly	 in	a	pegylated	 form	 (PEG-IFNα	 or	peginterferon),	and	nucleos(t)ide	
analogues	(NA).	The	advantages	of	IFNα	treatment	are	its	finite	duration,	the	lack	
of	induction	of	resistant	HBV	strains	[66]	and	it	was	thought	to	have	a	higher	chance	
of	reaching	HBsAg	loss	than	NA	treatment.	Furthermore,	unlike	NA,	peginterferon	
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Figure 3. Effects of HBeAg and HBsAg on monocytes and DC subsets. Depicted are the inhibitory 
effects (┴)	that	HBeAg	and	HBsAg	(in	red	boxes)	have	on	TLR	and	co-stimulatory	marker	expression,	
signaling cascade molecules expression and cytokine/chemokine production by APC. Also depicted are 
the activatory effects (↓)	that	HBsAg	(in	green	box)	has	on	cytokine	and	chemokine	(green)	expression	
by APC.
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can	lead	to	durable	off-treatment	HBeAg	seroconversions	after	a	finite	duration	of	
therapy	[66-69].	Although	no	real	head-to-head	comparisons	of	the	current	NA	and	
peginterferon have been performed, current studies show increases in HBsAg loss 
rates	similar	to	peginterferon	treatment	after	prolonged	use	of	NA	[70-72].	On	the	
downside,	the	efficacy	of	IFNα to obtain viral suppression and HBeAg seroconversion 
is merely moderate and its use is accompanied by more severe side-effects than 
NA treatment. NA treatment on the other hand offers a very potent antiviral effect, 
can	 be	 administered	 orally	 and	 is	 generally	 well-tolerated	 [66].	 A	 disadvantage	
is	 the	 indefinite	 duration.	 With	 the	 emergence	 of	 newer	 NA,	 including	 tenofovir	
and	entecavir,	 the	 risk	of	 resistance	 is	negligible	 in	 treatment-naïve	patients	 [70].	
Depending	on	the	clinical	situation,	either	a	finite	peginterferon	treatment	duration	
with sustained off-treatment responses or continuous well-tolerated and powerful 
antiviral	suppression	with	NA	can	be	chosen	 [73].	For	 the	 latter	choice,	 the	most	
potent	drugs	with	 the	optimal	 resistance	profile	should	be	used,	 i.e.	 tenofovir	and	
entecavir.	Although	several	clinical	trials	are	examining	combinations	of	IFNα with 
NA, or combinations of NA, none have up until now shown any advantage above 
monotherapy	with	either	peginterferon	or	NA	[66].	Some	 immunological	effects	of	
combination	of	IFNα and an NA, in this case ribavirin, are described in chapter 3.
Since	 treatment	 for	 chronic	 HBV	 results	 in	 complete	 viral	 clearance	 defined	 as	
HBsAg loss in only a minority of the treated patients, the search for more potent 
therapeutic options is ever ongoing. One drug that has received some attention is 
IFNλ;	a	type	of	IFN	that	we	focus	on	in	chapter	4.	Like	IFNα,	IFNλ inhibits replication 
of	HBV	 in	HBV-Met	cells,	a	differentiated	murine	hepatocyte	cell	 line	 [74].	As	 the	
receptor	for	IFNλ	is	restricted	to	certain	cells,	in	contrast	to	the	ubiquitous	expression	
of	the	receptor	for	IFNα	[75-79],	it	is	expected	that	the	effects	of	IFNλ are much more 
focused	without	a	lot	of	the	side-effects	associated	with	IFNα treatment.
Antigen-presenting cells in HBV infection
As	 described	 above	 for	 antiviral	 immunity	 in	 general,	 in	 case	 of	 HBV	 infection	
APC are key players in the initiation and regulation of antiviral immune responses, 
taking	up	viral	antigen	leading	to	virus	recognition,	production	of	pro-inflammatory	
cytokines	 and	 presentation	 of	 viral	 antigens,	 inducing	 adaptive	 immunity.	 This	
ensuing	 combined	 cellular	 and	humoral	 immunity	 ultimately	 allow	 control	 of	HBV	
infection	[13,	17]	as	depicted	in	Figure	1.
When	 immune	 control	 over	 HBV	 is	 lacking,	 both	 innate	 and	 adaptive	 immune	
responses are weak. Decreases in numbers of DC have been described in the 
peripheral	 blood	 of	 chronic	 HBV	 patients,	 inversely	 proportional	 to	 ALT	 levels	
that	 reflect	 liver	 damage	 [80,	 81].	 In	 contrast,	 increased	 numbers	 were	 shown	
intrahepatically, likely due to increased migration from the periphery to the location 
of	 infection	 [81].	Furthermore,	peripheral	monocyte	numbers	were	 reported	 to	be	
slightly	increased	in	chronic	HBV	patients,	while	also	intrahepatic	CD14+ CD16+ cells 
and CD68+	cells	 increased	 in	 frequency	correlating	with	serum	ALT	 levels	and/or	
histological	activity	 index,	which	are	both	measures	 for	 liver	 injury.	This	 indicates	
that,	like	suggested	in	chronic	HCV	and	LCMV	infection,	there	might	be	an	increase	
in	infiltrating	macrophages	and/or	a	local	expansion	of	KC	in	chronic	HBV	[82-84].	
Additionally,	 deficiencies	 in	 APC	 function	 may	 contribute	 to	 a	 weak	 innate	 and	
consequently	adaptive	immune	response	in	chronic	HBV	patients.	Functional	deficits	
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in DC or DC precursors have been reported. Minor phenotypical and functional 
alterations	 have	 been	 shown	 in	 chronic	 HBV	 patient-derived	 mDC	 compared	 to	
those	 derived	 from	 HC.	 TLR-stimulated	mDC	 of	 chronic	 HBV	 patients	 produced	
less	 TNF	 and	 IFNβ than mDC from healthy controls. However the production of 
IL-6, IL-1β,	and	 IL-12	was	similar	 [85].	Altered	cytokine	responses	possibly	affect	
the	T-cell-stimulatory	 capacity	of	mDC.	Correspondingly,	 it	was	shown	 that	mDC	
from	chronic	HBV	patients	are	less	efficient	in	inducing	T	cell	proliferation	than	mDC	
from	healthy	 controls	 [85,	 86],	 although	Tavakoli	et al.	 challenged	 these	 findings	
[87].	Also	impaired	function	of	pDC	from	chronic	HBV	patients	has	been	described.	
As	mentioned,	IFNα is a hallmark and pivotal part of the antiviral immune reaction 
to	virus	 infection,	but	HBV	was	found	not	 to	activate	IFN	production	by	pDC	[55].	
Moreover,	 the	 capacity	 of	 HBV	 patient-derived	 pDC	 to	 produce	 IFNα has been 
attenuated,	showing	less	IFNα production upon stimulation with various stimuli than 
pDC	from	healthy	controls	[80,	81,	85,	88,	89].	Together,	this	possibly	attributes	to	
the	absence	of	IFN-signaling	during	HBV	infection	[37,	39].	Correspondingly,	HBV	
and its proteins were shown to be able to cause impaired APC function in vitro	[55,	
62,	90].	Besides	being	activated	by	viral	proteins	and	HBV	virions,	monocyte	and	
KC functions can be attenuated by HBsAg, HBeAg, or hepatitis B virions leading to 
the	inhibition	of	TLR-induced	cytokine	production	[52-54,	60]	as	further	described	in	
chapter	2	of	this	thesis.	Taken	together,	there	are	indications	that	some	deficiencies	
in	APC	numbers	may	 underlie	 an	 inadequate	 antiviral	 immune	 response	 against	
HBV.	However,	questions	 like	 in	what	way	specific	 impairments	contribute	 to	 the	
problem and what the underlying mechanism is remain to be answered in order to 
identify	the	factors	involved	in	the	impaired	immune	response	towards	HBV.
Aim and outline of this thesis
This	thesis	focuses	on	specific	aspects	of	the	role	of	APC	in	chronic	HBV	infection.	
Several studies emphasize the importance of APC in the initiation and regulation of 
the antiviral immune response. Correspondingly, we hypothesize that APC play a 
pivotal	role	in	the	antiviral	immune	response	against	HBV.	However,	what	the	role	
of	each	APC	and	its	subsets	is	in	HBV	infection	remains	to	be	further	specified.	IFN	
are	used	as	antiviral	therapy	in	chronic	HBV	infection,	but	what	the	exact	effects	of	
IFN	on	APC	are	and	how	this	influences	the	role	of	APC	in	HBV	infection	remains	
elusive.	Furthermore,	APC	are	constantly	exposed	to	viral	proteins,	but	reports	on	
their interaction with APC are scarce while literature on their effects on APC seem 
contradictive	and/or	 insufficient.	Therefore,	our	aim	 is	 to	 investigate	 the	effects	of	
IFN	and	viral	proteins	on	APC	in	chronic	HBV	infection	to	further	define	the	role	of	
APC	in	HBV	infection.
In chapter 2 we describe the role that KC play and might play in chronic hepatitis B 
and	C	infections.	Subsequently,	part	I	(comprising	chapter	3	and	4)	of	the	original	
research addresses some effects of in vivo and in vitro	IFN	on	APC.	In	chapter 3 the 
effects	of	treatment	of	chronic	HBV	patients	with	IFN	monotherapy	vs	IFN/ribavirin	
combination therapy are studied on various immune parameters. In chapter 4, the 
immune	effects	of	the	novel	type	III	IFN	are	studied	in vitro by assessing its effect 
on	NK	cells	and	macrophages.	In	part	II	(chapter	5	and	6)	we	investigate	the	effect	
of viral proteins on the immune response. In chapter 5 the effects on monocytes 
of in vivo exposure to viral proteins and in vitro exposure to HBsAg are assessed 
functionally. In chapter 6	we	investigate	KC	from	chronic	HBV	patients	for	presence	
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of HBsAg and for their phenotype, and further assess the effect of HBsAg on the 
phenotype and function of KC and monocyte-derived macrophages. 
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Abstract
Globally, over 500 million people are chronically infected with the hepatitis B virus 
(HBV)	or	hepatitis	C	virus	(HCV).	These	chronic	infections	cause	liver	inflammation,	
and	may	result	in	fibrosis/cirrhosis	or	hepatocellular	carcinoma.	Albeit	that	HBV	and	
HCV	differ	in	various	aspects,	clearance,	persistence	and	immunopathology	of	either	
infection depends on the interplay between the innate and adaptive responses in the 
liver. Kupffer cells, the liver-resident macrophages, are abundantly present in the 
sinusoids	of	the	liver.	These	cells	have	been	shown	to	be	crucial	players	to	maintain	
homeostasis, but also contribute to pathology. However, it is important to note that 
especially	during	pathology,	Kupffer	cells	are	difficult	to	distinguish	from	infiltrating	
monocytes/macrophages and other myeloid cells. In this review we discuss our 
current understanding of Kupffer cells, and assess their role in the regulation of anti-
viral	immunity	and	disease	pathogenesis	during	HBV	and	HCV	infection.
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The characteristics of Kupffer cells
Kupffer	cells	(KC)	are	tissue-resident	macrophages	residing	 in	 the	 liver.	They	are	
located in the liver sinusoids, and are the largest population of innate immune cells 
in	 the	 liver	 [1-3].	Due	 to	 their	abundance	and	 localization,	KC	are	crucial	 cellular	
components of the intrahepatic innate immune system that are specialized to 
perform scavenger and phagocytic functions, thereby removing protein complexes, 
small	 particles	 and	 apoptotic	 cells	 from	blood	 [1-3].	 Together	with	 the	 sinusoidal	
endothelial	cells,	KC	are	the	first	barrier	for	pathogens	to	enter	the	liver	via	the	portal	
vein	[4].	This	is	extremely	important,	since	venous	portal	blood	is	rich	in	pathogen-
derived products, such as lipopolysaccharide, and pathogens from the gut, which 
need to be eliminated from the circulation to avoid systemic immune activation. 
The	specialized	function	of	KC	is	reflected	by	the	phenotype:	 they	were	 identified	
in the early 1970s as peroxidase-positive cells with cytoplasm containing numerous 
granules	 and	 vacuoles,	 and	 occasional	 tubular,	 vermiform	 invaginations	 [5-8].	 At	
present,	human	KC	are	identified	by	immunohistochemistry	or	flow	cytometry	using	
antibodies	directed	against	CD68,	CD14	and	CD16	[9-11].	However,	it	is	important	
to	mention	that	these	markers	are	not	unique	for	human	KC	and	macrophages	from	
other tissues, but are also expressed on monocytes, which are also considered 
a	source	of	precursor	cells	 for	KC,	and/or	dendritic	cells	 [12].	Different	 from	 their	
human	counterpart,	rat	KC	are	commonly	identified	by	antibodies	against	CD68	or	
CD163	(ED1	and	ED2,	respectively)	 [13],	and	mouse	KC	using	the	F4/80	marker	
[14].	However,	also	the	rat	and	mouse	markers	are	not	unique	for	KC,	but	are	shared	
with other leukocytes. 
The	ambiguity	 in	 the	 identification	of	KC	that	exists	under	steady	state	conditions	
is	even	more	challenging	under	pathological	conditions	 in	which	cellular	 infiltrates	
are	observed	consisting	of	inflammatory	monocytes	and/or	dendritic	cells	that	share	
certain surface markers. In rat studies, large and small KC were shown to be present 
in distinct area within the liver, i.e. in the peri-portal, and peri-venous and mid-zonal 
area,	respectively	[10,	15-19],	and	2	subpopulations	of	KC	have	been	isolated	from	
rat liver tissue: ED1+ED2- and ED1+ED2+	cells	[16,	17].	Similarly,	some	studies	have	
identified	 2	 subpopulations	 of	 mouse	 KC:	 F4/80+CD68+	 and	 F4/80+CD11b+ cells 
from	mouse	liver	tissue	[20].	It	is	likely	that	these	populations	either	illustrate	distinct	
differentiation phases rather than distinct KC subpopulations, or that they identify 
infiltrating	monocytes	 instead	of	resident	 tissue	macrophages.	 In	studies	from	our	
group,	we	defined	only	one	KC	population	in	mouse	liver	tissue	on	the	basis	of	F4/80	
and	CD11b	expression	[21].	This	was	in	line	with	a	study	in	humans	where	only	a	
single	population	of	KC	was	identified	as	CD14+, HLA-DR+, HLA-ABC+, CD86+ and 
DC-SIGN+	cells,	with	low	expression	of	CD1b,	CD40	and	CD83	[9].	It	is	preferable	to	
identify KC not solely based on the available markers, but also on their morphology 
and	phagocytic	ability	as	their	hallmark	function.	In	this	review,	KC	are	identified	as	
CD68+, CD14+ and/or CD11b+	cells	(human),	ED1+ and/ or ED2+	cells	(rat)	and	CD68+, 
F4/80+ and/ or CD11b+	cells	(mouse),	according	to	the	original	studies.	Under	steady	
state condition, the majority of tissue-resident macrophages in the mouse liver have 
a yolk sac origin and are self-maintained. Upon serious challenge, tissue resident 
KC can be replaced by precursor cells from bone marrow as well as monocytes, 
which	develop	into	tissue-resident	macrophages	[22].	Since	the	distinction	between	
tissue-resident	 KC	 and	 tissue-infiltrating	 monocyte/macrophages	 is	 difficult,	 and	
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since most studies did not discriminate between these cells with a different origin, 
we	will	use	the	term	“KC”	to	describe	both	cells.	
Studies on human KC are being performed using cells obtained from liver tissue or 
from liver graft perfusate. Liver graft perfusate is preserved in a different manner 
than liver tissue. Also, tissue-derived KC are commonly isolated using collagenase, 
a processing step not included for perfusate, which increases the amount of 
extracellular	debris	and	may	induce	phenotypic	and	functional	changes.	The	source	
of liver material as well as the method to process the samples are important to take 
into account when interpreting results on the phenotype and function of KC from the 
various studies.
Macrophages	are	specialized	in	sensing	and	responding	to	pathogens	and	equipped	
with	specific	pattern	recognition	receptors,	including	scavenger	receptors,	Toll-like	
receptors	 (TLR),	RIG-like	 receptors	 (RLR),	NOD-like	 receptors	 (NLR)	and	C-type	
lectins.	These	receptors	are	expressed	by	tissue-derived	as	well	as	in vitro-generated 
macrophages	(reviewed	in	[23]).	However,	only	few	of	them	have	been	described	
for KC and it is not clear whether the others are expressed by KC. Scavenger 
receptors and C-type lectins are important receptors mediating phagocytosis, which 
are	expressed	by	human,	rat	and	mice	KC	[24-26].	The	phagocytic	ability	of	human	
KC has been shown in relation to removal of erythrocytes, apoptotic cells and debris 
[27,	28].	In	line	with	that	notion,	we	and	others	have	shown	that	rat	and	mouse	KC	
are strongly phagocytic and possess a high level of basal reactive oxygen species 
(ROS)	production	[20,	21].	Upon	in vivo administration of dextran particles, E. coli or 
gadolinium chloride, rat and mouse KC take up these particles, produce high levels 
of	ROS,	and	demonstrate	high	lysosomal	activity	[17,	18,	20,	21].	Human	KC	were	
shown	to	express	TLR2,	TLR3	and	TLR4	[9,	29].	The	expression	of	other	TLR,	as	
well as NLR and RLR have not been described, but cannot be excluded since the 
murine	counterparts	were	 found	 to	express	 functional	TLR1-TLR9	and	RIG-I	 [25,	
30].	In	humans	and	rodents,	ligation	of	TLR	on	tissue-derived	and	in vitro-generated 
macrophages	resulted	in	cytokine	production	[31].	However,	to	date,	studies	on	the	
ability	of	KC	to	produce	cytokines	upon	TLR	ligation	resulted	in	divergent	conclusions.	
For	 instance,	we	and	others	show	that	KC	from	human	 liver	 tissue	and	perfusate	
release IL-10, IL-1β,	IL-6,	IL-12,	IL-18	and	TNF	upon	TLR2,	TLR3	and	TLR4	ligation	
ex	vivo	[9,	32,	33]	and	[Boltjes,	unpublished	data].	Similarly,	Kono	et	al	showed	that	
liver	 tissue-derived	 rat	KC	produce	superoxide,	TNF	and	 IL-6	upon	TLR4	 ligation	
ex	vivo	[17].	However,	examination	of	mouse	KC	isolated	from	liver	 tissue	by	our	
group	and	others	demonstrated	weak	induction	of	TNF	and	IL-12p40	upon	ex	vivo	
stimulation	with	agonist	 for	TLR4,	TLR7/8	or	TLR9	[20,	21],	whereas	no	data	are	
available on the cytokine-producing ability of liver perfusate-derived rat or murine 
KC.	Thus,	more	studies	using	highly	purified	KC	with	a	well-defined	phenotype	need	
to	be	conducted	to	obtain	conclusive	data	on	the	TLR	responsiveness	of	KC.	
A weak ability of KC to produce cytokines might be related to their tolerogenic function 
in	 a	 steady	 state	 condition.	 KC	 are	 frequently	 exposed	 to	 gut-derived	 antigens.	
Instead	of	exerting	 inflammatory	 responses,	human	and	murine	KC	constitutively	
express	TGFβ and PD-1, possess high levels of negative regulators downstream 
the	TLR	pathway	and	secrete	IL-10	upon	LPS	stimulation	[20,	21,	32,	34-36].	More	
importantly,	 the	ability	 of	murine	KC	 to	produce	pro-inflammatory	 cytokines	upon	
TLR4,	TLR7/8	and	TLR9	is	by	far	weaker	than	that	of	peritoneal	macrophages	[21].	
This	observation	suggests	that	KC	play	a	crucial	role	in	maintaining	liver	homeostasis	
in a steady state condition. Additionally, our mouse study and others show that 
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KC are superior in the ability 
to take up particles and have a 
higher basal ROS production, 
in comparison to splenic and 
peritoneal macrophages, which 
highlight their function to remove 
particulates from the circulation 
[21,	37].
Key Points
• Kupffer cells contribute to immune activation and anti-
viral immunity upon infection with HBV or HCV
• Both HBV and HCV are able to exploit the function of 
Kupffer cells 
• The receptors and molecular mechanisms involved in 
the interaction between Kupffer cells and HBV or HCV, 
or its components, need to be elucidated
• Kupffer cells and/or liver-infiltrating macrophages 
contribute to tissue damage and play a role in the 
regulation of fibrosis, cirrhosis, and hepatocellular 
carcinoma during chronic viral hepatitis
• The contribution of liver-resident Kupffer cells vs. 
liver-infiltrating macrophages in the regulation of viral 
immunity and disease pathogenesis is hampered by 
the lack of distinctive phenotypical markers
The role of KC during LCMV infections
Besides	their	barrier	[4]	and	janitor	function	[38,	39],	KC	have	been	shown	to	play	
a role in the response to pathogens, including viruses. Studies on the importance 
and	anti-viral	 immune	 functions	of	KC	 in	HBV	and	HCV	 infections	are	difficult	 to	
perform, since these viruses only infect and replicate in humans and non-human 
primates, and immunocompetent small animal models for viral hepatitis are not 
yet	 available	 (reviewed	 in	 [40,	 41]).	 As	 an	 alternative	 approach	 several	 mouse	
infection	 models,	 including	 lymphocytic	 choriomeningitis	 virus	 (LCMV),	 murine	
cytomegalovirus	 (MCMV),	 mouse	 hepatitis	 virus	 (MHV)	 and	 adenovirus	 models,	
have provided information on the role of KC in viral infection. However, in contrast 
to	HBV	and	HCV	where	infection	and	replication	is	restricted	to	hepatocytes,	these	
hepatitis mouse models also infect other cells and even other organs. Of these 
models,	 MHV	 and	 LCMV	 have	 been	 shown	 to	 replicate	 in	 KC	 [42,	 43].	 LCMV,	
MHV	and	adenovirus	particles	can	be	taken	up	from	the	circulation	by	murine	KC	
via	scavenger	and	complement	receptors,	which	may	limit	infection	[44-47].	It	has	
been	shown	that	failure	in	clearing	LCMV,	MHV	and	adenovirus	particles	during	the	
acute	phase	results	in	“spill-over”	infection	of	hepatocytes,	prolonged	infection	and	
exacerbated	 immunopathology	 [47-49].	 Studies	 using	 these	mouse	models	 have	
been instrumental in our understanding of the effects on KC during the early phases 
of virus infections. A number of studies have also evaluated KC during persistent 
infection	 in	mice.	 These	 studies	 are	 conducted	 using	 specific	 isolates	 of	 LCMV,	
the	clone	13	and	WE	strains.	The	development	of	persistent	 infection	with	a	high	
rate	of	replication	of	LCMV	is	similar	to	HBV	and	HCV,	and	important	mechanistic	
pathways	identified	in	LCMV	infected	mice,	were	later	confirmed	to	be	operational	
during	chronic	viral	 infections	 in	patients.	However,	 in	contrast	 to	HBV	and	HCV,	
murine	LCMV	infections	are	not	restricted	to	the	liver,	and	LCMV	replication	can	also	
be	found	in	the	spleen,	lung	and	kidney.	The	long-term	consequences	of	human	viral	
hepatitis,	such	as	fibrosis,	are	absent	in	mice,	although	virus-induced	liver	damage	
is	observed	 [44,	50].	The	effect	of	chronic	LCMV	infection	on	NK	cells	and	virus-
specific	 T	 cells	 has	 been	 extensively	 examined,	 however	 only	 few	 studies	 have	
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focussed	on	KC.	In	contrast	to	HBV	or	HCV,	active	replication	of	LCMV	in	the	liver,	
as evidenced by the detection of viral RNA and antigen, has been demonstrated 
in	 KC	 as	 well	 as	 in	 hepatocytes	 [43,	 51,	 52].	 During	 the	 first	 2	 weeks	 following	
LCMV	infection,	an	increase	of	the	number	of	F4/80+ cells is observed, followed by 
normalization	of	their	numbers	[19].	Although	differences	in	MHC	class-I	expression	
levels	 were	 observed	 within	 the	 F4/80	 population	 by	 immunohistochemistry,	 the	
relative	contribution	of	infiltrating	monocytes	versus	enhanced	activation	of	resident	
KC	is	difficult	to	determine.	
An elegant study by Lang et al. showed that chlodronate-mediated depletion of KC 
resulted	 in	 rapid	 LCMV	dissemination	 due	 to	 the	 inability	 to	 capture	 virus,	which	
led	to	replication	within	hepatocytes	and	subsequently	severe	CD8+	T	cell-mediated	
liver	damage	 [44].	The	study	 further	showed	 that	KC	 responded	 to	 type	 I	 IFN	by	
inducing	the	expression	of	interferon-stimulated	genes,	and	that	mice	lacking	IFNAR	
specifically	 on	 macrophages	 exhibited	 strongly	 enhanced	 viral	 titers.	 However,	
recently	 a	 detrimental	 influence	 of	 granulocytes	 and	 macrophages	 in	 spleen	
and	 liver	was	 reported	by	 their	ability	 to	produce	 reactive	oxygen	species	 (ROS)	
following	viral	infection,	although	ROS	production	by	liver	F4/80+	cells	was	low	[53].	
Importantly, the effect of ROS was an impairment of the immune response, and in 
the absence of ROS mice exhibited lower viral titers and less liver damage. In a 
different experimental mouse model, which makes use of transgenic intrahepatic 
expression	of	 the	HBV	large	envelope	protein,	ROS	activity	was	observed	 in	KC,	
and	 these	mice	 exhibited	 a	 chronic	 necroinflammatory	 liver	 disease,	 resembling	
human	chronic	active	hepatitis	[54].	
The	findings	from	the	LCMV	mouse	model	clearly	show	the	complexity	of	the	anti-
viral response in the liver since KC can both contribute to promote and suppress 
viral eradication and liver pathology. In the following section, we will focus on the 
interaction	of	KC	with	HBV	and	HCV,	and	the	functional	consequences.
The role of KC during HBV and HCV infections
Both	HBV	 and	HCV	 are	 transmitted	 predominantly	 via	 percutaneous	 and	 sexual	
exposure,	while	perinatal	exposure	is	often	seen	for	HBV	only	[55-57].	Infection	with	
these viruses can either resolve spontaneously or develop into chronic liver disease 
with	 continuous	 viral	 replication	 in	 hepatocytes	 [56-58].	 Chronic	 hepatitis	 poses	
an	increased	risk	for	liver	fibrosis	and	cirrhosis,	hepatic	failure,	and	hepatocellular	
carcinoma	(HCC)	[58,	59].	Patients	with	a	self-limiting	HBV	or	HCV	infection	show	
sustained,	 vigorous	 and	 multi-epitope-specific	 CD4+ or CD8+	 T	 cell	 and	 B	 cell	
responses,	whereas	 in	 chronic	HBV	and	HCV	 these	 responses	 are	weak	 and/or	
transient	[60-63].	This	demonstrates	that	clearance	of	the	infection	is	dependent	on	
strong	multi-epitope-specific	T	and	B	cell	responses,	which	is	only	possible	following	
effective	innate	immune	responses	[63,	64].	Here,	we	will	firstly	address	the	role	of	KC	
in	the	interaction	and	recognition	of	HBV	and	HCV,	and	their	role	in	the	induction	of	a	
pro-inflammatory	response.	Pro-inflammatory	mediators	are	important	for	inhibition	
of viral replication, the induction of resistance to infection of neighboring cells, and 
attraction	and	activation	of	other	immune	cells,	and	consequently	contribute	to	the	
development	of	effective	virus-specific	immunity.	Secondly,	we	will	discuss	KC-virus	
interactions that may inhibit the development of effective viral immunity, facilitate 
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viral persistence or promote liver damage. 
Interaction of KC with HBV and HCV
HBV	is	a	3.2	kb	partially	double-stranded	DNA	envelope-virus	which	replicates	via	
RNA	intermediates.	Hepatitis	B	core	protein	(HBcAg)-encapsulated	viral	DNA	and	
hepatitis	B	envelope	protein	(HBsAg)	form	a	complete	viral	or	Dane	particle.	HBV	
particles,	HBsAg,	and	hepatitis	B	early	antigen	(HBeAg;	a	truncated	form	of	HBcAg)	
are	secreted	by	infected	hepatocytes	and	can	be	detected	in	serum	of	HBV	patients	
[58,	65].
Evidence	 for	 productive	HBV	 infection	 of	 cells	 other	 than	hepatocytes	 is	 lacking.	
Also,	detailed	 information	on	 the	presence	of	HBV	(proteins)	 in	KC	 in vivo or the 
uptake	of	HBV	or	its	proteins	by	human	KC	ex	vivo	has	not	been	reported.	Although	
no	information	is	available	on	KC,	studies	using	THP-1	monocytic	cells,	monocytes	
and	dendritic	 cells	 have	 shown	binding	of	HBV	or	HBV	proteins,	 leading	 to	 their	
activation.	 For	 instance,	 TLR2	 and	 heparan	 sulfate	 proteoglycan	 (HSPG)	 were	
suggested	 to	 be	 responsible	 for	HBcAg	 recognition	 on	THP-1	 cells,	 and	HBcAg-
induced	 activation	 of	 THP-1	 cells	 resulted	 in	 production	 of	 IL-6,	 IL-12p40,	 and	
TNF	[66].	However,	since	HBcAg	is	only	found	within	infected	hepatocytes	or	viral	
particles, it is unclear whether HBcAg interacts with KC, via HSPG and/or another 
extracellular	receptor	like	TLR2.	Also,	other	receptors	expressed	by	KC	are	known	
to	interact	with	HBV	proteins	as	demonstrated	in	other	cell-systems	(Table	1).	For	
instance, HBsAg can interact with human blood monocytes in a CD14-dependent 
fashion	[67],	and	with	dendritic	cells	via	the	mannose	receptor	[68],	which	are	both	
receptors	 known	 to	 be	 also	 expressed	on	KC	 [69].	 Finally,	 complex	 formation	 of	
HBsAg with albumin may lead to enhanced uptake of HBsAg from the circulation by 
KC	and	endothelial	cells	[70].	
HCV	contains	a	9.6	kb	positive-strand	RNA	genome	that	translates	into	the	structural	
proteins, core and E1 and E2 envelope proteins, and the non-structural proteins 
NS1-NS5. After replication, they form a small-enveloped virus particle containing the 
newly	synthesized	RNA	genome	[71,	72].
Compared	 to	 HBV,	 there	 is	 a	 better	 understanding	 of	 the	 entry	 receptors	 on	
hepatocytes	used	by	HCV.	In	addition	to	claudin1,	occludin,	epidermal	growth	factor	
receptor	(EGFR)	and	ephrin	type-A	receptor-2,	HCV	infects	hepatocytes	by	attaching	
to	HSPG,	low-density	 lipoprotein	(LDL)	receptor,	scavenger	receptor	(SR)-B1	and	
CD81.	Some,	but	not	all,	receptors	are	expressed	by	KC	(Table	1)	[73-82].	It	has	
been	reported	that	incubation	of	human	liver	cells	with	HCV-E2	resulted	in	HCV-E2	
binding	to	KC	in	a	CD81-dependent	manner	[83],	but	also	DC-SIGN,	a	C-type	lectin	
not	expressed	by	hepatocytes,	has	been	demonstrated	to	bind	HCV	on	KC	[84-86].	
Although	it	 is	unlikely	that	HCV	can	replicate	in	KC,	activation	of	KC	by	HCV	and	
its	 proteins	 has	 been	 demonstrated.	 HCV	 core	 and	 NS3	 stimulate	 human	 liver	
perfusate-derived CD14+	 KC	 and	 monocyte-derived	 macrophages	 via	 TLR2	 to	
produce	pro-inflammatory	IL-1β,	IL-6,	and	TNF	and	immunosuppressive	IL-10	[84,	
87].	Recently,	it	was	shown	that	TLR4,	in	density	gradient-	and	adherence-isolated	
liver-derived	 human	 KC,	 mediates	 NS3	 recognition,	 resulting	 in	 TNF	 production	
[88].	However,	HCV	core	and	NS3	are	not	secreted	at	significant	levels	by	infected	
hepatocytes,	posing	 little	 relevance	 to	extracellular	 recognition	of	HCV	by	KC	via	
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these	 TLR.	 Alternatively,	 phagocytosis	 of	 infected	 hepatocytes	 by	KC	may	 allow	
intracellular exposure to viral RNA, but so far no evidence exists.
Stimulatory effects of HBV or HCV on KC function
There	 are	 only	 few	 publications	 that	 show	 a	 stimulatory	 effect	 of	 HBV	 or	 HBV	
proteins	on	the	function	of	KC.	Hösel	et al.	showed	that	HBV	particles	and	HBsAg	
induce IL-1β,	IL-6,	CXCL8	and	TNF	production	by	human	CD68+ cell-enriched non-
parenchymal	cells	via	NF-кB	activation	[89]	and	subsequently	inhibit	HBV	replication	
in	primary	hepatocytes.	This	inhibitory	effect	was	mainly	ascribed	to	IL-6,	but	also	
TNF	inhibited	HBV	replication	in	a	non-cytopathic	manner	[90].	In	contrast,	Li	et al. 
demonstrated that rat ED1+	adherent	KC	exposed	to	HBV	virions	hardly	expressed	
 HBV HCV 
 Mediators Reference Mediators Reference 
Binding/Uptake  
 HSPG 79 HSPG 79 
 CD14 9 SR-B1 82 
 mannose receptor 69 LDL-receptor 81 
   DC-SIGN 9, 85 
Pattern Recognition Receptors 
   TLR2 84, 87 
   TLR4 88 
Cytokines     
 IL-1β 89 IL-1β 84, 100 
 IL-6 89 TNF 84 
 TNF 89 IL-10 84 
 TGFβ 91   
Chemokines 
 CXCL8 89   
Co-stimulatory molecules 
   CD40 94 
   CD80 94 
   MHC class II 94 
Immune inhibition or promotion of tolerance 
 TGFβ 91 PD-L1 84, 137 
 PD-L2 30 IL-10 84 
 galectin-9 135 galectin-9 120 
Liver damage 
 IL-6 89 TRAIL 84 
 TRAIL 84 granzyme B 105, 106 
 FasL 106 perforin 105, 106 
 granzyme B 105   
 perforin 105   
 ROS 54   
 galectin-9 135   
 TGFβ 91   
 
Table 1: Surface molecules and secreted inflammatory mediators facilitating KC roles in HBV/HCV infection.
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IL-1β,	IL-6	or	TNF,	but	produced	the	immunoregulatory	cytokine	TGFβ	[91].	
During	chronic	HCV	infection,	KC	are	increased	in	numbers	in	the	liver	[92,	93],	and	
exhibit an activated phenotype with higher mRNA expression levels of the activation 
markers	CD163	and	CD33	 in	 livers	 of	 chronic	HCV	patients	 versus	 controls	 [94,	
95].	Recently,	it	was	reported	that	in	response	to	HCV	human	KC	release	IL-1β and 
IL-18 in vitro	[96].	In	line	with	these	findings,	stimulation	of	CD14+CD68+ cells from 
liver	perfusate	with	UV	irradiated	cell	culture-derived	HCV	induced	IL-1β production. 
To	support	this	data,	in vivo co-expression of IL-1β and CD68 was observed using 
immunofluorescence	on	liver	tissues	from	patients	with	chronic	HCV	[97].	Besides	
intrahepatic IL-1β, also elevated serum IL-1β levels were detected in patients as 
compared	to	healthy	individuals	[97].
Although	a	direct	effect	of	HCV-exposed	KC	on	HCV	replication	is	unknown,	it	was	
recently	reported	that	KC-derived	TNF	increased	the	permissivity	of	hepatoma	cells	
to	HCV.	 In	 this	study,	LPS	as	well	as	HCV	 induced	KC	 to	produce	TNF,	 thereby	
indirectly	 promoting	HCV	 infection	 [33].	On	 the	other	 hand,	HCV-	 or	TLR-ligand-
induced KC-derived cytokines, such as IL-6, IL-1β,	and	IFNβ	[84,	87,	97,	98],	were	
found	to	inhibit	HCV	replication	in	the	HCV	replicon	model	[98-100],	implying	that	KC	
are	also	capable	of	displaying	antiviral	activity	upon	HCV	exposure.
In addition, release of chemokines and cytokines by KC has an indirect effect on the 
immune	response	in	the	liver	by	recruitment	and	activation	of	infiltrating	leukocytes,	
as also discussed by Heydtmann et al.	[101].	This	may	result	in	a	complex	interaction	
between factors produced by liver parenchymal cells, liver resident immune cells 
including	KC,	and	infiltrating	leukocytes.	KC	are	able	to	activate	NK	cells	and	NKT	
cells, both present at relatively high numbers in the liver, via the production of pro-
inflammatory	cytokines	 [9].	 In	 turn,	NK	and	NKT	cells	produce	cytokines	such	as	
TNF	and	IFNγ	and	are	cytotoxic	in	nature	[9,	102].	Upon	HBV	exposure,	KC	were	
found	to	produce	CXCL8	[89],	which	potentially	attracts	NK	and	NKT	cells	during	
the	early	phase	of	HBV	infection.	KC	are	also	able	to	recruit	dendritic	cells	to	the	
liver,	which	involved	C-type	lectins	interactions	[103].	This	enhanced	dendritic	cell	
recruitment	may	initiate	and	promote	virus-specific	T	cell	responses.	In	contrast	to	
dendritic	cells,	KC	are	less	efficient	in	priming	naïve	T	cells.	Nevertheless,	mouse	
KC have been shown to present antigen to CD4+ and CD8+	T	cells,	inducing	these	
to	proliferate	and	produce	IFNγ	[104,	105].	The	relatively	high	expression	of	CD40,	
CD80 and MHC class II found on CD68+	cells	 in	chronic	HCV	patients	 [94]	might	
point towards possible antigen presentation by intrahepatic macrophages. 
Although lymphocytes such as NK cells and CD8+	T	cells	are	potent	effector	cells	
responsible to kill virus infected cells, KC have been reported to express cytotoxic 
molecules	 such	 as	 TRAIL,	 Fas-ligand,	 granzyme	 B,	 perforin	 and	 ROS,	 enabling	
them	to	lyse	infected	hepatocytes	[106-108].	However,	since	KC	act	in	an	antigen-
nonspecific	manner	and	hence	can	lyse	hepatocytes	irrespective	of	their	 infection	
state, it is tempting to speculate that KC cause more damage to the organ due to 
their cytotoxic capacity than that they provide protective immunity to the host.
In	summary,	only	limited	information	exists	on	the	direct	 interaction	between	HBV	
and	HCV	with	KC	in vivo	and	ex	vivo.	Macrophages	are	able	to	bind	HBV	or	HCV	
or virus-related proteins in vitro, triggering surface and/or intracellular receptors. 
However, receptors used for these purposes need to be further investigated. Several 
studies	indicate	that	KC	may	play	a	role	in	controlling	HBV	and	HCV	infections	by	
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inhibiting viral replication, either directly via the production of cytokines or via their 
interaction	with	other	cells,	as	well	as	in	shaping	the	inflammatory	response	towards	
the	induction	of	virus-specific	immunity.	However,	more	research	is	required	to	get	a	
better insight into the role of KC in regulating intrahepatic immunity. 
Suppressive effects of HBV and HCV on KC function
Besides the contribution of KC to viral clearance, viruses may actively interfere with 
the	pro-inflammatory	functions	of	KC	to	evade	host	immunity.	Various	studies	show	
that	HBV	and	HCV	are	able	 to	 interfere	with	TLR	pathways,	RIG-I	 signaling	and	
subsequent	pro-inflammatory	activities	of	hepatocytes	and	immune	cells	[109-113],	
but studies describing the effect on human KC are limited. Only one study described 
that	 type	I	 IFN	production	and	TRAIL	expression	by	human	perfusate-derived	KC	
were	suppressed	by	HCV	core	protein	via	disruption	of	the	TLR3/TRIF/TRK1/IRF3	
pathway	 [84].	 In	 addition,	 numerous	 studies	 on	 monocytes	 have	 demonstrated	
modulation	of	cytokine	production	by	HCV	proteins,	and	altered	TLR	responsiveness	
of	monocytes	obtained	from	chronic	HCV	patients	[114-116].	
Concerning	HBV,	pretreatment	of	non-parenchymal	cells	including	KC,	with	HBV-Met	
cell-derived supernatants, HBsAg, HBeAg or hepatitis B virions almost completely 
abrogated	TLR-induced	anti-viral	activity,	i.e.	IFNβ production, interferon-stimulated 
gene	 (ISG)	 induction,	 IRF3,	 NF-кB,	 and	 ERK1/2	 expression	 [117].	 Accordingly,	
incubating	 human	 monocytes	 with	 HBeAg	 or	 HBsAg	 inhibited	 TLR2-induced	
phosphorylation	of	p38	MAPK	and	JNK	MAPK,	and	subsequent	production	of	IL-6,	
TNF,	and	IL-12	[29,	118,	119].	In vivo,	TLR2	expression	by	KC	and	peripheral	blood	
monocytes	in	HBeAg-positive	chronic	HBV-infected	individuals	was	lower	than	that	
in	HBeAg-negative	patients	and	controls.	Moreover,	TLR2	ligation	induced	less	IL-6	
and	TNF	in	those	HBeAg-positive	patients	[29].	These	alterations	may	be	related	to	
the	inhibitory	effect	of	HBeAg	on	TLR2	signaling	demonstrated	in vitro. In addition, 
also	TLR3	expression	was	found	to	be	lower	on	PBMC	from	chronic	HBV	patients	
compared	to	control	patients	as	well	as	on	liver	cells,	including	KC	[120].	Antiviral	
therapy	of	chronic	HBV	patients	with	entecavir	or	pegylated	IFNα partially restored 
TLR3	expression,	but	it	is	unclear	whether	this	is	a	direct	viral	effect.
Tolerogenic effects of HBV and HCV related to KC
As mentioned above, KC are constantly exposed to pathogen-derived products from 
the	gut.	To	prevent	excessive	inflammation	and	pathology	of	the	liver,	continuous	
activation	 of	 KC	 is	 avoided	 as	 these	 cells	 become	 refractory	 to	 subsequent	
endotoxin	challenge,	a	phenomenon	known	as	endotoxin-tolerance	[121,	122].	This	
contributes to the well-described tolerogenic milieu in the liver. Besides modulation 
of	TLR-signaling	pathways,	also	expression	of	anti-inflammatory	mediators,	such	as	
IL-10	and	TGFβ, and other soluble and membrane-bound inhibitory molecules are 
underlying	the	intrahepatic	tolerance	[35,	105,	122,	123].	
A	 number	 of	 studies	 have	 reported	 that	 HBV	 and	 HCV	 components	 affect	 the	
production	of	immunoregulatory	cytokines,	and	consequently	promote	the	tolerogenic	
milieu	of	the	liver.	In	this	respect,	it	has	been	reported	that	HBV	particles	preferably	
induced	TGFβ	production	by	rat	KC	instead	of	pro-inflammatory	cytokines	[91].	One	
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of	the	activities	of	TGFβ is that it plays a role in maintaining tolerance towards self-
antigens	 by	 selectively	 supporting	 the	 differentiation	 of	 FoxP3+	 regulatory	T	 cells	
[124,	125].	Furthermore,	HCV	core	protein	induces	IL-10	production	by	human	KC	
[84,	87].	Elevated	intrahepatic	IL-10	levels	may	suppress	pro-inflammatory	cytokine	
production	by	intrahepatic	cells,	frustrate	KC-NK	cell	interaction	[9,	126]	and	antigen	
presentation	to	T	cells	and	their	activation	[105,	127-133].	Interestingly,	chronic	HBV	
and	HCV	patients	showed	higher	plasma	levels	of	IL-10	than	uninfected	individuals	
[134,	 135],	 which	 could	 be	 the	 result	 of	 a	 direct	 viral	 effect	 on	 KC	 and/or	 other	
cells, or the result of a negative feedback mechanism resulting from ongoing liver 
inflammation.	Recently,	the	role	of	KC	was	examined	in	an	established	HBV-carrier	
mouse model. In this model, KC as well as IL-10 were involved in the establishment 
of	antigen-specific	tolerance	towards	peripheral	HBsAg	vaccination	[136].
KC express membrane-bound inhibitory ligands that could facilitate a tolerogenic 
milieu	 in	 the	 liver.	 For	 instance,	 under	 steady	 state	 conditions,	KC	are	 known	 to	
express	PD-L1,	which	 is	 a	 ligand	 for	 PD-1	 and	 known	 to	 impede	T	 cell	 function	
by	 inhibiting	proliferation	and	 cell	 division	 [36].	 Immunohistochemical	 analyses	of	
liver biopsies from chronic viral hepatitis patients revealed that CD68+ macrophages 
expressed	increased	levels	of	PD-L2	compared	to	control	liver	tissue	[30,	123,	137].	
Similar results were reported for galectin-9 with enhanced expression by CD68+ 
cells	 by	 immunohistochemistry,	 which	 was	 confirmed	 by	 flow	 cytometry	 [137].	
Interestingly, enhanced serum levels of galectin-9 were observed in patients with 
biochemical	evidence	of	highly	active	chronic	HBV-related	liver	disease	(ALT>100	
U/L)	as	compared	 to	patients	with	 relatively	 low	ALT	 levels	 (<50	 IU/L)	or	healthy	
controls.	Also	comparison	of	plasma	galectin-9	levels	in	patients	with	chronic	HCV	
showed	higher	levels	in	patients	compared	to	healthy	individuals	[123],	Furthermore,	
co-localization of CD68 and galectin-9 was observed in the peri-portal regions of 
the	 livers	 of	 virtually	 all	 the	 patients	 with	 HCV	 infection,	 regardless	 of	 grade	 of	
inflammation	or	stage	of	fibrosis,	but	not	in	normal	control	livers	[123].	
These	 inhibitory	 ligands	are	known	 to	 inhibit	T	cell	 function	upon	cell-cell	contact	
via	interaction	with	PD-1	and	Tim-3,	respectively	[138],	which	is	of	relevance	since	
both	PD-1	 and	Tim-3	 are	 reported	 to	 be	 upregulated	 on	HBV-	 and	HCV-specific	
intrahepatic and peripheral blood-derived CD8+	T	cells	and	associated	with	T	cell	
dysfunction	and	exhaustion	during	chronic	viral	hepatitis	[123,	139,	140].	Intrahepatic	
expression	 levels	of	PD-L1,	PD-L2	and	PD-1	correlated	with	 liver	 inflammation	 in	
chronic	HBV	 [30].	Although	 it	has	been	shown	 that	HCV	core	protein	can	 induce	
PD-L1	expression	on	human	perfusate-derived	KC	[84],	it	is	not	clear	whether	the	
upregulation of inhibitory ligands on intrahepatic macrophages and its correlation 
with	inflammation	are	direct	effects	of	HBV	or	HCV,	or	are	components	of	negative	
feedback	mechanisms	that	develop	as	a	consequence	of	persistent	inflammation.	
Thus,	several	studies	indicate	that	both	HBV	and	HCV	compromise	anti-viral	immunity	
to	a	certain	extent	by	(1)	interfering	with	signaling	of	pathogen	recognition	receptors	
and	 the	 production	 of	 pro-inflammatory	 cytokines	 by	 KC	 and	 (2)	 increasing	 the	
tolerogenic	capacities	of	KC	resulting	in	the	elevated	expression	of	anti-inflammatory	
mediators.	 As	 persistent	 inflammation	 in	 general	 is	 accompanied	 by	 negative	
feedback	mechanisms,	 the	 KC-related	 anti-inflammatory	 signals	 observed	 during	
chronic viral hepatitis could be explained by direct viral effects, immune regulation as 
part	of	the	ongoing	inflammatory	response,	or	a	combination.	However,	also	immune	
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activating	functions	of	KC	have	been	described	upon	HBV/HCV	interaction.	These	
seemingly	contradictory	functions	probably	indicate	a	critical	balance	influenced	by	
the	extent	to	which	receptors	are	triggered	(or	over-triggered)	and	also	by	the	type	
of	KC	 receptors	 that	 are	 triggered.	Therefore,	 not	 only	 the	 concentration	of	 virus	
(proteins),	but	also	the	time	since	infection	may	strongly	affect	KC	function.	Whether	
also	age	influences	KC	function	as	one	of	the	mechanisms	explaining	the	self-limiting	
hepatitis	often	seen	in	HBV-infected	adults,	whereas	young	children	usually	develop	
chronic infection, has to be investigated.
Role of KC in viral hepatitis-related liver damage
Liver fibrosis
One	of	the	consequences	of	sustained	low-grade	injury	induced	by	persistence	of	
HBV	 and	HCV	 in	 the	 liver	 is	 fibrosis,	 which	 is	 characterized	 by	 excess	 collagen	
deposition	 and	 accumulation	 of	 extracellular	 matrix.	 HBV	 and	 HCV	 may	 induce	
fibrinogenesis	 by	 activating	 hepatic	 stellate	 cells	 directly	 or	 indirectly	 by	 inducing	
cellular injury, apoptosis and necrosis, which triggers a wound healing response. KC 
are	thought	to	be	involved	in	fibrogenesis	by	the	release	of	various	pro-fibrinogenic	
factors,	 such	as	ROS	and	certain	cytokines,	 such	as	 IL-6,	TNF,	 IL-1,	PDGF	and	
TGFβ,	that	induce	activation	of	hepatic	stellate	cells	[141].	In	addition,	KC	produce	
enzymes that are important or the breakdown of matrix, such as collagenases and 
metalloproteinases, but they also regulate the production of these factors by other 
cells, leading to disturbance of the homeostatic mechanisms involved in extracellular 
matrix	deposition	[142].	Recent	studies	in	experimental	animal	models	demonstrate	
that these activities are only partially conducted by liver-resident macrophages, but 
largely depend on recruitment of monocytes as precursors of macrophages into the 
inflamed	and	damaged	liver	[143,	144].	
Although, in patients with viral hepatitis, no causative role has been demonstrated for 
KC	in	the	development	of	liver	fibrosis,	increased	numbers	of	CD14+CD68+ KC were 
found	around	the	regions	of	damage	and	fibrosis	[134].	These	increased	numbers	
were	associated	with	 liver	 injury	 [93,	141,	145,	146].	A	detailed	study	by	Liaskou	
et al. observed that in liver tissue from non-viral hepatitis patients with end-stage 
liver	disease	a	specific	monocyte	subpopulation	accumulated	in	the	liver,	which	was	
able	to	conduct	phagocytic	activity	and	to	release	inflammatory	and	profibrinogenic	
cytokines	[147].	Interestingly,	a	study	in	HBV	replication-competent	transgenic	mice	
showed an opposite effect of KC by demonstrating that they did not contribute to 
liver damage, but prevented liver injury by removal of apoptotic hepatocytes during 
viral	hepatitis	 [39].	 In	 this	model,	clodronate-mediated	depletion	of	KC	resulted	 in	
higher	numbers	of	necrotic	hepatocytes	and	elevated	serum	ALT	levels.	In	line	with	
this,	in	a	different	mouse	model,	liver-infiltrating	monocyte/macrophages	mediated	
regression	of	fibrosis	via	phagocytosis	of	cellular	debris	[148].
Liver	 damage	 and	 ultimately	 the	 induction	 of	 fibrosis	 may	 be,	 at	 least	 in	 part,	
attributed to cytokines produced by KC. Moreover, during viral hepatitis KC have 
also	been	found	to	express	cytotoxic	molecules,	like	TRAIL,	Fas-ligand,	granzyme	
B, perforin and ROS, that enable them to kill infected as well as non-infected 
“bystander”	hepatocytes	[106-108].	Fas-ligand	expression	by	KC	was	increased	in	
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Figure 1. The role of  KC in anti-viral immunity and tissue damage during HBV and HCV infection. Exposure 
of  KC to HBV or HCV will lead to direct activation of  KC that, together with infected hepatocytes, release cytokines 
and chemokines, which are responsible for the attraction of  other leukocytes. Activation of  infiltrating immune cells 
leads to further production of  cytokines that indirectly activate KC. The secreted cytokines may inhibit viral replication 
(green text). However, persistent exposure of  KC to HBV or HCV will continuously activate KC leading to the ongoing 
release of  cytokines and chemokines attracting and activating more leukocytes. Likewise, continuous activation of  
infiltrating leukocytes leads to ongoing production of  cytokines that indirectly activate KC. Some of  the cytokines 
secreted are pro-fibrotic factors. 
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chronic	HBV	patients	and	associated	with	elevated	ALT	levels,	while	granzyme	B	
and	perforin	expression	by	KC	was	increased	in	both	chronic	HBV	and	HCV	patients	
[106,	107].	Interestingly,	a	direct	contribution	of	KC	to	the	pathogenesis	of	hepatitis	
has also been reported for viral infections by viruses that infect other organs and 
are	not	detected	 in	 the	 liver	 itself	 [149].	 In	 influenza	 infection,	KC	were	 indicated	
as	 the	effector	 cells	 killing	hepatocytes	 in	an	as	yet	unidentified	manner,	 leading	
to	 damage-associated	 hepatitis.	 KC	 can	 kill	 hepatocytes	 either	 directly	 via	 Fas-
dependent apoptotic pathways or indirectly by interacting with CD8+ (and possibly 
CD4+)	T	cells	through	stimulation	of	cytokine	secretion	and	other	mediators,	such	as	
ROS	[149].
Hepatocellular carcinoma
Chronic	 HBV/HCV	 and	 cirrhosis	 are	 major	 risk	 factors	 for	 the	 development	 of	
hepatocellular	carcinoma	[150].	Although	HCC	development	has	been	extensively	
studied in mice and rat, only few studies have directly assessed the importance 
of	KC	 in	HCC	development	 in	 chronic	HBV	setting,	and	no	studies	are	available	
from	chronic	HCV	setting.	Dying	hepatocytes,	likely	resulting	from	anti-viral	activities	
since	HBV	and	HCV	are	considered	non-cytopathic,	will	activate	neighboring	cells,	
including	KC	 [151],	 to	produce	cytokines	and	growth	 factors,	such	as	hepatocyte	
growth	 factor,	 IL-6	and	TNF,	which	will	 further	amplify	 the	 inflammatory	 response	
and	drive	 the	compensatory	proliferation	of	 surviving	hepatocytes	 [152].	Ongoing	
cycles of hepatocyte death and regeneration increase the chances of spontaneous 
mutations	and	DNA	damage	[153]	eventually	resulting	in	HCC.	In	HBV-transgenic	
mice,	KC	and/or	 infiltrating	macrophages	 produced	high	 levels	 of	ROS,	 resulting	
in extensive oxidative DNA damage in neighboring proliferating hepatocytes and 
development	of	HCC	 [54].	HBV/HCV	also	activate	KC	 to	produce	 these	 types	of	
pro-inflammatory	mediators,	which	may	support	the	development	of	HCC	[84,	89].	
Additionally, the immunoregulatory mediators expressed by KC, either as a direct 
virus-KC	interaction	or	as	a	consequence	of	the	inflammatory	response,	may	also	
inhibit	 tumor-specific	 immune	 responses.	 For	 instance,	 galectin-9	 expressed	 on	
intrahepatic macrophages caused senescence of CD4+ and CD8+	 Tim3+	 T	 cells,	
and	may	explain	part	of	the	mechanism	leading	to	the	development	of	HCC	[154].	
Furthermore,	one	of	the	HBV-derived	proteins,	HBxAg,	also	has	direct	tumorigenic	
effects	[155].	Hepatocyte	regeneration,	either	influenced	by	KC	or	not,	allows	HBxAg	
integration in DNA of hepatocytes, which is one of the processes involved in the 
development	of	HCC	(reviewed	in	[153]).	Whether	HBxAg	directly	interacts	with	KC	
is not described. 
In conclusion, KC play a central role in liver damage during hepatitis, having all 
the	tools	to	induce	inflammation,	cell	death,	fibrosis	and	ultimately	HCC,	but	further	
research	during	HBV/HCV	infection	remains	to	be	carried	out	to	determine	the	exact	
contribution of KC to liver damage in viral hepatitis.
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Figure 2. Role of KC in immune regulation and viral persistence during HBV and HCV infection. 
Exposure	of	KC	to	HBV	or	HCV	will	lead	to	their	activation	and	the	release	of	anti-inflammatory	cytokines	
and expression of inhibitory molecules. Combined with impaired antigen presentation by KC, these 
regulatory mechanisms will interfere with KC function and that of other immune cells, frustrating anti-viral 
immunity.
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Perspectives
Currently,	our	understanding	of	the	role	of	KC	in	viral	hepatitis	 is	 incomplete.	The	
detailed	 contributions	 of	 liver-resident	 KC	 versus	 liver-infiltrating	macrophages	 to	
various	processes	of	disease	pathogenesis	are	difficult	to	determine,	because	of	the	
highly overlapping characteristics of these cells. Nevertheless, we can appreciate 
several possible anti-viral roles of KC, including binding and/or uptake of virus leading 
to	immune	recognition	and	the	production	of	pro-inflammatory	mediators	resulting	in	
(1)	 inhibition	of	viral	 replication	 in	hepatocytes,	 (2)	activation	of	neighboring	cells,	
and	 (3)	 attraction,	 activation	 and	 interaction	 with	 other	 immune	 cells,	 which	 will	
further	 increase	the	anti-viral	and	 inflammatory	response	(Fig.	1.).	These	 immune	
activating	roles	of	KC	are	beneficial	to	combat	HBV	and	HCV	in	the	early	phases	
after infection, but may also contribute to tissue damage and the development of 
fibrosis,	cirrhosis	and	HCC	during	chronic	viral	hepatitis	(Fig.	1.).	Furthermore,	also	
immune	regulatory	functions	of	KC	have	been	described,	either	as	a	consequence	
of direct virus-KC interaction, or as part of the complex tolerogenic liver environment 
and	 the	 ongoing	 inflammatory	 response	 upon	 HBV	 and	 HCV-infection,	 which	
may counteract the development of effective anti-viral immunity and support viral 
persistence	and	related	disease	pathogenesis	(Fig.	2.).	
With	 our	 growing	 appreciation	 of	 the	 roles	 of	 intrahepatic	 macrophages	 in	 both	
protective and harmful responses, intrahepatic macrophages form an interesting but 
complex	cellular	target	for	treatment	options	in	viral	hepatitis.	The	versatile	features	
assigned	 to	 KC	 may	 partly	 belong	 to	 infiltrating	 monocytes/macrophages	 and	
therefore future efforts should focus on identifying phenotypical and/or functional 
characteristics	 discriminating	 KC	 from	 infiltrating	macrophages.	 Furthermore,	 the	
function of KC and other intrahepatic macrophages will largely depend on the type, 
the level and duration of receptors triggered pushing the balance towards either 
protective	or	harmful	responses.	Identification	of	receptors	and	underlying	molecular	
mechanisms involved in virus-cell interactions and insight into mechanisms involved 
in wanted and unwanted responses of the different macrophage populations that 
exert	distinctive	functions	during	the	early	and	later	phases	of	HBV/HCV	infection	
are	needed	to	move	the	field	forward.
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Abstract 
The	 combination	 of	 ribavirin	 and	 peginterferon	 is	 the	 current	 standard	 of	 anti-
viral	 treatment	 for	chronic	HCV	patients.	However,	 little	 is	known	on	 the	mode	of	
action	 of	 ribavirin	 in	 the	 anti-viral	 treatment	 of	 HCV	 patients.	 To	 investigate	 the	
immunomodulatory mechanism of ribavirin, we studied peginterferon alone versus 
peginterferon	and	ribavirin	in	chronic	HBV	patients.	The	addition	of	ribavirin	did	not	
affect	 the	number	of	myeloid	dendritic	cells	(mDC)	or	plasmacytoid	dendritic	cells	
(pDC),	nor	did	it	enhance	T-helper-1	cell	activity	or	T-cell	proliferation.	In	contrast,	
it increased upregulation of activation markers on mDC and pDC, which was 
sustained throughout treatment. However, the addition of ribavirin had no effect on 
IFNα	production	by	pDC.	Our	findings	demonstrate	that,	although	ribavirin	does	not	
lead to a viral load decline, in vivo treatment with ribavirin affects the activation of 
pDC	and	mDC	in	chronic	HBV	patients.
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Introduction
Chronic	infections	with	HBV	and	HCV	cause	serious	global	public	health	problems	that	
affect over 500 million people worldwide. Chronicity of these infections is the result 
of	complex	and	as	yet	ill-defined	interactions	between	the	replicating	non-cytopathic	
virus	 and	 inadequate	 antiviral	 immune	 responses	 [1-3].	 Due	 to	 complications	 of	
chronic viral hepatitis, such as liver failure and hepatocellular carcinoma, yearly over 
800,000	deaths	occur	globally	[4].
	IFNα	is	an	important	antiviral	cytokine,	which,	in	its	pegylated	form,	is	used	as	first-
line	 treatment	 for	 chronic	HBV.	 Peginterferon	 leads	 to	 sustained	 viral	 responses	
in	only	30%	of	 the	patients	and	 in	only	7-18%	of	HBeAg-negative	patients	 [5,	6].	
For	 chronic	 HCV	 patients,	 the	 combination	 of	 peginterferon	 and	 the	 nucleoside	
analogue	ribavirin	is	the	current	standard	of	treatment	[7].	The	addition	of	ribavirin	
to	the	monotherapy	with	peginterferon	to	treat	patients	with	chronic	HCV	infections	
doubles	the	sustained	viral	response	rate	[7,	8].	The	mechanism	of	action	of	ribavirin	
in	combination	therapy	against	HCV	is	still	a	matter	of	debate.	As	well	as	inhibiting	
viral replication by interfering with viral mRNA, ribavirin has been reported to modulate 
the	immune	response	[9,	10].	It	has	been	shown	by	some	groups	that	ribavirin	can	
promote	 the	 development	 of	 T-helper	 1	 (TH1)	 cells	 as	 shown	 by	 enhanced	 IFNγ 
production	[11-13],	while	others	failed	to	do	so	[14].	The	effect	of	ribavirin	on	dendritic	
cells	(DC)	is	not	entirely	clear,	because	of	the	use	of	different	cell	types	from	different	
species. Using human immature monocyte-derived DC stimulated with poly-I:C, 
addition	of	ribavirin	caused	a	reduction	of	the	production	of	cytokine	production	[15],	
which could not be explained by enhanced cell death or apoptosis. However, using 
mouse bone marrow derived DC, the effect of ribavirin was an enhancement of IL-
12p40	production	accompanied	by	a	reduction	of	IL-10	production	[16].	In	this	study,	
cytokine production was induced by ribavirin alone without the additional triggering 
via	TLR	or	other	receptors.	No	data	are	available	on	the	in vivo effects of ribavirin on 
human DC. 
Previously,	we	 reported	 that	 -despite	 the	promising	 results	 of	 earlier	 studies	 [17,	
18]	-	the	addition	of	ribavirin	to	peginterferon	treatment	in	chronic	HBV	patients	did	
not	improve	the	efficacy	of	therapy	[6].	Since	viral	load	decline,	and	virological	and	
biochemical responses were comparable in both treatment arms, we now had the 
opportunity to compare the immunological features between the two groups without 
any interfering clinical differences.
In	our	cohort	of	chronic	HBV	patients	[6]	we	aimed	to	better	understand	the	modulation	
of	ribavirin	on	immunological	processes,	which	can	not	be	studied	in	chronic	HCV	
patients	where	ribavirin	addition	leads	to	viral	decline.	We	here	examined	whether	
the addition of ribavirin to the treatment protocol affected the phenotype or function 
of	myeloid	and	plasmacytoid	DC	of	HBV	patients,	as	well	as	their	T	cell	responses.	
This	study	contributes	to	the	ongoing	discussion	on	whether	ribavirin	can	enhance	
innate and adaptive immunity.
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Material and methods
Patients
Table	 1	 shows	 the	 patient	 characteristics	 of	 14	 chronic	 HBV	 patients	 who	 were	
HBeAg-negative, anti-HBe positive and had been HBsAg-positive for over 6 months. 
These	 patients	 were	 part	 of	 the	 PARC	 multicenter	 study,	 and	 received	 either	
combination therapy with 180 μg peginterferon α-2a (Pegasys, Hoffmann-La Roche 
Ltd.,	Basel,	Switzerland)	weekly	and	ribavirin	(Copegus,	Hoffmann-La	Roche	Ltd.)	
1,000	mg	daily	(body	weight	<75	kg)	or	1,200	mg	daily	(body	weight	≥75	kg);	or	
monotherapy with 180 μg peginterferon α-2a	once	per	week	and	placebo.	Therapy	
was for 48 weeks, after which a follow-up period of 24 weeks ensued. As part of the 
diagnostic	evaluation,	serum	HBV	load	and	alanine	aminotransferase	levels	(ALT)	
were determined at indicated time points. Heparinized peripheral blood samples 
were obtained at baseline and after 12, 24, 36, 48 weeks of therapy. A follow up 
sample	was	obtained	24	weeks	 after	 treatment.	 The	 study	was	approved	by	 the	
local ethics committee, and all patients in the study gave informed consent before 
inclusion in the study.
Leukocyte numbers and phenotypes
Myeloid and plasmacytoid DC numbers were determined in fresh whole blood 
samples	 by	 white	 blood-cell	 counting	 and	 flow	 cytometry	 after	 staining	 with	
antibodies	against	CD123	(BD	Pharmingen,	San	Diego,	CA,	USA),	CD45	(Beckman	
Coulter,	Brea,	CA,	USA),	CD20	 (ExBio	Nuclilab,	 The	Netherlands),	BDCA-1	 and	
BDCA-4	(Miltenyi	Biotec,	Bergisch	Gladbach,	Germany).	To	analyze	the	frequency	
of leukocyte subpopulations and expression of chemokine receptors, activation 
markers, and other phenotypical markers we stained fresh and/or thawed peripheral 
blood	mononuclear	cells	 (PBMC)	with	antibodies	against	CD3,	CD4,	CD8,	CD14,	
CD56,	HLA-DR	(all	BD),	CD14	(BD	Pharmingen),	CD11a,	CD16,	CD80	(all	Beckman	
Coulter),	 CCR3,	 CD86	 (both	 BioLegend,	 San	 Diego,	 CA,	 USA),	 CD11c,	 CD20,	
CD40,	HLA-DR	(all	eBioscience,	San	Diego,	CA,	USA),	BDCA-1,	BDCA-3,	BDCA-4	
(Miltenyi),	CCR4,	CCR5	and	CCR7	(all	R&D).	PBMC	were	isolated	from	blood	by	
Ficoll-Paque	(GE	Healthcare,	Uppsala,	Sweden)	gradient	centrifugation.	Data	was	
acquired	on	a	FACScalibur	or	FACScanto	(both	BD)	and	analysed	with	FlowJo	(Tree	
Star,	Inc.,	Ashland,	OR,	USA)	and	FACSdiva	software	(BD).
Intracellular cytokine staining
Thawed	PBMC	(1x106	mL-1)	were	cultured	in	48-well	plates	(Corning,	Lowell,	MA,	
USA)	in	250	μl	RPMI	culture	medium	(Lonza,	Verviers	Sprl,	Belgium)	containing	10%	
heat-inactivated	human	serum	(Lonza),	penicillin/streptavidin	(Gibco)	and	L-glutamin	
(Lonza)	for	4	hours	at	37°C,	5%	CO2.	The	cells	were	either	unstimulated	or	stimulated	
with 10 ng mL-1 PMA and 0.4 μg mL-1 ionomycin (both Sigma-Aldrich, St. Louis, 
MO,	USA).	During	the	last	3	hours	of	culture,	brefeldin	(10	μg	mL-1;	Sigma-Aldrich)	
was	added.	The	cells	were	harvested,	fixed	with	2%	formaldehyde,	permeabilized	
with	0.5%	saponin	(VWR,	West	Chester,	PA,	USA)	and	stained	for	IFNγ, IL-4, CD3 
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(all	BD)	and	CD4	(eBioscience).	Where	appropriate,	isotype	antibodies	were	used	
as	controls.	Data	was	acquired	and	analyzed	as	above.
Proliferation assay
To	analyze	the	proliferation	of	T	cells,	thawed	PBMC	were	cultured	in	quadruplicate	
in	round-bottom	96-well	plates	(Corning)	in	a	final	concentration	of	1x106 cells per 
ml	 in	200	μl	RPMI	culture	medium	at	37°C,	5%	CO2. On day 0, cells were either 
unstimulated or stimulated with HBcAg (1 μg mL-1; American Research Products, 
Belmont,	 MA,	 USA),	 CMV	 (35	 μg	 mL-1;	 Microbix	 Biosystems,	 Toronto,	 Ontario,	
Canada)	or	antibodies	against	CD3	 (400	ng	mL-1;	Orthoclone	OKT®3;	 Janssen-
Cilag,	Tilburg,	 the	Netherlands)	and	CD28	(1	μg	mL-1;	BioLegend).	At	day	5,	 the	
cells	were	pulsed	for	16	hours	with	0.5	μCi	per	well	[3H]-Thymidine	(Amersham,	Little	
Patient # Age 
(yr) 
Sex HBV	
Genotype 
Viral	load	
(geq/ml) 
ALT	(U/l) Therapy Response to therapy 
1 34 M D 9.0x104 76 Peg Biochemical 
2 31 M D 9.5x106 443 Peg Combined 
3 52 M A 4.5x105 63 Peg Poor 
4 29 F E 3.8x107 109 Peg Poor 
5 35 F D 4.3x104 47 Peg Combined 
6 36 M D 3.6x107 99 Peg Poor 
7 47 M D 7.3x103 183 Peg Poor a 
8 35 M D 1.8x106 61 Peg Biochemical 
9 32 M D 1.3x107 196 Peg/riba Poor 
10 65 M A 4.2x107 201 Peg/riba Virological 
11 41 M D 7.2x106 110 Peg/riba Poor 
12 63 M A 7.1x104 63 Peg/riba Virological 
13 52 F C 3.7x104 71 Peg/riba Combined 
14 41 M C 2.8x106 61 Peg/riba Combined 
 
Table 1
Patient characteristics
Response	 to	 therapy	 at	 week	 72	 (end	 of	 follow-up	 period):	 Poor	 response:	 Viral	 load	
>103	 HBV	 copies/ml	 and	 ALT	 >40	 for	 male,	 >30	 for	 female;	 Biochemical	 response:	 ALT	
normalization	 (<30/40	 for	 F/M,	 resp.);	 Virological	 response:	 Viral	 load	 <103	 HBV	 copies/
ml;	 Combined	 response:	 Viral	 load	 <103	 HBV	 copies/ml	 and	 normalization	 of	 ALT;	 
a	Switched	to	adefovir	after	12	weeks;	geq	=	genome	equivalents
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Chalfont,	UK).	Proliferation	was	determined	by	liquid	scintillation	and	expressed	as	
counts	per	minute	(cpm).
Statistics
To	 compare	 therapy	 groups,	 peginterferon	 treatment	 was	 analyzed	 against	
peginterferon	 and	 ribavirin	 treatment	 at	 the	 same	 time	 point.	 These	 data	 were	
analyzed	 using	 the	 non-parametric	Mann–Whitney	U	 test.	 Data	 from	 time	 points	
during therapy and during follow-up were pair analyzed against start of therapy, 
and	end	of	follow	up	was	pair	analyzed	against	end	of	treatment.	These	data	were	
analyzed	 using	 the	 non-parametric	 Wilcoxon	 Signed	 Ranks	 Test	 with	 two-tailed	
P-values. Data from cytokine expression are normalized and given as percentages of 
the appropriate control. Data on expression of costimulatory molecules, chemokine 
receptors and adhesion molecules are expressed as geometric mean ± SEM. A P¬-
value	of	<	0.05	was	considered	statistically	significant.
 
Results
Frequency of DC populations decreases during peginterferon-based therapy 
in chronic HBV patients
To	 investigate	 the	 effect	 of	 peginterferon	monotherapy	 and	 combination	 therapy	
with ribavirin on circulating antigen-presenting cells, peripheral blood samples were 
assessed	 for	 the	 frequency	 and	 numbers	 of	DC	 populations.	 As	 a	 consequence	
of therapy, there was a reduction in the absolute leukocyte numbers (data not 
shown).	The	absolute	cell	numbers	and	frequency	of	BDCA-1+	myeloid	DC	(Figure	
1)	and	BDCA-3+	myeloid	DC	(Supplementary	Figure	S1)	decreased	during	therapy,	
irrespective of whether peginterferon alone or peginterferon in combination with 
ribavirin was given. However, the absolute and relative numbers of BDCA-4+ 
plasmacytoid DC did not change during either therapy. Additionally, albeit not 
significant,	the	frequency	of	total	monocytes	showed	a	decline	during	therapy,	which	
was accompanied by a higher contribution of the CD14+ CD16+ subpopulation within 
the	total	monocytes	(Supplementary	Figure	S1).	
Modulation of chemokine receptors and activation markers on myeloid DC 
during treatment 
To	 assess	 whether	 the	 decline	 in	 the	 frequency	 of	 BDCA-1+ myeloid DC during 
therapy may be due to altered migration, we examined the expression of chemokine 
receptors	 and	 adhesion	 molecules	 on	 myeloid	 DC	 (Supplementary	 Figure	 S2).	
As	 shown	 in	 Figure	 2A,	 the	 expression	 of	 the	 homeostatic	 chemokine	 receptor	
CCR7	was	not	altered	as	a	consequence	of	 therapy,	neither	was	 the	expression	
of	the	adhesion	molecule	CD11a.	For	both	therapy	groups,	a	trend	was	observed	
for	 augmented	 expression	 of	 the	 inflammatory	 chemokine	 receptors	 CCR4	 and	
CCR5 on myeloid DC following start of treatment. However, statistically only the 
peginterferon	therapy	group	showed	a	significant	increase	at	24	weeks	during	the	
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treatment period. Besides the effect on chemokine levels, we also analyzed the 
modulation	 of	 the	 activation	 status	 of	myeloid	 DC	 as	 a	 consequence	 of	 therapy	
and	the	addition	of	ribavirin	(Supplementary	Figure	S2).	During	therapy,	the	basal	
expression of the co-stimulatory molecules CD40, CD80 and CD86 on myeloid DC 
showed a mild upregulation, especially early after start of therapy, whereas HLA-DR 
expression	on	myeloid	DC	was	not	affected	(Figure	2B).	Significant	therapy-induced	
enhanced expression of costimulatory molecules on myeloid DC were observed 
in the group receiving peginterferon plus ribavirin, but not in the group receiving 
peginterferon alone. 
Peginterferon with or without ribavirin therapy does not lead to augmented T 
cell proliferation or TH1 development
To	 investigate	 whether	monotherapy	 or	 combination	 therapy	 differently	 affects	 T	
cell	 activity,	 we	 determined	 T-cell	 proliferation	 and	 differentiation	 using	 patient-
derived	PBMC.	As	shown	in	Figure	3A,	HBcAg-specific	T-cell	proliferation	declined	
shortly after start of treatment, remaining low during the entire treatment phase, and 
increasing again in a small number of patients after termination of therapy (at week 
72;	Figure	3A	top	panel).	Although	CMV-specific	T-cell	proliferation	was	higher	than	
Figure 1. Frequency of antigen presenting cells during IFN-based therapy in chronic HBV patients. 
Frequencies	of	myeloid	and	plasmacytoid	DC	were	determined	in	whole	blood	samples	by	flow	cytometry.	
Myeloid	DC	were	defined	as	CD20- BDCA1+ and plasmacytoid DC as CD123+ BDCA4+ cells. Shown are 
the	absolute	numbers	and	frequencies	(mean	±	SEM)	of	myeloid	DC	and	plasmacytoid	DC	within	total	
PBMC	from	patients	treated	with	peginterferon	alone	(n=8)	or	with	the	combination	of	peginterferon	and	
ribavirin	(n=6).	*p<0.05	compared	to	t=0,	Wilcoxon	signed-rank	test.
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HBcAg-specific	T-cell	proliferation,	a	similar	pattern	was	observed	during	 therapy	
(Figure	3A	middle	panel).	Polyclonal	stimulation	of	PBMC	using	antibodies	against	
CD3	showed	that	during	therapy,	T	cells	exhibit	less	proliferation,	but	are	still	viable	
(Figure	3A	bottom	panel).	The	addition	of	ribavirin	to	the	treatment	regimen	did	not	
lead	to	differential	T	cell	proliferative	responses	as	compared	to	monotherapy.	
It has been proposed that interferon-alpha and ribavirin both promote the development 
of	TH1	cells	or	 lead	 to	higher	 levels	of	 IFNγ in vitro	 [11-13,	19,	20].	To	determine	
whether addition of ribavirin to the treatment regimen consisting of peginterferon 
leads	to	more	potent	TH1	cell	development,	we	evaluated	the	T-helper	cell	profile	as	
defined	by	 their	cytokine	production	during	 the	course	of	 therapy	(Supplementary	
Figure	S3).	Upon	polyclonal	stimulation	of	PBMC,	the	percentage	of	IFNγ-producing 
T	cells	decreased	during	therapy,	whereas	no	effect	of	treatment	was	observed	for	the	
frequency	of	IL-4-producing	T	cells	(Figure	3B).	Importantly,	there	were	no	differences	
Figure 2. Therapy increases basal maturation status of myeloid DC. The	 expression	 levels	 of	
chemokine receptors, adhesion molecules and co-stimulatory molecules on myeloid DC was determined 
by	flow	cytometry	in	PBMC	from	patients	treated	with	peginterferon	alone	(n=8)	or	with	the	combination	
of	 peginterferon	 and	 ribavirin	 (n=6).	Myeloid	DC	were	 defined	 as	CD3- CD20- CD11c+ BDCA-1+. (A)
Shown	are	the	mean	±	SEM	expression	in	MFI	of	chemokine	receptors	CCR4	and	CCR5	(inflammatory	
chemokine	receptors),	CCR7	(homeostatic	chemokine	receptor)	and	CD11a.	*p<0.05	compared	to	t=0,	
Wilcoxon	 signed-rank	 test.	 (B)	 Shown	 are	 boxplots	 with	whiskers	 from	minimum	 to	maximum	 of	 the	
expression	of	maturation	markers	CD40,	CD80,	CD86	and	HLA-DR	ex	vivo.	*p<0.05	compared	to	t=0,	
Wilcoxon	signed-rank	test.
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between	the	two	therapy	groups,	indicating	that	T-helper	cell	differentiation	was	not	
changed	 towards	a	more	pronounced	TH1	profile	as	a	consequence	of	 treatment	
with	peginterferon	or	peginterferon	and	ribavirin	combination	therapy	in	chronic	HBV	
patients. 
Combination therapy with ribavirin leads to stronger and more sustained 
plasmacytoid DC activation
As with myeloid DC, we also checked for chemokine expression levels on 
plasmacytoid	DC	 (Supplementary	Figure	S4).	 In	accordance	with	what	was	seen	
on	myeloid	DC,	 expression	 of	 the	 inflammatory	 chemokine	 receptors	CCR4	 and	
CCR5	increased	on	plasmacytoid	DC	regardless	of	the	therapy	group	(Figure	4A).	
Interestingly, expression of the homeostatic chemokine receptor CCR7 was increased 
in both groups, but was most pronounced in patients treated with the combination 
of	peginterferon	and	ribavirin,	albeit	not	significantly.	No	significant	differences	were	
observed	for	CD11a	on	plasmacytoid	DC	during	the	course	of	treatment	(Figure	4A).	
Next, we investigated whether the activation status of plasmacytoid DC was affected 
by	IFN-based	treatment	in	combination	with	ribavirin.	Compared	to	a	transient	effect	
of peginterferon alone, combination therapy induced a higher upregulation of basal 
Figure 3. Addition of ribavirin to peginterferon therapy neither increases proliferation nor induces 
skewing towards a TH1 profile. (A)	PBMC	from	patients	treated	with	peginterferon	alone	(n=8)	or	with	
the	combination	of	peginterferon	and	ribavirin	(n=6)	were	stimulated	with	HBcAg	(top	panel),	CMV	(middle	
panel)	or	anti-CD3	(bottom	panel).	Depicted	is	the	proliferation	in	cpm	of	an	individual	patient,	open	circles	
(peginterferon	therapy)	or	crosses	(peginterferon	and	ribavirin	therapy).	Lines	reflect	the	grand	mean	of	
proliferation within a therapy group for that given time point. (B)	PBMC	were	stimulated	with	PMA	and	
ionomycin	and	analysed	for	IFNγ and IL-4 production by intracellular cytokine staining gated on CD4+	T	
cells.	Cytokine	production	is	presented	as	mean	±	SEM	IFNγ-positive	or	IL-4-positive	TH	cells.	*p<0.05	
compared	to	t=0,	Wilcoxon	signed-rank	test.
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CD40, CD80, CD86 and HLA-DR expression on plasmacytoid DC that was sustained 
during	the	entire	treatment	period	(Figure	4B).
Ribavirin does not influence IFNα production by plasmacytoid DC 
It was previously reported that plasmacytoid DC with a more mature phenotype 
produce	less	IFNα,	a	key	cytokine	produced	by	plasmacytoid	DC	[21].	We	therefore	
examined whether the addition of ribavirin to peginterferon monotherapy led to 
modulation	of	IFNα	levels	upon	stimulation	with	the	TLR9-ligand	CpG.	A	decline	of	
Figure 4. Addition of ribavirin to peginterferon therapy enhances and prolongs augmentation of 
plasmacytoid DC basal maturation status. Chemokine receptor, adhesion molecules and maturation 
marker	expression	by	plasmacytoid	DC	was	assessed	 in	PBMC	by	 flow	cytometry.	 plasmacytoid	DC	
were	defined	as	CD3- CD20- CD11c- BDCA-4+. (A)	Shown	are	the	mean	±	SEM	expression	 in	MFI	of	
chemokine	 receptors	 CCR4	 and	 CCR5	 (inflammatory	 chemokine	 receptors),	 CCR7	 (homeostatic	
chemokine	receptor)	and	CD11a.	*p<0.05	compared	to	t=0,	Wilcoxon	signed-rank	test.	(B)	Shown	are	
box plots with whiskers from minimum to maximum of the expression of co-stimulatory markers CD40, 
CD80,	CD86	and	MHC	class	II	molecule	HLA-DR	ex	vivo.	*p<0.05	compared	to	t=0,	Wilcoxon	signed-
rank	test.	**p<0.05	compared	between	therapy	groups,	Mann–Whitney	U	test.
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IFNα-positive plasmacytoid DC was observed during therapy, and this was observed 
for	 both	 therapy	 regimens	 to	 the	 same	 extent	 (Figure	 5).	 Thus,	 the	 addition	 of	
ribavirin	did	not	alter	the	percentage	of	IFNα-positive plasmacytoid DC as compared 
to peginterferon monotherapy.
 
Discussion
To	better	understand	the	underlying	mechanisms	of	the	nucleoside	analogue	ribavirin	
in antiviral therapy, we investigated whether the addition of ribavirin to peginterferon 
monotherapy had any effect on the numbers, phenotype and function of PBMC 
derived	from	chronic	HBV	patients.	We	observed	that	the	addition	of	ribavirin	to	the	
IFN-based	therapy	had	no	effect	on	the	frequencies	of	antigen	presenting	cells.	Also	
no differences were observed on the expression levels of chemokine receptors, and 
T	cell	activity	was	not	different	between	both	treatment	groups.	However,	the	basal	
activation	 status	of	myeloid	 and	plasmacytoid	DC	was	higher	 on	 cells	 from	HBV	
patients receiving peginterferon and ribavirin combination treatment as compared to 
monotherapy. As we previously reported, the addition of ribavirin to peginterferon did 
not improve treatment outcome compared to peginterferon monotherapy in chronic 
HBV	patients	[6].	This	lack	of	clinical	effect	of	ribavirin	in	HBV	patients	allowed	us	to	
assess the immunological effects of adding ribavirin independently of a simultaneous 
decrease	in	HBV-DNA.
Myeloid	DC	are	crucial	players	in	antiviral	immune	responses	[22].	We	therefore	first	
examined the effect of ribavirin on myeloid DC function, and show that the addition 
of ribavirin to peginterferon monotherapy did not affect the number and phenotype 
of	myeloid	DC	in	chronic	HBV	patients.	The	expression	of	costimulatory	molecules	
was	weakly	higher	in	myeloid	DC	obtained	from	patients	exposed	to	ribavirin.	These	
findings	differ	 from	the	observations	 in	other	models,	 including	 in vitro cell-culture 
systems	[15,	16].	The	mildly	enhanced	myeloid	DC	activation	by	ribavirin	was	not	
reflected	by	the	degree	of	HBcAg-specific	and	CMV-specific	proliferation,	which	was	
weak, and could not be improved by the addition of ribavirin.
Figure 5. IFNα production by plasmacytoid DC upon CpG stimulation is not influenced by addition 
of ribavirin to peginterferon monotherapy. Percentage	of	IFNα-producing plasmacytoid DC in PBMC 
upon	CpG	stimulation.	PBMC	were	obtained	from	patients	treated	with	peginterferon	alone	(n=8)	or	with	
the	combination	of	peginterferon	and	ribavirin	(n=6)	and	were	defined	as	CD3- CD20- CD123+ BDCA-4+.
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Ribavirin	has	been	suggested	to	mount	a	TH1 type immune response by promoting 
the	 production	 of	 TH1-inducing	 cytokines	 –	 such	 as	 IL-12	 –	 by	 DC	 [16].	 Some	
researchers	have	shown	that	 ribavirin	can	skew	towards	a	TH1 subset phenotype 
and	 increase	 IFNγ	 production,	 also	 during	 HBV	 infection	 [11-13].	 Although	 TH1 
induction	is	known	to	be	crucial	in	antiviral	immunity	[22,	23],	we	found	that	ribavirin	
does	not	promote	TH1	activity.	This	apparent	discrepancy	may	well	be	explained	by	
differences in experimental setup. Unlike these earlier studies, which examined the 
effect of ribavirin in in vitro	models	[11-13]	or	an	in vivo	mouse	model	[11],	we	use	
clinical	samples	derived	from	chronic	HBV	patients	treated	with	ribavirin.	Aside	from	
a	TH1	effect,	we	also	checked	ribavirin	for	a	possible	TH17-promoting effect; however, 
due to low and often undetectable levels of IL-17 production in our cultures, we could 
not	conclude	that	ribavirin	modulates	this	response	(data	not	shown).
Analysis of ex vivo obtained plasmacytoid DC showed that basal expression of 
costimulatory	molecules	was	significantly	higher	during	ribavirin	and	peginterferon	
combination therapy than during peginterferon monotherapy, albeit that these 
plasmacytoid	 DC	 still	 exhibited	 an	 immature	 phenotype.	 From	 these	 in vivo 
observations	we	can	not	draw	firm	conclusions	about	the	functional	consequences	
of enhanced expression of CD40, CD80, and CD86. However, it is likely that 
stronger	expression	of	costimulatory	molecules	may	affect	the	quality	of	the	T	cell	
response.	Alternatively,	 interactions	of	plasmacytoid	DC	with	non-T	cells	such	as	
NK cells may be modulated by a more activated phenotype of plasmacytoid DC. 
Furthermore,	it	is	important	to	note	that	increased	maturation	of	plasmacytoid	DC	is	
accompanied	with	a	decreased	capacity	to	produce	IFNα	[21],	which	may	suggest	
a shift of plasmacytoid DC function towards cellular immune responses. Although 
we	show	 that	 IFNα production by plasmacytoid DC upon CpG stimulation during 
therapy	 is	 reduced,	no	differences	 in	 IFNα production between peginterferon and 
peginterferon	and	ribavirin	therapy	were	observed.	This	suggests	that	administration	
of	peginterferon,	 rather	 that	 ribavirin,	 leads	 to	suppression	of	 IFNα production by 
plasmacytoid DC, and is not caused by an altered activation status of plasmacytoid 
DC.	Recently,	 levels	of	CD80	on	plasmacytoid	DC	of	chronic	HCV	patients	were	
found	to	be	predictive	for	treatment	outcome	[24],	further	demonstrating	the	functional	
importance of differential plasmacytoid DC activation. 
Since	ribavirin	is	a	purine	analogue,	it	is	possible	that	it	may	directly	trigger	TLR7-	or	
TLR9-mediated	signalling,	and	consequently	activate	plasmacytoid	DC.	Although,	
on	the	basis	of	our	findings,	we	can	not	conclude	whether	plasmacytoid	DC	were	
activated directly or indirectly upon administration of ribavirin, others have shown 
previously	 that	TLR7	 transfected	cells	are	only	minimally	activated	by	 ribavirin	at	
supra-physiological concentrations in vitro,	and	no	activation	by	TLR9	transfected	
cells	[25].
In	conclusion,	our	findings	demonstrate	that	addition	of	ribavirin	to	interferon-based	
therapy	 of	 chronic	HBV	 patients	 increases,	 although	mildly,	 the	 activation	 status	
of	myeloid	and	plasmacytoid	DC	during	 treatment.	Further	studies	are	needed	 to	
examine	whether	 the	effects	 of	 ribavirin	 on	 the	DC	compartment	 in	 chronic	HBV	
patients	are	disease	specific,	and	thus	whether	these	effects	may	explain	why	the	
addition of ribavirin to peginterferon monotherapy was not clinically effective in 
chronic	HBV	patients.
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Supplementary figure 1. Frequency of BDCA-3+ myeloid DC and monocytes during IFN-based 
therapy in chronic HBV patients. Frequencies	of	BDCA-3+ myeloid DC and monocytes were determined 
in	whole	blood	samples	by	flow	cytometry.	Monocytes	are	defined	as	CD3- CD20- CD56- BDCA-1- BDCA-
4- and CD14+ and/or CD16-. Shown are the mean ± SEM percentages of DC and monocytes within 
total PBMC, and mean ± SEM percentages of monocyte subsets (CD14+ CD16-, CD14+ CD16+, CD14- 
CD16+)	within	total	monocytes	derived	from	patients	treated	with	peginterferon	alone	(n=8)	or	with	the	
combination	of	peginterferon	and	ribavirin	(n=6).	*p<0.05	compared	to	t=0,	Wilcoxon	signed-rank	test.
Data supplement
Supplementary figure 2. Analysis of BDCA-1+ myeloid DC phenotype by flow cytometry. 
Representative pseudocolor density plots of chemokine receptor expression levels (A)	and	costimulatory	
molecule levels (B)	on	myeloid	DC	at	baseline;	expression	levels	depicted	as	geometric	mean	fluorescence	
intensity	(MFI).
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Supplementary figure 3. Analysis of T helper cell cytokine response by flow cytometry. 
Representative	pseudocolor	density	plots	showing	IFNγ-producing	and/or	IL-4-producing	T	helper	cells	
upon stimulation of PBMC at baseline with medium or PMA-ionomycin; cytokine-producing cells depicted 
as percentage of total CD4+	T	helper	cells.
Supplementary figure 4. Analysis of plasmacytoid DC phenotype by flow cytometry. Representative 
pseudocolor density plots of chemokine receptor expression levels (A)	and	costimulatory	molecule	levels	
(B)	on	plasmacytoid	DC	at	baseline;	expression	levels	depicted	as	geometric	mean	fluorescence	intensity	
(MFI).
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Abstract
With	 increasing	 interest	 in	 alternative	 options	 to	 interferon-alpha	 (IFNα)-based	
treatments,	IFNλ has shown therapeutic promise in a variety of diseases. Although 
the	antiviral	activity	of	IFNλ has been extensively studied, there is limited knowledge 
regarding	the	 immunological	 functions	of	 IFNλ and how these differ from those of 
other	classes	of	IFNs.	In	this	study,	we	investigated	the	effects	of	IFNλ on natural 
killer	 (NK)	 cells,	 both	 in	 a	 direct	 and	 indirect	 capacity.	 We	 demonstrate	 that	 in	
contrast	to	IFNα,	IFNλ is unable to directly stimulate NK cells, due to the absence 
of	IFNλ	receptor	chain	1	(IFNλR1)	on	NK	cells.	However,	IFNλ, in combination with 
TLR4	challenge,	 is	able	 to	 induce	 the	production	of	 select	members	of	 the	 IL-12	
family	of	cytokines	in	monocyte-derived	macrophages.	We	further	show	that	through	
macrophage-mediated	IL-12	production,	IFNλ is able to indirectly affect NK cells and 
ultimately	induce	IFNγ production.
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Introduction
Natural	 killer	 (NK)	 cells	 play	 an	 important	 role	 in	 the	 innate	 immune	 response,	
specifically	in	their	ability	to	recognize	and	respond	to	stressed	cells,	including	virus-
infected, transformed, and damaged cells. Activated NK cells respond to these stress 
signals by excretion of cytotoxic factors, including perforin and granzymes, as well 
as cytokines, such as interferon-γ	(IFNγ)	and	tumor	necrosis	factor	(TNF),	that	act	
as	a	first	response	to	control	the	source	of	distress	as	well	as	to	activate	subsequent	
adaptive	immune	responses	[1,	2].
NK cell activation ensues after interacting with altered cells, shifting the balance 
of	 inhibitory	and	activating	stimuli	delivered	via	specific	surface	molecules.	These	
include stress-induced surface markers, including altered MHC expression, as well 
as soluble factors, of which IL-12 and IL-18 are well-described and known triggers 
of	NK	cell	 effector	activity	 [1-3].	Various	cell	 types,	 such	as	dendritic	 cells	 (DCs)	
and macrophages, are able to modulate the function of NK cells by changing the 
cytokine	micro-environment	and	interacting	with	reciprocal	surface	molecules	[4-7].	
These	 interactions	 have	 been	 shown	 to	 play	 an	 important	 role	 in	 anti-tumor	 and	
anti-inflammatory	responses	in	a	myriad	of	diseases.	In	line	with	this,	the	activity	of	
NK cells can be promoted by exposure to interferon-α	(IFNα),	e.g.	during	interaction	
with	IFN-producing	activated	plasmacytoid	DCs	leading	to	enhanced	activation	and	
cytolytic	activity	[8-10],	and	thereby	promoting	antiviral	immunity.
In	 recent	 years	 the	 type	 III	 family	 of	 IFNs,	 comprised	 of	 IFNλ1,	 IFNλ2,	 IFNλ3, 
and	 IFNλ4, has received increased attention, especially after the discovery of 
polymorphisms within its gene locus that were associated with spontaneous as 
well	as	therapy-induced	clearance	of	hepatitis	C	virus	(HCV)	[11-14].	All	members	
of	 the	 IFNλ	 family	 use	 a	 specific	 receptor	 heterodimer,	 the	 IFNλR1 and IL-10R2 
complex,	which	structurally	differs	from	the	IFNα receptor complex, but is similar in 
its	 triggering	of	downstream	JAK/STAT	signal	 transduction,	ultimately	 resulting	 in	
the	 initiation	of	gene	 transcription.	 In	contrast	 to	 the	ubiquitously	expressed	 IFNα 
receptor,	the	distribution	of	the	IFNλ receptor is more limited. Murine models have 
shown	 that	 epithelial	 cells	 express	 the	 receptor	 complex	 and	 responded	 to	 IFNλ 
stimulation	 by	 eliciting	 an	 antiviral	 response	 [15].	 Outside	 of	 non-hematopoietic	
cells,	specifically	epithelial	cells	and	hepatocytes,	expression	of	the	IFNλR1 chain 
in	humans	has	been	well-described	on	plasmacytoid	DCs,	fibroblasts	[16,	17],	and	
recently	on	macrophages	[18].	
We	have	previously	demonstrated	that	monocyte-derived	macrophages	expressed	a	
functional	IFNλ receptor complex, and that triggering of this receptor in combination 
with	activation	via	specific	toll-like	receptors	(TLRs)	resulted	in	an	enhancement	of	
macrophage	IL-12p40	production.	This	was	in	contrast	to	IFNα,	which	inhibited	TLR-
induced	IL-12p40	production	in	monocyte-derived	macrophages.	Further	functional	
differences	 have	 been	 described	 between	 IFNα	 and	 IFNλ in their modulation of 
hepatocytes,	where	 IFNλ has been shown to activate a more restricted subset of 
cells	as	well	as	induce	weaker	interferon-stimulated	gene	responses	[19,	20].	
To	 further	 define	 a	 role	 for	 IFNλ in antiviral immune responses, the goal of this 
study	was	 to	determine	whether	 IFNλ could exert any immunomodulatory effects 
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on	NK	cells,	and	if	so,	how	that	response	compared	to	the	action	of	type	I	IFNs.	A	
previous	study	had	described	IFNλ as being able to partially inhibit NK cell-derived 
IFNγ	production	upon	IL-12/15	stimulation	[21,	22],	but	an	effect	of	IFNλ on NK cells 
could	not	be	reproduced	in	an	ensuing	response	to	the	original	article	[23].	To	better	
understand	 the	biological	 role	of	 IFNλ,	we	 investigated	 the	effects	of	 IFNλ on NK 
cells	in	both	a	direct	and	indirect	capacity	through	its	modulation	of	TLR-activated	
macrophages. 
Materials and Methods
Cell culture and isolation
Human	peripheral	blood	mononuclear	cells	(PBMCs)	were	isolated	from	buffy	coats	
(Sanquin	 Blood	 Supply)	 using	 density	 gradient	 centrifugation	 (Ficoll-Paque,	 GE	
Healthcare).	Monocytes	and	NK	cells	were	then	purified	from	the	PBMC	fraction	using	
magnetic	labeled	CD14	micro-beads	(Miltenyi	Biotec)	and	human	NK	Cell	Isolation	
Kit	 (Miltenyi	Biotec)	 according	 to	 the	protocol	 provided	by	 the	manufacturer.	The	
purity of monocytes and NK cells isolated and used in this study always exceeded 
95%.
Macrophages	 were	 generated	 from	 the	 aforementioned	 purified	 monocytes	 by	
culturing	with	20	ng/ml	GM-CSF	(Leukine®	(sargramostim))	in	6-well	plates	(Costar)	
at	a	density	of	0.75*106	cells/ml	in	RPMI1640	medium	(Lonza)	supplemented	with	
10%	 fetal	calf	serum	(Sigma),	penicillin/streptomycin	 (Gibco),	L-glutamin	 (Lonza),	
and	HEPES	(Lonza).	The	medium	was	partially	refreshed	at	days	2	and	5,	and	the	
monocyte-derived macrophages were harvested at day 6 for use in various assays.
HEK293	cells	 that	were	stably	 transfected	 to	express	 the	 IFNλ receptor (HEK293 
R19)	 were	 cultured	 using	 RPMI1640	 medium	 supplemented	 with	 10%	 fetal	 calf	
serum.	THP-1,	NK92,	and	K562	cell	 lines	were	cultured	using	 the	 recommended	
conditions	by	the	ATCC.	
Stimulation of monocyte-derived macrophages
Monocyte-derived	macrophages	were	cultured	 in	X-Vivo	medium	(Lonza)	with	10	
ng/ml	 IFNα-2b	 (Intron	A,	Merck)	or	100	ng/ml	 IFNλ1	 (Bristol-Myers	Squibb)	 for	5	
hours	and	then	further	challenged	with	the	TLR4	agonist	lipopolysaccharide	(100	ng/
ml;	LPS-SM	Ultrapure,	InvivoGen)	for	an	additional	6	or	24	hours	at	a	cell	density	of	
1x106 cells/ml. Cells were harvested at 4 hours for mRNA analysis, and supernatants 
were harvested at 24 hours for immunosorbent and further assays. In a fraction of 
the	assays,	10	ng/ml	IFNγ	(Miltenyi	Biotec)	was	supplemented	along	with	the	LPS	
addition for the production of bioactive IL-12 for later stimulation of NK cells.
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Stimulation and intracellular cytokine analysis of NK/NK92 cells
Isolated	primary	NK	cells	and	NK92	cells	were	stimulated	with	10	ng/ml	 IFNα-2b 
(Intron	A,	Merck)	or	100	ng/ml	IFNλ1	(Bristol-Myers	Squibb)	alone	or	in	combination	
with	100ng/ml	IL-18	(R&D	Systems)	for	5	hours	for	quantitative	PCR	or	overnight	for	
surface marker expression and intracellular cytokine production. Cellular activation 
and	surface	marker	expression	was	measured	using	flowcytometric	analysis	with	
anti-CD69-Pacific	 Blue	 (FN50,	 Biolegend),	 anti-NKG2A-PE	 (Z119,	 Beckman	
Coulter),	and	anti-NKG2D-PerCP	(ID11,	BD	Pharmingen).	
The	aforementioned	supernatants	of	monocyte-derived	macrophages	were	diluted	
in	a	1:1	 ratio	with	RPMI1640	containing	10%	FCS	and	used	 to	stimulate	primary	
NK	cells	and	NK92	cells	for	24	hours	with	the	supplementation	of	IL-18	(100	ng/ml).	
Antibodies	against	IFNαR1/2	(MRHAR-2,	Millipore)	and	IL-12p40	(C8.6,	eBioscience)	
were added for blocking and neutralizing purposes, respectively.
For	analysis	of	cytokine	production	in	NK	cells,	10	μg/ml	brefeldin	A	(Sigma)	was	
added after 18 hours and cells were incubated for an additional 3 hours. Samples 
were	then	fixed	with	2%	formaldehyde,	and	permeabilized	for	intracellular	staining	
with	anti-IFNγ-PE-Cy7	(eBioscience)	and	anti-TNF-PE	(BD	Pharmingen).	Cytokine-
producing	cells	were	detected	by	flow	cytometry	(FACS	Canto	II,	BD)	and	analyzed	
using	FlowJo	(Tree	Star	Incorperated).
NK cell CD107a degranulation
Isolated NK cells (0.1x106	cells/200	μl)	were	seeded	with	K562	cells	in	a	96	well	plate	
in	a	1:1	effector	to	target	ratio.	IFNα-2b	(10	ng/ml;	Intron	A,	Merck)	or	recombinant	
IFNλ1	 (100	 ng/ml;	 Bristol-Myers	 Squibb)	 as	 well	 as	 anti-CD107a-PE	 (H4A3,	 BD	
Pharmingen)	were	added	to	the	culture	and	after	90	minutes,	GolgiStop	(BD)	was	
added, followed by incubation for an additional 3.5 hours. Degranulated cells were 
detected	by	flow	cytometry	(FACS	Canto	II,	BD)	and	analyzed	using	FlowJo	(Tree	
Star	Incorporated).
Immunoassay for detection of cytokines in supernatants
The	 concentrations	 of	 various	 cytokines	 were	 measured	 in	 the	 supernatants	 of	
stimulated	 macrophages	 by	 the	 use	 of	 sandwich	 ELISAs	 specific	 for	 IL-12p40	
(clones	C8.6	and	C8.3,	Biolegend),	IL-12p70,	IL-23,	IL-27,	and	TNF	(Ready-Set-Go	
Kits,	eBioscience)	with	a	sensitivity	of	30	pg/ml,	4	pg/ml,	15	pg/ml,	64	pg/ml,	and	4	
pg/ml, respectively.
Quantification of IFNαR1/2, IFNλR1, and IL-12 family subunits mRNA expression
Total	 RNA	was	 isolated	 from	HEK293	R19,	 THP-1,	 and	NK92	 cell	 lines	 as	 well	
as	from	primary	human	hepatocytes	(isolated	from	healthy	donors	 livers),	primary	
NK cells, monocytes, and monocyte-derived macrophages using the RNeasy kit 
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(Qiagen)	and	cDNA	was	prepared	using	the	Primescript	cDNA	synthesis	kit	(Takara)	
from	 500	 ng	 RNA.	 All	 real-time	 PCR	 reactions	 were	 performed	 using	 a	 MyIQ5	
detection	system	(Bio-Rad)	and	relative	mRNA	expression	 levels	were	calculated	
using	 the	 housekeeping	 gene	GAPDH.	 The	 following	 primer/probe	 sets	 (Applied	
Biosystems)	or	forward/reverse	SYBR	Green	primer	sequences	were	used	for	the	
genes of interest: 
GAPDH	 (Hs00266705_g1),	 IFNαR1	 (Hs01066115_m1),	 IFNαR2 (Hs01022060_
m1),	IFNλR1	(Hs00417120_m1)	GZMB	(Hs01554355_m1)
IL-12p35:	Fw:	5’-CCACTCCAGACCCAGGAATG-3’,	Rv:	
5’-GACGGCCCTCAGCAGGT-3’
IL-12p40:	Fw:	5’-ACGGACAAGACCTCAGCCAC-3’,	Rv:	
5’-GGGCCCGCACGCTAA-3’
IL-23p19:	Fw:	5’-GAGCCTTCTCTGCTCCCTGAT-3’,	Rv:	
5’-AGTTGGCTGAGGCCCAGTAG-3’
IL-27p28:	Fw:	5’-GCGGAATCTCACCTGCCA-3’,	Rv:	
5’-GGAAACATCAGGGAGCTGCTC-3’
EBI-3:	Fw:	5’-CCGAGCCAGGTCCTACGTCC-3’,	Rv:	
5’-CCAGTCACTCAGTTCCCCGT-3’
Statistical analysis
Data	are	expressed	as	the	mean	value	±	standard	error	of	the	mean	(SEM)	unless	
indicated	otherwise.	Data	was	analyzed	with	Prism	5.0	software	(GraphPad)	using	
the	Mann-Whitney	U	 test	 to	compare	variables	between	 independent	groups	and	
the	 Spearman	 rank	 correlation	 coefficient	 test	 for	 nonparametric	 correlations.	 In	
all	analyses,	a	2-tailed	P	value	of	less	than	0.05	(confidence	interval	of	95%)	was	
considered	statistically	significant.
 
Results
IFNαR1/2 is expressed across primary NK cells, monocytes, and NK92/THP-1 
cell lines, whereas IFNλR1 is only expressed after monocyte to macrophage 
differentiation
The	direct	effects	of	IFNα	on	NK	cells	have	been	well	described	[9,	10],	but	the	ability	
of	IFNλ	to	act	on	NK	cells	has	received	little	attention.	To	address	this	issue,	our	first	
approach	was	to	determine	if	human	NK	cells	express	a	functional	IFNλ receptor. 
This	was	achieved	by	comparing	the	mRNA	expression	of	IFNα	and	IFNλ receptors 
on	primary	NK	cells	and	NK92	cells	by	quantitative	PCR	(qPCR).	A	HEK293	cell	
line	stably	transfected	to	express	IFNλ receptor mRNA as well as primary human 
hepatocytes,	 known	 to	 express	 the	 receptor	 and	 respond	 to	 IFNλ	 [19,	 20],	were	
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included	as	comparative	positive	controls,	while	 the	monocytic	THP-1	cell	 line	as	
well as primary human monocytes were included as negative controls. Although 
both	 IFNαR1	and	 IFNαR2	chains	were	ubiquitously	expressed	across	all	 primary	
cells	 and	 cell	 lines	 (Figure	 1A),	 IFNλR1 mRNA expression was not detected in 
either	primary	NK	or	NK92	cells	(Figure	1B).	Monocytes	were	also	devoid	of	IFNλR1 
expression; however, differentiation of monocytes to macrophages by culture with 
granulocyte	macrophage	colony-stimulating	factor	(GM-CSF)	resulted	in	an	induction	
and	continuous	upregulation	of	IFNλR1	over	a	6	day	period	(Figure	1C).	IFNαR1 and 
IFNαR2, both already highly expressed on monocytes, remained relatively unaltered 
across the differentiation process.
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Figure 1. IFNαR1/2 is expressed across primary NK cells, monocytes, and NK92/THP-1 cell lines, 
whereas IFNλR1 is only expressed after monocyte to macrophage differentiation. qPCR	assays	
for	IFNαR1,	IFNαR2 (both A),	and	IFNλR1 (B)	were	performed	on	THP-1	and	NK92	cell	lines	as	well	as	
the primary NK cells and monocytes, using primary hepatocytes and HEK293 cells stably transfected to 
express	IFNλR1 as positive controls. (C)	mRNA	expression	of	IFNαR1,	IFNαR2,	and	IFNλR1 measured 
in	monocytes	(n=6)	at	day	0,	2,	4,	and	6	of	culture	with	GM-CSF	to	induce	macrophage	differentiation.
IFNα, but not IFNλ1, is able to directly stimulate and enhance effector function 
in NK cells
To	further	investigate	NK	cell	responsiveness	to	type	III	IFNs,	isolated	primary	NK	
cells	 were	 incubated	 with	 either	 IFNα	 or	 IFNλ1 overnight and analyzed for their 
expression of various activation markers and inhibition/activation receptors, including 
CD69, an marker of lymphoid cell activation, and C-type lectin transmembrane 
receptors	NKG2A	and	NKG2D.	The	percentage	of	CD69	expressing	NK	cells	was	
increased	by	almost	seven-fold	in	IFNα	cultures	(76.3%)	compared	to	those	exposed	
to	medium	alone	(11.3%)	or	IFNλ1	(13.5%)	(Figure	2A)	while	expression	of	inhibitory	
receptor	NKG2A	remained	unaffected	in	all	conditions.	The	cytolytic	capacity	of	IFN-
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Figure 2. IFNα, but not IFNλ1, directly stimulates and enhances effector function in NK cells. (A, 
D)	Surface	marker	and	intracellular	FACS	analysis	of	CD69	(n=5),	NGK2A	(n=4),	IFNγ	(n=4)	in	isolated	
cells	that	were	stimulated	with	IFNα	or	IFNλ1	alone	or	in	combination	with	IL-18	overnight.	IFNα was able 
to	induce	NK	cell	activation	and	enhance	IL-18	induced	IFNγ	in	NK	cells,	whereas	IFNλ1 had no direct 
effect. (B, C)	The	cytolytic	capacity	of	IFN	stimulated	NK	cells	was	assessed	by	measuring	degranulation	
marker	CD107a	after	co-culture	with	target	cell	line	K562	(n=4),	and	by	qPCR	to	measure	mRNA	expres-
sion	of	protease	granzyme	B	(GZMB)	(n=4).	Elevated	levels	of	both	CD107a	and	GZMB	expression	were	
only	seen	in	the	IFNα condition.
stimulated NK cells was assessed by measuring the degranulation marker CD107a 
after co-culture with the target cell line K562, and by mRNA expression of protease 
granzyme	B	(GZMB).	NK	cells	exposed	to	IFNα during the 5 hour co-culture period 
with	K562	cells	expressed	higher	 levels	of	CD107a	 (32.2%)	while	co-culture	with	
IFNλ1	 (21.1%)	 showed	no	difference	 from	 the	medium	condition	 (19.8%)	 (Figure	
2B).	Stimulation	with	IFNα, in combination with IL-18, was also able to upregulate 
GZMB	expression	10-fold	after	5	hours,	whereas	IFNλ1 again remained ineffective 
(Figure	2C).	Lastly,	 isolated	primary	NK	cells	were	 incubated	with	either	 IFNα or 
IFNλ1,	 in	 addition	 to	 IL-18,	 overnight	 and	analyzed	by	 intracellular	 flowcytometry	
for	production	of	IFNγ	and	TNF	(Figure	2D).	In	contrast	to	IFNα,	IFNλ1 was unable 
to	directly	 increase	 the	 frequency	of	primary	NK	cells	producing	 IFNγ upon IL-18 
stimulation.	This	highlights	a	direct	action	of	IFNα on NK cells, resulting in activation, 
cytotoxicity,	and	cytokine	production,	that	does	not	exist	for	IFNλs, most likely due to 
the	absence	of	IFNλ receptor expression.
TLR-mediated IL-12 family cytokine expression is differentially modulated by 
IFNλ1 and IFNα in macrophages
The	 interactions	 between	 NK	 cells	 and	 other	 innate	 immune	 cells	 have	 been	
well documented in various diseases, with implications for anti-tumor and anti-
inflammatory	 responses	 [4-7].	 Although	 we	 determined	 that	 IFNλ1 is unable to 
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directly affect NK cells, an indirect effect was still feasible, exerted through cross-
talk	 between	macrophages	 and	NK	 cells	 in	 a	 cytokine-dependent	manner.	 First,	
monocyte	derived-macrophages,	primed	with	IFNα	or	IFNλ1, were further challenged 
with	TLR4	agonist	LPS	 for	an	additional	4	hours	 for	gene	expression	analysis	or	
24	 hours	 for	 immunoassay	 analysis	 of	 pro-inflammatory	 cytokines.	 To	 determine	
to	 what	 extent	 IFNλ1 stimulation regulates macrophage IL-12 related cytokine 
production,	qPCR	for	various	subunits	of	the	IL-12	family	were	performed.	As	shown	
in	Figure	3A,	increased	expression	of	IL12B	(encoding	IL-12p40),	IL23A	(IL-23p19),	
and	EBI3	was	 observed	 in	 IFNλ1/LPS-stimulated macrophages compared to the 
IFNα/LPS	 conditions.	 IL27A	 (IL-27p28)	mRNA	was	 upregulated	 by	 incubation	 of	
both	IFNα/LPS	and	IFNλ1/LPS,	whereas	IL12A	(IL-12p35)	mRNA	expression	was	
undetectable	in	all	conditions	(data	not	shown).	
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Figure 3. TLR-mediated IL-12 family of cytokines are differentially modulated by IFNλ1 and IFNα in 
macrophages. (A)	mRNA	(n=3)	and	(B, C)	protein	(n=13)	levels	of	the	IL-12	family	members	in	macro-
phages	stimulated	with	IFNα	or	IFNλ1 for 5 hours and then further challenged with LPS for an additional 
4	or	24	hours,	respectively.	IFNλ induced upregulation of IL12B, IL23A, IL27A, and EBI3 mRNA expres-
sion, but only IL-12p40 and IL-23 were detected at a protein level in the supernatants of these activated 
macrophages. (D)	The	addition	of	IFNγ to LPS stimulation of macrophages resulted in the production of 
bioactive	IL-12p70	(n=8).
To	 determine	 if	 the	 mRNA	 levels	 measured	 correlated	 with	 protein	 production,	
cytokine levels of IL-12 family members were measured by ELISA in the supernatants 
of stimulated macrophages. Increased levels of IL-12p40 and IL-23 were detected in 
the	supernatants	of	IFNλ1/LPS-stimulated	cells,	in	contrast	to	IFNα/LPS stimulation 
(Figure	 3B-C).	 IL-12p70	 and	 IL-27	 were	 not	 detected	 in	 any	 condition,	 partially	
explained	 by	 the	 lack	 IL-12p35	 mRNA	 expression	 previously	 seen	 by	 qPCR.	
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Bioactive	IL-12	was	produced	by	supplementation	of	IFNγ	to	the	TLR	challenge	of	
macrophages	after	 the	 initial	priming	with	 IFNλ1,	but	not	after	 IFNα pre-treatment 
(Figure	 3D).	 Overall,	 differences	 between	 IFNα	 and	 IFNλ1	 in	 modulating	 TLR	
induced production by macrophages were observed across multiple members of the 
IL-12 family.
IFNλ1-mediated IL-12 production by macrophages induces IFNγ production by 
NK and NK92 cells
To	test	the	effects	of	IFNк	on	cross-talk	between	macrophages	and	NK/NK92	cells,	
supernatants	from	macrophages	incubated	with	IFNα	or	IFNλ1 in combination with 
LPS	and	 IFNγ were used to stimulate primary NK cells and NK92 cells overnight 
supplemented	with	IL-18.	The	NK	cell/NK92	effector	function	was	then	determined	by	
intracellular	FACS	analysis	of	IFNγ	and	TNF	production	in	the	respective	conditions.	
Supernatants	 from	IFNλ1/LPS-stimulated macrophages were able to increase the 
percentage	of	IFNγ-producing	cells,	but	not	TNF-producing	cells	(data	not	shown)	
when compared with 3 NK cell donors treated with supernatants from medium/LPS- 
stimulated	macrophages	(Figure	4A,	B).	The	same	was	true	for	NK92	cell	cultures,	
where	a	2.5-fold	increase	in	IFNγ positive cells was observed compared to NK92 cell 
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Figure 4. IFNλ1 mediated 
IL-12 production of 
macrophages is able to 
induce effector function 
in NK and NK92 cells. 
(A-C)	 Supernatant	 from	
macrophages treated with 
IFNα	 or	 IFNλ1 in combination 
with	LPS	and	 IFNγ were used 
to stimulate isolated primary 
NK	 cells	 from	 3	 donors	 (n=5	
per	 donor)	 and	 NK92	 (n=8)	
cells overnight supplimented 
with IL-18. Supernatants from 
macrophages treated with 
IFNλ1	 induced	 a	 significantly	
higher	 frequency	 of	 IFNγ-
producing NK cells compared 
to the medium control, and 
NK92 cells showed an increase 
in	 IFNγ-producing cells 
compared to both the medium 
control	 and	 IFNα conditions. 
(D)	 Individual	 results	 for	
supernatants of multiple donors 
for	macrophage-mediated	IFNγ 
production in NK92 cells. 
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cultures	treated	with	supernatants	from	both	medium/LPS	and	IFNα/LPS stimulated 
macrophages	 (p=0.008)	 (Figure	 4C,	 D).	 It	 should	 be	 noted	 that	 increased	 IFNγ 
production	was	also	seen	with	the	IFNα pre-treated supernatants; this can partially 
be	attributed	to	the	direct	action	of	IFNα on NK and NK92 cells. 
IFNγ production in NK92 cells is IL-12 dependent in IFNλ1/LPS-stimulated but 
not in IFNα/LPS-stimulated macrophages
To	determine	the	mechanism	of	action	for	induction	of	NK92	effector	function	by	IFN-
stimulated macrophages, various blocking and neutralization assays were performed. 
Neutralization	of	IL-12p40	in	IFNλ1/LPS-stimulated macrophages abrogated IL-12-
mediated	 IFNк	production	 in	NK92	cells	 (p=0.01)	while	neutralization	of	 IL-12p40	
in	 IFNα/LPS-stimulated	 macrophages	 partially	 abrogated	 IL-12-mediated	 IFNк	
production	 in	NK92	cells	(p=0.01)	(Figure	5A-C).	Blocking	of	 the	IFNα receptor in 
macrophages	stimulated	with	IFNα/LPS	showed	a	strong,	but	not	significant,	trend	
in	 reduction	 in	 IFNγ	 production	 in	 NK92	 cells(p=0.065),	 however	 no	 effect	 was	
observed	after	stimulation	with	IFNλ1/LPS.	These	results	confirm	the	direct	action	of	
IFNα	on	NK	cell	effector	function,	and	demonstrate	that	IFNλ1 acts indirectly on NK 
cells through macrophage-derivedIL-12 production.
Discussion
The	focus	of	this	study	was	to	investigate	the	ability	of	IFNλ1 to modulate the activity 
of	NK	cells	 in	both	a	direct	and	an	 indirect	capacity.	We	demonstrate	 that	unlike	
IFNα,	IFNλ1 is unable to directly activate and promote effector function in NK cells, 
presumably	due	to	the	lack	of	cellular	expression	of	the	type	III	IFN	receptor	complex.	
However,	 IFNλ1	 priming,	 in	 combination	 with	 TLR4	 activation,	 is	 able	 to	 induce	
select members of the IL-12 family of cytokines in monocyte-derived macrophages. 
We	further	show	that	IFNλ1 is able to indirectly affect NK cells through macrophage-
mediated	IL-12	production,	ultimately	inducing	IFNγ production.
As	 a	 first	 step,	we	 demonstrate	 that	NK	 cells	 do	 not	 express	 the	 IFNλR1 chain, 
and	that	consequently	 IFNλ1	 is	unable	 to	directly	act	on	 this	cell	population.	This	
is	 in	 contrast	 to	 previous	 reports	 suggesting	 that	 type	 III	 IFNs	have	an	 inhibitory	
effect	on	IFNγ	production	upon	IL-12/IL-15	stimulation	[21,	22].	This	study	not	only	
investigated	the	effects	of	type	I	and	III	IFNs	on	cytokine	production,	but	also	on	NK	
cell	activation	and	cytotoxicity.	We	showed	that	IFNα is able to activate as well as 
promote	cytolytic	action	and	IFNγ	production	by	NK	cells,	whereas	IFNλ1 was unable 
to	alter	any	of	these	parameters.	These	findings	are	corroborated	in	a	response	to	
Dring	 et.	 al.	 that	 questioned	 their	 original	 findings,	 also	 reporting	 the	 absence	of	
IFNλR1	receptor	expression	in	primary	NK	cells	and	the	inability	of	IFNλ to induce 
IFNγ	production	or	degranulation	in	any	capacity	[23,	24].	Combined,	these	results	
convincingly	show	that	IFNλ lacks the ability to directly activate and affect multiple 
facets of NK cell effector function.
We	 do,	 however,	 propose	 for	 the	 first	 time	 an	 indirect	 link	 between	 IFNλ1 and 
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NK	cells,	mediated	 through	 the	stimulation	of	macrophages.	This	 interaction	was	
unique	to	IFNλ1,	due	to	differences	in	immunomodulatory	properties	between	IFNα 
and	 IFNλ1,	 specifically	 in	 their	 regulation	 of	 various	 subunits	 of	 the	 IL-12	 family	
of	 cytokines	 (IL12B,	 IL23A,	 EBI3)	 in	 macrophages.	 In	 contrast	 to	 IFNλ1, which 
promoted	the	production	of	specific	IL-12-related	cytokines,	IFNα actually reduced 
macrophage-facilitated	IL-12	production.	Through	the	blocking	of	IFNαR1/2 on NK 
cells	and	neutralizing	IL-12	in	supernatants	from	IFN-primed	macrophages,	we	were	
able	to	show	that	enhancement	of	NK-celled	derived	IFNγ	production	by	IFNα was 
mainly mediated by a direct interaction with NK cells, and minimally affected by IL-
12	neutralization.	IFNλ1, on the other hand, was dependent on IL-12, with almost 
complete	abrogation	of	IFNγ-producing NK cells after IL-12 neutralization. Despite 
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Figure 5. Macrophage-mediated IFNγ production in NK92 cells is IL-12-dependent in IFNλ1/LPS but 
not in IFNα/LPS-stimulated macrophages. (A,B)	Neutralization	of	IL-12p40	in	IFNλ1/LPS-stimulated 
macrophages	abrogated	 IL-12-mediated	 IFNγ	 production	 in	NK92	 cells	 but	 only	 partial	 reduced	 IFNγ 
production	 after	 IFNα/LPS	stimulation.	Blocking	of	 the	 IFNα	 receptor	 reduced	 the	 frequency	of	 IFNγ-
producing	NK92	cells	after	 treatment	with	supernatants	 from	macrophages	stimulated	with	 IFNα/LPS, 
but	had	no	effect	on	the	IFNλ1/LPS	stimulations	(n=8).	(C)	Individual	results	for	IL-12p40	neutralization	in	
supernatants	from	multiple	donors	for	macrophage-mediated	IFNγ production in NK92 cells.
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having	different	modes	of	action,	both	the	direct	effects	of	IFNα and indirect effects 
of	IFNλ1 were found to be independent of cell-to-cell contact since soluble factors 
in	 IFN/TLR-challenged	macrophage	supernatants,	supplemented	with	 IL-18,	were	
sufficient	 to	 induce	 IFNγ production in NK cells. Previous publications have also 
described a role for IL-12-related cytokines in macrophage-NK cell interactions. 
Specifically,	 macrophage-derived	 expression	 of	 IL-23	 and	 IL-27	 induced	 the	
production	of	IFNγ	and	GM-CSF	in	NK	cells	[25-27].	Although	the	production	of	IL-
23	and	IL-27	was	monitored	in	IFNλ-stimulated macrophages, the effects on NK cell 
function was not explored in this study.
In	contrast	 to	 the	ubiquitous	expression	of	 the	 IFNαR1/2 subunits across various 
cell	populations,	resting	monocytes	do	not	express	IFNλR1 until after the initiation 
of	macrophage	 differentiation	 via	 culture	 with	 GM-CSF,	 resulting	 in	 an	 induction	
and	 constant	 upregulation	 of	 receptor	 expression.	 The	 expression	 of	 the	 IFNα 
receptor	on	NK	cells	and	the	ability	of	IFNα to directly activate these cells, promoting 
degranulation,	cytotoxicity,	and	IFNγ	production,	is	distinct	from	the	effects	of	IFNλ. 
These	 features	of	 IFNα activation make it an important mediator in the induction 
of an immediate immune response upon challenge in the peripheral as well as the 
tissue	 compartments.	 In	 contrast,	 the	 restricted	 expression	 of	 IFNRλ1 prevented 
a	 direct	 action	 of	 IFNλ on both NK cells and monocytes, with only responses 
observed	on	differentiated	macrophages.	This	suggests	that	IFNλ might play a more 
prominent	 role	 in	 tissue-specific	 responses	as	 compared	 to	 the	periphery,	 in	 line	
with	other	studies	describing	that	IFNλ1 has a more delayed and prolonged effect 
through	 activation	 of	 specific	 tissue-resident	 cells,	 specifically	 epithelial	 cells	 and	
hepatocytes	[19,	20].	TLR-dependent	crosstalk	between	NK	cells	and	macrophages	
has	already	been	described	in	tissue-specific	interactions	in	the	liver.	TLR-activated	
liver-resident macrophages have been shown to exert effector function in NK cells, 
specifically	by	inducing	their	activation	and	IFNγ	production	[28].	The	ability	of	IFNλ1 
to	modulate	TLR-induced	crosstalk	between	macrophages	and	NK	cells	could	have	
implications	in	the	enhancement	of	IFNγ production by liver NK cells, a critical factor 
in	 the	 inhibition	of	HCV	 replication	and	 in	 the	 response	 to	HBV	 infection	 [29-31].	
The	delayed	activation	of	NK	cells	by	 IFNλ, mediated through macrophage IL-12 
production, could explain the observed differences in biological functions between 
the	 type	 I	and	 type	 III	 IFNs	 in	 inflammatory	 responses,	but	also	by	differences	 in	
kinetics or sustainability of the response. It should be noted that a similar kinetic on 
innate	immune	response	activation	by	type	III	IFNs	has	been	previously	described	
for	DCs	and	hepatocytes	[20,	24,	32].
Collectively,	this	study	provides	the	first	example	of	an	indirect	regulatory	effect	unique	
to	 IFNλ1, mediated through macrophage cytokine production and independent of 
cell-to-cell	contact.	This	is	distinct	from	IFNα, which directly activates NK cells, and 
can	 inhibit	macrophage	IL-12	production.	Further	studies	of	both	 the	antiviral	and	
immunoregulatory	effects	of	IFNλ1 are warranted to understand the basic biology of 
type	III	IFNs	and	their	activities	as	therapeutic	agents.
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Abstract
Individuals	who	are	chronically	infected	with	the	hepatitis	B	virus	(HBV)	are	highly	
heterogenous	with	 respect	 to	 serum	 levels	of	HBV	DNA,	HBV	particles	and	viral	
proteins. Since circulating leukocytes, such as monocytes, are constantly exposed 
to these viral components, it is likely that the functionality of these cells is affected. 
However,	 at	 present,	 little	 information	 is	 available	 on	 the	 consequences	 of	 the	
interaction	 between	 monocytes	 and	 viral	 components.	 Therefore,	 we	 examined	
the in vitro	effects	of	HBV	surface	antigen	 (HBsAg)	on	monocytes	and	evaluated	
whether	these	effects	were	reflected	in vivo.
We	observed	that	in vitro HBsAg exposure of monocytes induced robust production 
of	 IL-6	 and	 TNF.	 However,	 between	 chronic	 HBV	 patients	 with	 distinct	 levels	 of	
serum	HBsAg,	HBV	early	antigen	(HBeAg),	and	HBV	DNA,	TLR-induced	monocyte	
cytokine production did not differ. Importantly, HBsAg-induced cytokine production 
by monocytes was similar between patients and healthy controls showing that earlier 
in vivo exposure to HBsAg does not affect the in vitro response. Additionally, we 
show that IL-10 is able to inhibit cytokine production by HBsAg-induced monocytes.
In conclusion, we demonstrate that monocytes can recognize and respond to 
HBsAg,	resulting	in	vigorous	pro-inflammatory	cytokine	production	in vitro. However, 
phenotype	and	function	of	the	monocyte	compartment	in	chronic	HBV	patients	are	
not	influenced	by	differences	in	levels	of	serum	viral	components,	suggesting	that	
regulatory mechanisms are active to avoid excessive in vivo monocyte activation.
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 Introduction
Hepatitis	B	virus	(HBV)	 infection	 is	a	major	health	problem.	Although	the	majority	
of infected individuals clear the virus spontaneously, a fraction of patients is unable 
to	 clear	 the	 virus	 and	 develops	 a	 chronic	 form	 of	 hepatitis.	 Their	 numbers	 have	
already	reached	over	240	million	people	[1].	In	time,	persistence	of	HBV	can	lead	
to	progressive	 liver	damage,	which	 increases	the	patient’s	risk	of	developing	 liver	
cirrhosis,	liver	failure	and	liver	cancer.	Chronicity	of	HBV	is	the	result	of	a	complex	
interaction	between	the	replicating	virus	and	an	inadequate	immune	response	[2-4].	
After infection, viral replication takes place inside hepatocytes, and the secretion of 
infectious	virions	can	take	place	for	decades	at	high	rates,	and	consequently	HBV	
DNA,	as	well	as	viral	proteins,	 like	HBV	early	antigen	 (HBeAg)	and	HBV	surface	
antigen	(HBsAg),	can	be	easily	detected	in	serum.	The	levels	of	these	clinical	markers	
may	fluctuate	over	time	and	are	a	reflection	of	disease	activity	and	commonly	used	
to	define	the	patients’	disease	stage	[3,4].
Although circulating monocytes represent about 10% of leukocytes in human 
blood,	 relatively	 little	 is	known	on	 the	consequences	of	chronic	viral	 infections	on	
monocytes.	In	HIV	infections	impaired	monocyte	functions	have	been	reported	[5,6],	
and	we	 recently	 demonstrated	 altered	Toll-like	 receptor	 (TLR)	 responsiveness	 of	
monocytes	obtained	from	patients	with	chronic	HCV	infections	[7,8].	Monocytes	can	
be divided into two distinct subpopulations that are discerned based on their surface 
expression of CD14 and CD16. CD14highCD16- monocytes make up the majority 
(80-90%)	of	blood	monocytes,	and	have	been	reported	to	produce	relatively	high	IL-
10	and	weak	TNF	levels,	whereas	the	CD14+CD16+ subpopulation produces higher 
levels	of	pro-inflammatory	cytokines,	such	as	TNF	and	IL-1β	[9,10].	
Also	in	chronic	HBV,	some	studies	reported	modulation	of	the	monocyte	compartment	
as	a	result	of	the	disease.	Depending	on	the	clinical	phase	of	the	chronic	HBV	infection	
altered	monocyte	subsets	frequencies	were	reported	[11,12].	Moreover,	PBMC	from	
HBeAg-positive	patients	produced	 less	TNF	and	 IL-6	upon	stimulation	with	TLR2	
agonists	 as	 compared	 to	HBeAg-negative	 patients	 [13],	 which	was	 explained	 by	
lower	expression	of	TLR2	in	HBeAg-positive	patients	[14].	Furthermore,	exposure	of	
monocytes	to	HBsAg	suppressed	LPS-induced	TNF	and	IL-1β	production	[15],	while	
others	reported	that	HBsAg	has	an	immunostimulatory	effect	by	inducing	TNF	and	
IL-10	production	[16].	Since	the	consequences	of	constant	exposure	of	peripheral	
monocytes to viral particles and the viral proteins HBeAg and HBsAg are still not 
completely understood, we here studied the in vitro and in vivo effects of these 
molecules on the phenotype and function of peripheral monocytes.
Materials and methods
Patients and ethics statement
Peripheral	 blood	 was	 collected	 from	 patients	 chronically	 infected	 with	 HBV	 who	
visited the outpatient clinic of the Erasmus Medical Center. Patients eligible for the 
study were positive for HBsAg, and were not on-treatment before blood samples 
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were	 taken	 for	 this	 study.	 Patients	 co-infected	 with	 human	 immunodeficiency	
virus, hepatitis A virus, hepatitis C virus or hepatitis D virus were excluded. Patient 
characteristics	 are	 presented	 in	 Table	 1.	 The	 medical	 ethical	 committee	 of	 the	
Erasmus MC University Medical Center approved the study and all patients gave 
written informed consent before inclusion. 
Laboratory measurements
HBsAg levels and HBeAg levels were measured in sera from a total of 45 chronic 
HBV	patients	using	the	Architect	HBsAg	assay	(Abbott	Laboratories,	Abbott	Park,	
IL,	USA;	range	0.05–250	IU/ml)	or	HBeAg	assay	(Abbott	Laboratories;	interpreted	
using	 a	 ratio	 of	 the	 sample	 relative	 light	 unit	 (RLU)	 rate	 to	 the	 cut-off	 RLU	 (S/
CO)).	HBV	DNA	levels	were	measured	in	serum	using	the	Cobas	TaqMan	(Roche	
Diagnostics;	 lower	 limit	of	quantification,	20	IU/ml).	ALT	was	measured	as	part	of	
standard	diagnostic	procedures.	HBV	genotype	was	determined	by	means	of	 the	
INNO-LiPA	assay	(Innogenetics,	Gent,	Belgium).	
Flow cytometric analysis of monocyte subpopulations
To	determine	the	frequencies	of	monocyte	subpopulations,	whole	blood	was	lysed	
and stained with antibodies against CD14 and CD16 (61D3 and 3G8, respectively; 
both	eBioscience,	San	Diego,	CA,	USA),	and	measured	by	flow	cytometry	using	a	
BD	FACSCanto	II	(BD	Biosciences,	San	Diego,	CA,	USA).	Data	was	analyzed	using	
FlowJo	7.6.5	software	(Tree	Star,	Inc.,	Ashland,	OR,	USA).
Monocyte stimulation and ELISA
Peripheral	 blood	 was	 collected	 from	 chronic	 HBV	 patients	 or	 healthy	 controls	 in	
sodium-heparin	 tubes,	and	PBMC	were	 isolated	by	Ficoll-Paque	 (GE	Healthcare,	
Uppsala,	Sweden)	gradient	centrifugation,	and	frozen.	PBMC	(1x106	cells/ml)	were	
 
 Group 1 Group 2 Group 3 
Number 14 20 11 
Sex	(F:M) 5:9 11:9 6:5 
Age 41.1 (24-59)a 35.1 (20-53) 31.4 (18-48) 
ALT	(IU/L) 83 (21-366) 37 (15-102) 111 (22-443) 
Viral	load	(IU/mL) 63.8x106 (28,300-6.0x108) 1,767 (20-6,490) 1.0x109 (29,200-2.6x109) 
HBeAg	level	(IU/mL) 7.96 (0-66.65) 0.17 (0-2.38) 944 (389-3,259) 
HBsAg	level	(IU/mL) 10,341 (56-31,660) 3032 (108-17,448) 53,581 (542-125,820) 
Table 1
Patient characteristics
a	Values	for	age,	ALT,	viral	load,	HBeAg	level	and	HBsAg	level	are	mean	(minimum	–	maximum	value)
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thawed	and	stimulated	in	96-well	plates	in	250	μl	X-VIVO	culture	medium	(Lonza,	
Verviers	 Sprl,	 Belgium)	 containing	 penicillin/streptomycin	 (Gibco,	 Paisley,	 UK),	
L-glutamin	(Lonza),	and	HEPES	(Lonza)	as	described	previously	[7]:	the	cells	were	
cultured	either	unstimulated	or	 stimulated	with	100	ng/ml	Toll-like	 receptor	 (TLR)	
2	 ligand	Pam3CSK4,	100	ng/ml	TLR4	 ligand	LPS	 (both	 from	 Invivogen),	1	μg/ml	
TLR7/8	 ligand	R848	 (Enzo	 Life	Sciences,	Antwerp,	Belgium),	 or	 human	 plasma-
derived	pHBsAg	Ay	(American	Research	Products	(ARP),	Waltham,	MA,	USA)	at	
a concentration of 5 μg/ml unless mentioned otherwise. In the experiment shown in 
Figure	S1,	in	parallel	to	plasma-derived	HBsAg	Ay	(5	μg/ml)	stimulation,	PBMC	were	
also	stimulated	with	recombinant	HBsAg	(1	μg/ml;	Prospec,	Rehovot,	Israel)	for	5	
hours. In the IL-10 inhibition experiment, 10 ng/ml IL-10 (Miltenyi Biotec, Bergisch 
Gladbach,	Germany)	or	medium	as	a	negative	control,	was	added	at	the	same	time	
as	pHBsAg	(1	μg/ml;	ARP).	After	a	total	of	18	hours	of	culture,	supernatants	were	
harvested,	and	cytokine	production	(IL-6	and	TNF)	was	determined	by	ELISA	(all	
kits	from	eBioscience).	
Intracellular cytokine staining
The	 frequency	 of	 cytokine-producing	 monocytes	 was	 determined	 by	 measuring	
cytokines	 with	 intracellular	 cytokine	 staining	 using	 flow	 cytometry.	 PBMC	 were	
stimulated	with	TLR	ligands	or	pHBsAg	Ay	(ARP)	as	described	above,	After	culturing	
for	2	hours,	brefeldin	A	(10	μg/ml;	Sigma-Aldrich,	St.	Louis,	MO,	USA)	was	added	
to	all	wells.	After	 16	hours,	 the	 cells	were	harvested,	 incubated	with	LIVE/DEAD	
Fixable	Aqua	Dead	Cell	Stain	(Invitrogen,	Ltd.,	Paisley,	United	Kingdom),	fixed	with	
2%	formaldehyde,	permeabilized	with	0.5%	saponin	(VWR,	West	Chester,	PA,	USA)	
and	 stained	 for	 IL-6	 (MQ2-13A5;	 eBioscience),	 and	 TNF	 (Mab11;	 eBioscience),	
and the surface markers CD14 and CD45 (61D3 and HI30, respectively; both 
eBioscience).	Flow	cytometric	data	was	acquired	and	analyzed	as	described	above.
Statistical analysis
To	 compare	 clinical	 groups,	 groups	 were	 analyzed	 using	 the	 non-parametric	
Kruskal-Wallis	test,	followed	by	Dunn’s	multiple	comparisons	test.	The	frequencies	
of cytokine-producing cells determined at different HBsAg doses were normalized 
to the values obtained under the 1 μg/ml HBsAg condition. Differences between the 
cytokine	expression	of	the	healthy	individuals	and	the	group	with	chronic	HBV	patients	
were	analyzed	using	the	Mann-Whitney	U	test.	A	P-value	of	<0.05	was	considered	
statistically	significant.	Graphpad	Prism	5	was	used	for	statistical	analysis.
Results
HBsAg induces cytokine production by monocytes in vitro
To	 investigate	 the	 modulatory	 effect	 of	 HBsAg	 on	 the	 functionality	 of	 blood	
monocytes, PBMC from healthy individuals were cultured in the presence of HBsAg. 
We	 compared	 monocytes,	 defined	 in	 Figure	 1A	 as	 CD45	 and	 CD14-expressing	
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cells	with	their	characteristic	FSC	and	SSC	profile,	after	overnight	culture	with	either	
medium	or	HBsAg.	As	shown	in	Figure	1B	and	quantified	in	Figure	1C,	the	frequency	
of cytokine-producing monocytes was increased upon exposure to HBsAg in vitro. 
Upon exposure to HBsAg in vitro,	the	mean	frequency	of	IL-6	and	TNF-producing	
monocytes was increased from 2.6% to 61% and from 3.5% to 59%, respectively 
(Figure	1C).	The	percentages	of	monocytes	producing	 IL-12p40,	 IL-15,	and	IL-10	
were relatively low, while the chemokines CCL4 and CXCL8 were strongly induced 
(data	not	shown).
Figure 1. HBsAg induces cytokine production by monocytes. PBMC from healthy individuals were 
stimulated	with	HBsAg.	After	overnight	incubation,	cells	were	stained	for	CD14,	IL-6	and	TNF.	(A)	Gating	
strategy:	Viable	monocytes	were	identified	on	the	basis	of	their	forward-sideward	scatter	profile	and	their	
membrane expression of CD14. (B)	Representative	intracellular	cytokine	stainings	are	presented	showing	
IL-6	and	TNF-producing	monocytes	upon	 incubation	with	medium	and	HBsAg.	(C)	The	frequencies	of	
monocytes	producing	IL-6	or	TNF	upon	incubation	with	medium	or	HBsAg	are	presented	(n=9,	**	p<0.01,	
Wilcoxon	signed	rank	test).
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The ratio of monocyte subpopulations is comparable in chronic HBV patients 
with different levels of HBV DNA or serum HBV protein levels
The	 stimulatory	 effect	 of	 HBV	 proteins	 on	 blood	 monocytes	 upon	 exposure	 in 
vitro	may	 have	 consequences	 for	 the	 functionality	 of	 the	monocyte	 compartment	
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in	patients	chronically	 infected	with	HBV.	To	examine	this,	we	selected	groups	of	
chronic	HBV	patients	differing	 in	the	 levels	of	HBV	DNA,	HBeAg,	and	HBsAg.	As	
shown	in	Figure	2A,	three	groups	were	identified	based	on	HBV	DNA	and	HBeAg	
levels.	 The	 experimental	 groups	 differed	 not	 only	 in	 the	 levels	 of	HBV	DNA	and	
HBeAg,	but	also	in	HBsAg	levels	(Figure	2B).	We	defined	group	1	as	having	low	or	
undetectable	HBeAg	levels,	and	intermediate	HBV	DNA	levels	and	HBsAg	levels;	
group	2	as	having	low	or	undetectable	HBeAg,	and	low	HBV	DNA	and	HBsAg	levels;	
group	3	as	having	high	levels	of	HBeAg,	HBV	DNA	and	HBsAg	(Figure	2;	Table	1).	
Patient groups did not differ with respect to age or gender.
Figure 2. Chronic HBV patients divided into three groups based on HBV DNA and HBeAg levels. 
HBeAg	levels,	HBsAg	levels	and	HBV	DNA	were	measured	in	45	chronic	HBV	patients.	(A)	HBV	patients	
were	divided	into	an	HBeAgnegative/HBeAglow	group	(<100	IU/ml),	and	an	HBeAghigh	group	(>100	IU/
ml).	Based	on	these	two	groups	and	HBV	DNA	levels,	three	groups	of	chronic	HBV	patients	were	defined	
(groups	1,	2	and	3).	(B)	Groups	1-3	were	compared	based	on	HBV	DNA	levels,	HBeAg	levels	and	HBsAg	
levels.	***	p<0.0001,	Kruskal-Wallis	test,	followed	by	Dunn’s	multiple	comparison	test.
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Monocytes can be divided on the basis of their expression of CD14 and CD16, 
and	these	subpopulations	have	been	reported	to	exert	distinct	functions	[9,10].	To	
examine	whether	the	chronic	HBV	patients	in	group	1,	2	and	3	differed	in	monocyte	
composition,	we	first	determined	the	frequency	of	the	monocytes	expressing	CD14	
and	CD16	in	fresh	peripheral	blood	samples	from	patients.	As	shown	in	Figure	3,	
the ratio of CD14++CD16- and CD14+CD16+ monocytes did not differ between the 
distinct	patient	groups,	indicating	that	chronic	exposure	to	different	amounts	of	HBV	
DNA, HBsAg and HBeAg did not lead to changes in the composition of the monocyte 
compartment.
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Figure 3. Different HBV DNA, HBeAg and HBsAg levels do not alter the frequency of monocyte 
subpopulations.	Whole	blood	samples	from	chronic	HBV	patients	were	stained	for	CD14	and	CD16	to	
analyze	frequencies	of	the	monocyte	CD14++CD16- and CD14+CD16+ subpopulations. (A)	Gating	strategy:	
monocytes	were	identified	on	the	basis	of	their	forward-sideward	scatter,	and	divided	into	CD14++CD16- 
and CD14+CD16+ populations. (B)	The	frequencies	of	monocyte	subpopulations	were	compared	between	
groups	1-3	(n=45).
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Monocyte function does not differ between HBV patient groups
Since we showed that in vitro exposure of monocytes to HBsAg strongly induced 
the	 production	 of	 IL-6	 and	TNF,	we	 explored	whether	 the	 function	 of	monocytes	
was affected by continuous exposure of monocytes to viral proteins in patients. 
To	examine	this,	PBMC	obtained	from	the	patients	with	distinct	serum	HBV	DNA,	
HBeAg	and	HBsAg	levels	were	incubated	overnight	with	medium	or	the	TLR2	ligand	
Pam3CSK4,	the	TLR4	ligand	LPS,	or	the	TLR7/8	ligand	R848,	and	cytokine	production	
was measured by intracellular cytokine staining and ELISA. A high percentage of 
monocytes	produced	 IL-6	and	TNF	after	TLR	stimulation	 (Figure	4A	and	4B).	As	
shown	in	figure	4B,	TLR	ligation	of	PBMC	from	chronic	HBV	patients	with	distinct	
serum	 levels	of	HBV	DNA,	HBeAg	and	HBsAg	 resulted	 in	similar	percentages	of	
IL-6	and	TNF-producing	monocytes.	This	was	observed	for	agonists	against	TLR2,	
TLR4	and	TLR7/8.	Importantly,	also	the	baseline	frequencies	of	cytokine-producing	
monocytes were not different between the three patient groups, suggesting 
that circulating monocytes from patients were not at a higher activation state as 
evidenced by spontaneous cytokine secretion. Next, detailed data-analysis using 
SPICE software was performed to evaluate the simultaneous production of multiple 
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cytokines	by	individual	TLR-stimulated	monocytes	[17].	Again,	no	differences	were	
observed	when	comparing	the	patient	groups	(data	not	shown).	Besides	frequencies,	
we	also	evaluated	the	intensity	of	the	fluorescent	signals	representing	the	amounts	
of cytokines produced by monocytes upon stimulation, and also these parameters 
were	not	different	between	the	patient	groups	(data	not	shown).	In	line	with	the	above	
findings,	also	the	amounts	of	TLR-induced	IL-6	and	TNF	produced	by	monocytes,	as	
measured	by	ELISA,	were	similar	in	the	three	groups	of	chronic	HBV	patients	that	
differed	in	their	serum	levels	of	HBV	DNA,	HBsAg	and	HBeAg	(Figure	4C).
Figure 4. Monocytes from different patient groups display similar TLR-induced cytokine produc-
tion. PBMC	from	patients	with	distinct	HBV	DNA,	HBeAg	and	HBsAg	profiles	were	incubated	overnight	
with medium, Pam3CSK4, LPS or R848 to investigate the in vivo	effect	of	HBV	DNA	levels,	HBeAg	levels	
and HBsAg levels on monocyte function. (A)	Gating	strategy:	viable	monocytes	were	 identified	on	the	
basis	of	 their	 forward-sideward	scatter	profile,	and	subsequently	CD14+ monocytes were gated to as-
sess	cytokine	production	by	intracellular	cytokine	staining	(n=45).	(B,	left)	The	frequencies	of	monocytes	
producing	IL-6	and	TNF	upon	medium	or	TLR	ligand	stimulation	were	compared	between	groups	1-3.	
(B,	right)	Representative	dot-plots	showing	cytokine-positive	cells	induced	by	medium	and	R848	in	one	
patient. (C)	The	cytokine	levels	measured	in	supernatant	by	ELISA	(in	ng/ml)	upon	stimulation	of	PBMC	
were	compared	between	patient	groups	1-3	(n=30).
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Monocytes obtained from patients exposed in vivo to distinct levels of HBV 
DNA, HBeAg and HBsAg, react similarly to HBsAg stimulation in vitro
In contrast to the in vitro	findings	where	exposure	of	monocytes	to	HBsAg	leads	to	high	
cytokine induction, comparison of circulating monocytes obtained from patients with 
different levels of viral proteins in vivo,	showed	no	higher	spontaneous	or	TLR-induced	
cytokine induction. One possible explanation could be that continuous exposure of 
patient’s	leukocytes	to	HBV	proteins	makes	them	less	sensitive	to	re-exposure.	To	
examine this, we compared the in vitro effects of HBsAg on monocytes obtained from 
chronic	HBV	patients	and	from	age-	and	sex-matched	healthy	individuals.	Exposure	
of	PBMC	from	patients	to	HBsAg	resulted	in	IL-6	and	TNF	production,	depicted	by	
IL-6-positive	(86.1±	2.0%)	and	TNF-positive	(62.1±	6.6%)	CD14+ monocytes, while 
also	monocytes	from	healthy	individuals	were	positive	for	IL-6	(78.2±	5.4%)	and	TNF	
(55.4±	9.0%).	Next,	to	examine	whether	monocytes	from	patients	and	controls	were	
equally	sensitive	to	the	stimulatory	effect	of	HBsAg,	cells	were	stimulated	with	a	dose-
range	of	the	HBsAg	protein.	As	shown	in	Figure	5,	monocytes	from	healthy	controls	
and	HBV	patients	were	equally	sensitive	 to	HBsAg	at	 low,	 intermediate	and	high	
doses	of	HBsAg,	and	consequently	the	responsiveness	of	monocytes	to	overnight	
HBsAg stimulation was similar between both groups. Likewise, HBsAg stimulation of 
PBMC	for	5	hours,	instead	of	18	hours,	also	showed	similar	frequencies	of	IL-6	and	
TNF-producing	monocytes	between	healthy	controls	and	HBV	patients,	as	shown	in	
Figure	S1.	This	supplementary	figure	shows	not	only	stimulation	with	pHBsAg	Ay	as	
used throughout the paper, but also with recombinant HBsAg, both resulting in no 
difference between the groups. Also, assessment of overnight cytokine production 
by	ELISA	confirmed	that	monocytes	from	healthy	individuals	and	from	HBV	patients	
Figure 5. Monocytes from patients 
and healthy controls are equally sen-
sitive to HBsAg in vitro. PBMC from 
healthy	individuals	or	HBV	patients	with	
distinct in vivo exposure histories to 
HBV	DNA,	 HBeAg	 and	 HBsAg	 (group	
3)	were	stimulated	with	HBsAg	and	the	
relative	frequency	of	cytokine-producing	
monocytes	was	determined	 (n=5-6).	 In	
the box-whisker plots, the line in the 
middle of the box is the median, while 
the whiskers depict the minimum and 
the maximum value.
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Discussion
In the present study, we demonstrate that HBsAg has a potent stimulatory effect 
on human monocytes upon in vitro culture. However, detailed comparison of 
monocytes	obtained	from	chronic	HBV	patients	showed	that	the	differences	in	viral	
load,	and	levels	of	viral	proteins	did	not	influence	the	functionality	of	the	monocyte	
compartment, suggesting that mechanisms are in place to prevent in vivo activation 
of monocytes by viral proteins such as HBsAg. 
The	majority	of	chronic	HBV	patients	who	are	not	being	treated	have	relatively	high	
levels	of	HBsAg	 in	serum.	We	showed	that	monocytes	are	responsive	 to	HBsAg,	
and	get	activated	as	a	consequence	of	 in vitro exposure to HBsAg as evidenced 
by	the	release	of	 IL-6	and	TNF.	 In	agreement	with	our	observations,	others	have	
demonstrated	that	patient-derived	HBsAg	induced	the	production	of	TNF	and	IL-10	
by	monocytes	[16],	and	that	monocyte-derived	DC	produced	IL-12	upon	stimulation	
with	HBsAg	[25].	However,	there	is	controversy	on	the	effect	of	HBsAg,	since	it	was	
also	reported	that	HBV,	HBeAg	and	HBsAg	are	inhibitory	and	can	in	some	cases	
suppress	TLR-induced	cytokine	production	 in	various	cell	 types	 [26-30],	 including	
monocytes in vitro	 [31]	 and	 in vivo	 [13].	 Importantly,	 using	 the	 same	preparation	
of	 HBsAg,	 we	 previously	 demonstrated	 suppression	 of	 TLR9-induced	 IFNα by 
plasmacytoid	DC	as	a	consequence	of	exposure	to	HBsAg	[29].	Furthermore,	to	rule	
IL-10 in vitro potently inhibits HBsAg-induced cytokine production by 
monocytes
Having	 demonstrated	 that	 monocytes	 from	 chronic	 HBV	 patients	 and	 healthy	
individuals	 are	 equally	 sensitive	 to	 HBsAg,	 we	 considered	 the	 activity	 of	
immunosuppressive	 cytokines,	 such	 as	 IL-10.	 In	 chronic	HBV	patients	 increased	
serum	 IL-10	 levels	have	been	demonstrated	by	 various	 research	groups	 [18-22].	
Enhanced production of this immunosuppressive cytokine and increased sensitivity 
of activated monocytes to IL-10 may prevent monocyte activation by HBsAg in vivo 
[23,24].	As	depicted	 in	Figure	6,	 the	presence	of	 IL-10	clearly	abrogated	HBsAg-
induced cytokine production, demonstrating a possible in vivo mechanism to curb 
HBsAg-induced cytokine production by monocytes.
 
Figure 6. IL-10 inhibits the frequency of monocytes producing cytokines upon HBsAg exposure. 
PBMC from healthy individuals were stimulated with HBsAg, with or without IL-10. After overnight incuba-
tion,	cells	were	stained	for	CD14	and	intracellularly	for	cytokines.	The	frequencies	of	IL-6-positive	(A)	and	
TNF-positive	(B)	monocytes	were	compared	between	HBsAg	and	HBsAg	and	IL10	(n=3).
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out	that	the	stimulatory	effects	on	monocytes	were	unique	for	the	preparation,	we	
tested different preparations from different suppliers and showed that the stimulatory 
capacity of HBsAg on monocytes was a general feature (rHBsAg (Prospec, Rehovot, 
Israel),	pHBsAg	Adr,	pHBsAg	Ayw	(both	Jena	Bioscience	GmbH,	Jena,	Germany),	
data	not	shown).	This	could	mean	that	monocytes	contribute	to	the	initiation	phase	
of	 an	 anti-viral	 immune	 response	 against	HBV,	 being	 able	 to	 recognize	 the	 viral	
envelope	 protein	 and	 produce	 pro-inflammatory	 cytokines	 in	 the	 periphery,	 and	
possibly	also	in	the	liver	during	inflammation.	
Since the HBsAg concentrations that were used for in vitro stimulations are in 
the	 same	 range	as	 found	 in	 the	 serum	of	 chronic	HBV	patients	 (5	 μg/ml	HBsAg	
corresponding	 to	 ±22,000	 IU/ml	 HBsAg)	 [32],	 and	 since	 monocytes	 have	 been	
shown to interact in vivo	with	HBsAg	[33],	one	might	expect	that	this	has	a	profound	
effect	on	the	monocyte	compartment	in	patients.	Consequently,	it	is	expected	that	
patients	with	 distinct	 levels	 of	 serum	HBsAg,	 but	 also	 of	HBV	DNA	and	HBeAg,	
demonstrate	an	altered	monocyte	phenotype	and	function.	Our	findings	show	that	
the distribution of CD14++CD16- and CD14+CD16+ monocytes was not different 
between	patients	with	distinctive	virological	characteristics.	Our	findings	appear	not	
be	 in	agreement	with	a	study	by	Zhang	et al., which showed increased numbers 
of CD16+ monocytes in immune-active HBeAg-positive patients as compared to 
healthy	individuals	or	immunotolerant	patients	[12].	It	should	be	noted	that	monocyte	
subset	 frequencies	 correlate	 with	 ALT	 values	 in	 chronic	 HBV	 patients	 [12],	 and	
that	the	study	by	Zhang	et	al,	and	ours	differ	considerably	with	respect	to	the	ALT	
ranges	 included	(13-1656	versus	15-443	IU/L).	Therefore,	differences	 in	 inclusion	
criteria	of	patients	to	address	the	respective	research	questions	may	likely	explain	
the results. Additionally, we showed that also the functionality, as demonstrated by 
the	frequency	of	TLR-induced	cytokine	producing	monocytes	and	the	TLR-induced	
cytokine	production	in	PBMC	was	comparable	in	chronic	HBV	patients	with	different	
levels	of	viral	DNA	and	viral	proteins.	This	important	finding	on	limited	modulation	
of	the	monocyte	compartment	in	chronic	HBV	patients	in vivo	is	not	reflected	by	the	
immunostimulatory effect of HBsAg on monocytes in vitro, and clearly demonstrates 
that comparison of the in vivo and in vitro	findings	is	complex.	It	is	also	important	to	
note	that	reported	findings	on	the	effects	of	HBsAg	on	immune	cells	use	other	cell	
types or cell lines than primary monocytes and different recombinant or plasma-
derived preparations of HBsAg, which complicates the interpretation of the in 
vitro	findings	 [26-31,34].	Our	findings	are	 in	 line	with	Gehring	et al., who showed 
that	 despite	 a	 constant	 exposure	 to	 HBsAg,	 ex	 vivo–isolated	monocytes	 did	 not	
constitutively	activate	HBV-specific	CD8+	T	cells	[33]	Evaluation	of	monocytes	from	
chronic	HBV	patients	showed	that	the	induction	of	cytokines	upon	TLR	ligation	was	
not	affected	by	the	clinical	phase.	Furthermore,	the	spontaneous	cytokine	release	
of these monocytes was similar between all groups, suggesting that the continuous 
exposure	to	variable	concentrations	of	HBV	DNA,	HBeAg	or	HBsAg	did	not	result	in	
modulation of the ex vivo activation state of these cells. 
Combined	these	findings	suggest	that	the	monocyte	compartment	of	patients	is	not	
affected	as	a	consequence	of	exposure	to	different	concentrations	of	viral	proteins	and	
HBV	DNA	in	serum.	Since	this	is	in	apparent	conflict	with	the	in vitro experiments in 
which monocytes were exposed to HBsAg, it is tempting to speculate that regulatory 
and/or compensatory mechanisms are in place in vivo, which prevent excessive 
activation	of	monocytes	by	serum	HBsAg.	We	demonstrated	that	it	is	unlikely	that	
unresponsiveness	 of	 patients’	 monocytes	 to	 HBsAg	 due	 to	 desensitization	 as	 a	
consequence	of	recent	exposure	to	the	same	protein	may	explain	the	discrepancy	
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between the in vitro and in vivo observations, since monocytes from patients are 
similarly responsive to HBsAg as monocytes from healthy individuals, as shown by 
dose titrations. However, a likely candidate that may contribute to explain the in 
vivo data is the immunosuppressive cytokine IL-10 since it has been reported that 
chronic	HBV	patients	have	increased	serum	IL-10	levels	[18-22].	Our	data	indeed	
show that IL-10 is able to inhibit cytokine production by HBsAg-induced monocytes, 
suggesting	a	possible	role	of	IL-10	in	restraining	pro-inflammatory	cytokine	production	
by	monocytes	 in	HBV	patients	with	high	 levels	of	HBsAg,	HBeAg	and	HBV	DNA.	
However,	 also	 other	 candidate	molecules	 present	 in	 serum,	 such	 as	 TGFβ may 
further	regulate	monocyte	function	in	chronic	HBV	patients.
In summary, we demonstrate that HBsAg has potent stimulatory effects on monocytes 
in vitro.	 However,	 in	 chronic	 HBV	 patients,	 the	 functionality	 of	 the	 monocyte	
compartment	is	not	influenced	by	variations	in	the	levels	of	serum	viral	components,	
suggesting that regulatory mechanisms are in place to prevent excessive in vivo 
activation of monocytes.
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Supplementary Figure 1. Monocytes from patients and 
healthy controls are equally sensitive to HBsAg in vitro. 
PBMC from healthy individuals or HBV patients with distinct in 
vivo exposure histories to HBV DNA, HBeAg and HBsAg (group 
3) were stimulated for 5 hours with patient plasma-derived 
HBsAg or recombinant HBsAg and the frequency of cytokine-
producing monocytes was determined (n=5-6). In the 
box-whisker plots, the line in the middle of the box is the 
median, while the whiskers depict the minimum and the 
maximum value.
Figure S1. Monocytes from patients and 
healthy controls are equally sensitive to HB-
sAg in vitro. PBMC from healthy individuals or 
HBV	patients	with	distinct	in vivo exposure histo-
ries	 to	HBV	DNA,	HBeAg	and	HBsAg	 (group	3)	
were stimulated for 5 hours with patient plasma-
derived HBsAg or recombinant HBsAg and the 
frequency	of	cytokine-producing	monocytes	was	
determined	(n=5-6).	In	the	box-whisker	plots,	the	
line in the middle of the box is the median, while 
the whiskers depict the minimum and the maxi-
mum value.
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Abstract 
Background:	 Based	 on	 their	 localization,	 Kupffer	 cells	 (KC)	 likely	 interact	 with	
hepatitis	B	virus	(HBV).	However,	the	role	of	KC	in	inducing	immunity	towards	HBV	is	
poorly	understood.	Therefore,	the	interaction	of	hepatitis	B	surface	antigen	(HBsAg)	
and	KC,	and	possible	functional	consequences,	were	assessed.
Methods:	KC	in	liver	tissue	from	chronic	HBV	patients	were	analysed	for	presence	
of HBsAg and for their phenotype, and compared to KC in control liver tissue. Liver 
graft perfusate-derived KC and in vitro-generated monocyte-derived macrophages 
were investigated for functional interaction with patient-derived HBsAg.
Results: Intrahepatic KC were positive for HBsAg and more activated than those 
from control livers. KC bound HBsAg in vitro, which did not change their phenotype, 
but	strongly	induced	pro-inflammatory	cytokine	production.	Additionally,	monocyte-
derived macrophages also bound HBsAg leading to activation and cytokine 
production.	Furthermore,	HBsAg-exposed	macrophages	and	KC	activated	NK	cells	
resulting	in	increased	CD69	expression	and	IFNγ production.
Conclusions: KC directly interact with HBsAg in vivo and in vitro. HBsAg-induced 
function	 of	 KC	 and	 monocyte-derived	 macrophages	 and	 subsequent	 NK	 cell	
activation	could	be	an	early	event	 in	viral	containment	and	 the	 induction	of	HBV-
specific	immunity	in	the	early	phase	after	HBV	infection,	but	could	also	contribute	to	
liver pathology.
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Introduction
Hepatitis	B	virus	(HBV)	can	cause	chronic	liver	disease	and	may	elicit	progressive	
liver injury leading to increased risk of developing liver cirrhosis, liver failure and liver 
cancer	 [1,	2].	The	 immunological	mechanisms	determining	either	 the	 induction	of	
effective anti-viral immunity leading to self-limiting hepatitis or the lack of effective 
immune response towards the virus leading to chronic hepatitis B are still unclear. 
Although	recently	an	HBV	receptor	has	been	identified	on	hepatocytes	[3],	the	early	
steps	in	the	recognition	of	the	virus	by	immune	cells	and	the	functional	consequences	
of this interaction remain to be resolved.
Kupffer	 cells	 (KC)	 are	 the	 resident	 macrophages	 of	 the	 liver	 [4,	 5]	 that	 besides	
being	maintained	by	 liver-derived	precursors	[6],	have	been	shown	to	derive	from	
monocytes	[7]	in	an	M-CSF	dependent	manner	[5,	8].	They	form,	together	with	the	
sinusoidal	endothelial	cells,	the	first	barrier	for	pathogens	to	enter	the	liver	via	the	
portal	vein	[9].	In	humans,	KC	have	been	identified	by	the	expression	of	CD68	and	
CD14	[10-12].	Their	number	and	 location,	but	also	 typical	macrophage	properties	
like	endocytic	capacity,	expression	of	pattern	recognition	receptors	(PRR),	MHC	and	
co-stimulatory	molecules,	and	ability	to	produce	cytokines	upon	stimulation	[10,	13-
18],	potentially	render	KC	effective	immune	cells	contributing	to	either	viral	clearance	
or persistence.
Despite	their	potential,	the	exact	role	of	KC	in	viral	 infection	of	the	liver,	and	HBV	
infection in particular, is still unclear. On one hand KC are considered to contribute 
to	 intrahepatic	 tolerance	as	demonstrated	by	 rat	KC	exposed	 to	HBV	 that	hardly	
expressed	pro-inflammatory	cytokines,	but	instead	preferably	produced	TGFβ	[19].	
On	the	other	hand,	stimulation	of	human	non-parenchymal	cells	with	HBV	was	found	
to	 induce	the	production	of	 the	pro-inflammatory	cytokines	which	was	ascribed	to	
KC-HBsAg	interaction	[20].	However,	whether	human	KC	are	able	to	bind/take	up	
HBV	in vivo or in vitro is not known.
Therefore,	 we	 investigated	 the	 interaction	 between	 HBsAg	 and	 human	 KC	 by	
assessing the presence of HBsAg within the CD14+ intrahepatic macrophage 
population	and	the	phenotype	of	KC	during	HBV	infection	as	well	as	the	functional	
consequences	of	HBsAg-KC	interaction	 in vitro using both liver-derived KC and in 
vitro-generated macrophages.
Materials and methods
Kupffer cell phenotype
Excess material of percutaneous needle liver biopsies obtained from 7 chronic 
HBV	patients	(Table	1)	and	14	incisional	biopsies	obtained	from	donor	liver	during	
transplantation procedure was dissected into small pieces, incubated in RPMI 
culture	medium	(Lonza,	Verviers	Sprl,	Belgium)	containing	0.5	mg/ml	collagenase	
(Sigma-Aldrich,	 St.	 Louis,	 MO)	 and	 0.1	 mg/ml	 DNAse	 (Roche,	 Indianapolis,	 IN,	
USA),	 penicillin/streptomycin	 (Gibco,	 Carlsbad,	 CA,	 USA),	 L-glutamin	 (Lonza),	
and	HEPES	 (Lonza)	 for	 30	minutes,	 filtered	 through	 a	 70	 μm	 nylon	 cell	 strainer	
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(BD,	San	Diego,	CA,	USA)	to	acquire	a	 liver	cell	suspension.	Subsequently,	cells	
were	stained	with	antibodies	against	CD11b	(ICRF44;	BD	Pharmingen,	San	Diego,	
CA,	USA),	CD16	(CB16;	eBioscience),	CD14	(61D3),	CD40	(5C3),	HLA-DR	(LN3;	
all	 eBioscience),	CD45	 (2D1;	BD),	CD80	 (MAB104;	Beckman	Coulter,	Brea,	CA,	
USA),	CD86	 (IT2.2),	HLA-ABC	 (W6/32;	both	Biolegend,	San	Diego,	CA,	USA)	 in	
PBS	supplemented	with	1%	human	AB-serum	(Lonza)	and	0.02%NaN3.	Data	were	
acquired	on	a	FACSCanto	(BD)	and	analysed	with	FlowJo	(Tree	Star,	Inc.,	Ashland,	
OR,	USA).
Patient # 
 
Age	(yr) Sex HBV	
genotype 
Viral	load 
(geq/ml) 
HBeAg 
status 
ALT	(U/l) 
1 49 F ND 4,78x101 - 209 
2 36 F D 7,01x103 - 53 
3 44 M C 6,63x106 + 50 
4 26 F A 3,55x107 - 50 
5 19 M A 1,68x109 + 97 
6 24 F C 1,05x109 + 41 
7 27 F B 2,86x107 + 164 
 
Table 1
Patient characteristics
ND	=	Not	determined;	geq	=	genome	equivalents
HBsAg staining on patient-derived blood and liver tissue
Excess material of percutaneous needle liver biopsies were obtained from 13 chronic 
HBV	patients	and	9	non-HBV	liver	disease	patients	(Table	2),	collected	in	RPMI	and	
filtered	through	a	70	μm	nylon	cell	strainer	(BD)	to	acquire	a	single-cell	suspension.	In	
parallel, peripheral blood was obtained from these patients and PBMC were isolated 
by	Ficoll-Paque	(GE	Healthcare,	Uppsala,	Sweden)	density	gradient	centrifugation.	
Liver	 cells	 and	 PBMC	 were	 stained	 with	 antibodies	 against	 CD14	 (MOP9)	 and	
CD45	(SK7;	both	BD)	in	PBS	(Lonza)/1%FCS	(Sigma)/0.02%NaN3,	fixed	with	2%	
formaldehyde,	 permeabilized	with	0.5%	saponin	 (VWR,	West	Chester,	PA,	USA)	
and stained using an antibody against HBsAg (recognizing subtypes HBsAg ad and 
ay;	Acris	Antibodies	GmbH,	Hiddenhausen,	Germany)	in	0.5%	saponin	(VWR).	Data	
were	acquired	on	a	FACSCanto	 (BD)	and	analysed	with	FlowJo	 (Tree	Star)	 and	
FACSDiva	software	(BD).	
The	 medical	 ethical	 committee	 of	 the	 Erasmus	 MC	 University	 Medical	 Center	
declared to have no objections against the use of excess patient biopsy material and 
all patients with liver disease gave informed consent before inclusion.
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Cell purification and culture
Liver	mononuclear	cells	(LMNC)	were	isolated	from	liver	graft	perfusates	as	previously	
described	[21].	LMNC	were	isolated	from	fresh	perfusates	derived	from	the	second	
back	table	flush	which	contains	minimal	contamination	with	donor	peripheral	blood	
cells	 [21,	 22].	 LMNC	 were	 isolated	 using	 Ficoll-Paque	 (GE	 Healthcare)	 density	
gradient	centrifugation,	and	subsequently	 frozen	 for	 future	use.	KC	were	 isolated	
from LMNC using CD14 MACS microbeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany)	or	using	FACS	sorting	by	selecting	CD14+	(M5E2;	BD	Pharmingen)	cells	
using	a	FACSAria	II	(BD).
HBV patients         
Patient # 
 
Age (yr) Sex Disease HBV	
genotype 
Viral	load 
(geq/ml) 
HBeAg 
status 
HBsAg 
status 
ALT 
 
1 29 M HBV D 4,17x103 - + 38 
2 45 M HBV D 5,12x109 - + 155 
3 31 M HBV D 6,46x104 - + 78 
4 25 M HBV C 8,48x108 + + 444 
5 44 M HBV A 3,05x106 - + 58 
6 28 M HBV D 2,50x107 + + 56 
7 31 M HBV ND 4,34x103 - + 28 
8 39 F HBV D 7,16x105 - + 30 
9 26 F HBV E 2,39x103 - + 41 
10 40 M HBV ND 2,25x1010 + + 101 
11 22 F HBV D 2,14x103 ND + 86 
12 32 F HBV D 2,37x108 + + 46 
13 27 F HBV ND 2,27x104 - + 38 
 
Non-HBV patients 
       
15 54 M HCV NA ND ND - 160 
16 64 F HCV NA ND ND - 182 
17 47 M HCV NA ND ND - 16 
18 43 M Sjögren's	syndrome	 NA ND ND - 63 
19 52 F PSC NA ND - - 281 
20 41 M Steatohepatitis NA ND ND - 43 
21 45 M HCV NA ND - - 59 
22 22 M HCV NA ND ND - 43 
23 35 F HCV NA ND ND - 78 
 
Table 2
Patient characteristics
HCV	=	Hepatitis	C	virus;	PSC	=	Primary	sclerosing	cholangitis;	ND	=	Not	determined;	NA	=	Not	
applicable;	geq	=	genome	equivalents;	ALT	=	Alanine	transaminase
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To	generate	monocyte-derived	macrophages,	PBMC	were	isolated	from	buffy	coats	
from	healthy	blood	donors	 (Sanquin)	 using	Ficoll-Paque	 (GE	Healthcare)	 density	
gradient centrifugation. Monocytes were isolated using CD14 MACS microbeads 
(Miltenyi	Biotec).	Macrophages	were	generated	 in	6-well	plates	 (Costar,	Corning,	
NY,	USA)	by	culturing	1.5x106 monocytes in 2 ml/well RPMI 1640 containing 10% 
heat-inactivated	FCS	(Sigma),	penicillin/streptomycin	 (Gibco),	L-glutamin	 (Lonza),	
and	HEPES	(Lonza),	in	the	presence	of	10	ng/ml	M-CSF	(R&D,	Minneapolis,	MN,	
USA).	After	 7	 days	monocyte-derived	macrophages	were	 harvested	 and	 used	 in	
experiments.
NK cells were isolated from LMNC or buffy coat-derived PBMC using an NK isolation 
kit	(Miltenyi	Biotec)	or	FACS	sorting	by	selecting	CD3-	(UCHT1)	CD56+	(MY31;	both	
BD)	cells	using	a	FACSAria	II	(BD).
In vitro binding/uptake of HBsAg
In vitro-generated macrophages (5x104/well)	 or	 LMNC	 (1x106/well)	 were	 cultured	
in	 96-well	 plates	 in	 125-150	 μl	RPMI	 1640	 containing	 10%	heat-inactivated	FCS	
(Sigma),	penicillin/streptomycin	(Gibco),	L-glutamin	(Lonza),	and	HEPES	(Lonza),	
at	 37°C	 in	 the	 absence	 or	 presence	 of	 2.5	 μg/ml	 patient	 plasma-derived	HBsAg	
serotype	 Ay	 (American	 Research	 Products	 (ARP,	Waltham,	MA,	 USA)	 that	 was	
unlabelled or directly labelled via conjugation of maleimide-activated DyLight 650 
(Thermo	Fisher	Scientific,	Rockford,	IL	USA)	to	free	reduced	sulfhydryl	(-SH)	groups,	
according	 to	 manufacturer’s	 protocol.	 After	 conjugation	 unbound	 conjugate	 was	
removed by dialysis against PBS as dialysis buffer, using dialysis units of pore size 
20,000	kDa	(Thermo	Fisher	Scientific).	After	1-4	hours,	cells	were	harvested,	fixed	
with	2%	formaldehyde,	permeabilized	with	0.5%	saponin	(VWR),	and	either	stained	
with	biotin-labeled	goat	polyclonal	anti-HBsAg	Ad/Ay	(Abcam,	Cambridge,	UK),	and	
Streptavidin-PerCP	 (BD)	or	directly	 stained	 for	 surface	marker	CD14	 (61D3)	and	
CD3	 (SK7;	 both	 eBioscience),	 and	 subsequently	 analysed	 by	 flow	 cytometry	 as	
described above.
HBsAg stimulation of Kupffer cells and in vitro-generated macrophages
Liver perfusate-derived KC or in vitro-generated macrophages were cultured in 
96-well	plates	in	250	μl	RPMI	1640	containing	10%	heat-inactivated	FCS	(Sigma),	
penicillin/streptomycin	 (Gibco),	 L-glutamin	 (Lonza),	 and	 HEPES	 (Lonza),	 in	 the	
absence or presence of 2.5 μg/ml plasma-derived HBsAg serotype Ay (pHBsAg; 
ARP)	 or	 CHO-derived	 recombinant	 HBsAg	 (rHBsAg;	 Prospec,	 Rehovot,	 Israel)	
for	 48	 hours.	 Supernatants	 were	 harvested,	 and	 cytokine	 production	 (IL-6,	 TNF	
and	IL-10)	was	determined	by	ELISA	(all	kits	 from	eBioscience).	After	 removal	of	
supernatants,	 cells	 were	 harvested,	 stained	 for	 CD40	 (5C3;	 eBioscience),	 CD80	
(MAB104;	Beckman	Coulter),	and	CD86	 (IT2.2;	Biolegend)	and	analysed	by	flow	
cytometry as described above.
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HBsAg stimulation of LMNC: intracellular cytokine staining
LMNC (1x106	cells/ml)	were	cultured	in	96-well	plates	(Corning,	Lowell,	MA,	USA)	in	
250	μl	X-VIVO	culture	medium	(Lonza,	Verviers	Sprl,	Belgium)	containing	penicillin/
streptavidin	(Gibco),	L-glutamin	(Lonza),	and	HEPES	(Lonza)	for	18	hours	at	37°C,	
5% CO2. Cells were either unstimulated or stimulated with 2.5 μg/ml human plasma-
derived	HBsAg	 (ARP).	During	 the	 last	16	hours	of	culture,	brefeldin	A	 (10	μg/ml;	
Sigma-Aldrich)	 was	 added.	 Cells	 were	 harvested,	 incubated	 with	 LIVE/DEAD	
Fixable	Aqua	Dead	Cell	Stain	(Invitrogen,	Ltd.,	Paisley,	United	Kingdom),	fixed	with	
2%	 formaldehyde,	 permeabilized	 with	 0.5%	 saponin	 (VWR)	 and	 stained	 for	 IL-6	
(MQ2-13A5),	TNF	(Mab11;	all	eBioscience),	CXCL8	�	IL-8	(6217),	IL-15	(34559;	both	
R&D),	 IL-10	(JES3-19F1	;	BioLegend),	 IL-12p40	(C11.5)	or	CCL4	�	MIP-1β (D21-
1351;	both	BD	Pharmingen)	and	CD14	(61D3)	and	CD45	(HI30;	both	eBioscience),	
and	analysed	by	flow	cytometry	as	described	above.
Macrophage-NK cell co-culture
1x105 liver perfusate-derived KC or in vitro-generated macrophages were co-
cultured with autologous perfusate-derived NK cells or peripheral blood NK cells, 
respectively, in a 1:1 ratio in 48-well plates in 250 μl RPMI 1640 containing 10% 
heat-inactivated	FCS	 (Lonza),	penicillin/streptomycin	 (Gibco),	L-glutamin	 (Lonza),	
and	HEPES	 (Lonza)	either	with	or	without	2.5	μg/ml	pHBsAg-Ay	 (ARP).	After	48	
hours, supernatants and cells were harvested. Cells were stained with antibodies 
against	CD3	(UCHT1),	CD56	(MY31),	and	CD69	(L78;	all	BD)	and	analysed	by	flow	
cytometry	as	described	above.	Supernatants	were	assessed	for	IFNγ production by 
ELISA	(eBioscience,	detection	limit	4	pg/ml)	according	to	manufacturer’s	protocol.
Results
Kupffer cells display an activated phenotype in chronic HBV and interact with 
HBsAg in vivo
To	investigate	the	effect	of	chronic	hepatitis	B	virus	infection	on	KC,	we	compared	
the phenotype of CD45+CD14+	cells	present	 in	 liver	biopsy	 tissue	of	chronic	HBV	
patients	with	control	 liver	 tissue	derived	 from	healthy	 transplant	donor	 livers.	The	
percentages of KC expressing CD11b, CD11c, CD163 and CD204 were comparable 
between	 both	 groups	 (Fig.	 1A),	 albeit	 that	 the	 expression	 levels	 of	 CD11c	 and	
CD163	were	 significantly	 higher	 on	 KC	 from	HBV	 patients	 than	 on	 those	 of	 HC	
(Supplementary	 Fig.	 1B,	 p<0.05).	 Only	 the	 percentage	 of	 CD16-expressing	 KC	
was	significantly	lower	in	chronic	HBV	compared	to	healthy	control	livers	(Fig.	1A).	
With	regard	to	the	expression	of	activation	markers,	we	observed	that	KC	present	
in control liver tissues showed a low expression of CD40, which differed between 
donors, and were almost negative for CD80, whereas they expressed high levels 
of	CD86,	MHC	class	 I	 and	 II	molecules	 (Fig.	 1B).	The	activation	 status	of	KC	 in	
HBV-infected	 livers	 was	 found	 to	 be	 increased	 as	 demonstrated	 by	 significantly	
increased expression of CD40, HLA-ABC and HLA-DR and also the expression of 
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CD86	tended	to	be	increased	(Fig.	1B).	
We	next	analysed	blood	and	liver	biopsy	samples	from	either	chronic	HBV	patients	
or	patients	with	non-HBV	related	liver	disease	for	presence	of	HBsAg.	Whereas	a	
small,	but	significant,	percentage	of	KC	from	chronic	HBV	patients	stained	positive	
for HBsAg, peripheral blood CD14+ monocytes from the same patients did not. As 
expected, CD14+	cells	derived	from	non-HBV	patients	were	negative	for	HBsAg	(Fig.	
1CD).	These	data	clearly	indicate	that	KC	have	the	ability	to	interact	with	HBsAg	in 
Figure 1. Kupffer cells in chronically HBV-infected livers. KC phenotype (A)	and	activation	status	(B)	
was	determined	in	liver	biopsy	samples	from	HC	(n=11-14)	and	HBV	patients	(n=5-7)	by	flow	cytometry.	
Expression is shown as percentage positivity on CD14+ cells (A)	or	as	MFI	with	background	staining	
subtracted (B).	CD14+ peripheral blood monocytes and KC were analysed for HBsAg-positivity in blood 
and	 liver	biopsy	samples	of	CHB	patients	(n=13)	and	non-HBV-related	 liver	disease	patients	(n=9)	by	
flow	cytometry.	Shown	are	representative	dot	plots	(C)	and	individual	and	mean	HBsAg-positivity	of	all	
patients (D).	*p<0.05,	**p<0.01,	***p<0.001,	Mann-Whitney	test.
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vivo and that CD45+CD14+	cells	present	in	HBV-infected	livers	are	significantly	more	
activated than those present in healthy control livers. 
HBsAg interacts with KC in vitro inducing cytokine production
To	 further	 investigate	 this	 KC-HBsAg	 interaction,	 LMNC	 or	 isolated	 KC	 were	
incubated with pHBsAg in vitro. After incubation of LMNC, very high HBsAg-positivity 
was seen in CD14+	KC	(90%±6.4%),	while	CD3+CD56-	T	cells,	used	as	a	control	
population within the same LMNC population, showed hardly any HBsAg-binding 
(Fig.	2AB).	These	data	show	the	high	potential	of	KC	to	interact	with	pHBsAg.	To	
investigate	whether	 the	activated	phenotype	of	KC	 in	chronic	HBV	patients	could	
be ascribed to a direct effect of HBsAg, liver graft perfusate-derived KC were 
isolated	and	cultured	either	in	presence	or	absence	of	pHBsAg	for	48	hours.	These	
KC expressed high levels of CD11b, intermediate to high levels of CD163 varying 
widely	between	donors	(range	18.5	–	98.7%	CD163+	KC),	and	low	levels	of	CD204	
(Supplementary	Fig.	2A).	Expression	of	activation	markers	on	perfusate-derived	KC	
was	very	similar	 to	KC	present	 in	healthy	control	 liver	 tissue	(Supplementary	Fig.	
2B,	data	not	shown).	Neither	exposure	to	pHBsAg	nor	exposure	to	rHBsAg	changed	
the	 expression	 of	 co-stimulatory	molecules	 (Fig.	 2C	 and	 data	 not	 shown),	 MHC	
molecules,	or	differentiation	markers	CD11b,	CD163	and	CD204	(data	not	shown).
To	assess	the	effect	of	HBsAg	on	cytokine	and	chemokine	production,	LMNC	were	
cultured in the absence or presence of pHBsAg and CD14+ KC were measured 
for intracellular cytokine expression. HBsAg induced many KC to produce the pro-
inflammatory	cytokines	IL-6,	TNF	and	chemokines	CCL4	and	CXCL8	in	all	donors	
tested,	while	 it	 weakly	 stimulated	 IL-10	 and	 IL-15	 expression	 (Fig.	 2D).	 Also	 the	
percentage of IL-12p40-producing KC was weakly enhanced in 4/5 experiments 
with	different	donors	 (Fig.	2D).	To	confirm	 the	direct	effect	of	HBsAg	on	KC,	KC	
were isolated from these perfusate-derived LMNC and assessed for HBsAg-induced 
cytokine	 secretion.	Both	pHBsAg	and	 rHBsAg	stimulated	KC	 to	 secrete	TNF,	 IL-
10	and	copious	amounts	of	 IL-6	 (Fig.	2E	and	Supplementary	Fig.	2C).	Together,	
these	data	show	that	HBsAg	is	able	to	interact	with	KC	and	induce	pro-inflammatory	
cytokine production without inducing an activated phenotype based on co-stimulatory 
molecule and MHC expression.
HBsAg also functionally interacts with in vitro-generated macrophages 
KC are thought to originate from liver precursor cells as well as from monocytes 
in	 an	M-CSF	 dependent	 manner	 [5,	 7,	 8].	 Since	monocyte-derived	macrophage	
development	likely	increasingly	occurs	during	inflammation,	a	situation	often	present	
in	 HBV-infected	 livers,	 we	 also	 investigated	 the	 effect	 on	 M-CSF-driven	 human	
monocyte-derived macrophages. Compared to perfusate-derived KC, in vitro-
generated macrophages expressed similar levels of CD11b, CD40, CD80 and HLA-
DR, higher levels of CD163, CD204 and CD86 and lower HLA-ABC (Supplementary 
Fig.	 3AB).	 Upon	 pHBsAg	 exposure	 in vitro-generated macrophages interacted 
actively with HBsAg as demonstrated by a high percentage of HBsAg-positive 
cells	 (Fig.	 3A).	 In	 contrast	 to	KC,	 incubation	of	 in vitro¬-generated macrophages 
with pHBsAg induced an activated phenotype showing increased CD40 and CD80 
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Figure 2. HBsAg interacts with KC in vitro inducing cytokine production. LMNC were incubated 
with/without	fluorescent	pHBsAg	(1h)	and	analysed	for	HBsAg-positivity	in	CD14- and CD14+	cells	by	flow	
cytometry. Shown are representative pseudo-colour density plots (A)	and	HBsAg-positivity	in	KC	(CD14)	
and	T	cells	(CD3)	derived	from	different	donors	(B).	(C)	Isolated	KC	were	cultured	with/without	pHBsAg	
for	48	hours.	Their	activation	status	was	assessed	by	flow	cytometry	and	expressed	as	mean±SEM	MFI	
(n=4-5).	(D)	Intracellular	cytokine-positive	KC	within	LMNC	exposed	to	pHBsAg	or	medium	per	donor	as	
assessed	by	flow	cytometry	(n=5)	(E)	Cytokine	production	by	isolated	KC	cultured	with	or	without	pHBsAg	
for	48h	as	determined	by	ELISA	on	supernatants	(mean±SEM,	n=8).	*p<0.05,	**p<0.01;	Wilcoxon	signed	
rank test.
expression,	and	decreased	CD86	expression	(Fig.	3B),	besides	inducing	IL-6,	TNF	
and	IL-10	production	(Fig.	3C).	
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HBsAg-activated macrophages induce NK cell function
To	further	examine	the	functional	consequence	of	the	interaction	between	HBsAg	
and macrophages, we investigated the interaction of KC and in vitro-generated 
macrophages with autologous liver-derived NK cells and peripheral blood-derived 
NK	cells,	respectively.	When	culturing	in vitro-generated macrophages together with 
NK cells in the presence of pHBsAg, NK cells not only strongly upregulated CD69 
expression	(Fig.	4A),	but	also	significantly	increased	IFNγ	production	(Fig.	4B).	The	
basal	CD69	expression	of	liver	NK	cells	is	already	high,	as	demonstrated	before	[23]	
and	could	hardly	be	further	increased	upon	exposure	to	HBsAg-stimulated	KC	(Fig.	
4C).	Also	for	the	KC-NK	cell	co-cultures,	induction	of	IFNγ production by NK cells 
was	demonstrated	(Fig.	4D).	Adding	pHBsAg	to	NK	cells,	KC	or	macrophages	alone	
neither	changed	CD69	expression	nor	induced	IFNγ	production	(data	not	shown).
Discussion
A virus-induced innate immune response is generally considered to be crucial for 
early	viral	containment	and	the	induction	of	virus-specific	immunity.	However,	due	
to	 delayed	 onset	 of	 symptoms	 in	 HBV-infected	 humans	 and	 lack	 of	 appropriate	
animal	models,	HBV-induced	innate	immune	responses	are	largely	undefined.	We	
demonstrated,	 for	 the	first	 time,	a	direct	 interaction	between	HBsAg	and	KC	both	
in vivo and in vitro.	The	interaction	of	KC	as	well	as	 in vitro-generated monocyte-
derived macrophages with HBsAg resulted in cytokine production and the induction 
of	IFNγ production by NK cells.
The	finding	of	HBsAg-positive	KC	in	HBV-infected	livers	together	with	the	production	
of cytokines, and the induction of NK cell function, supports the hypothesis that 
Figure 3. Interaction of monocyte 
-derived macrophages with 
HBsAg. Monocyte-derived mac-
rophages were incubated with/
without pHBsAg. (A)	 After	 4	 hours	
HBsAg positivity was assessed 
by	 flow	 cytometry,	 as	 shown	 in	 a	
representative histogram overlay 
(left	 panel)	 and	 as	 mean±SEM	 of	
6 independent experiments with 
different	 donors	 (right	 panel).	 The	
effect of 48h culture in the absence 
or presence of pHBsAg on in vitro-
generated macrophage on the (B)	
expression of co-stimulatory mol-
ecules	 (n=9)	 and	 (C)	 cytokine	 se-
cretion	 (n=9)	 as	 assessed	 by	 flow	
cytometry and ELISA, respectively. 
Data are shown as mean±SEM. 
*p<0.05;	**p<0.01,	Wilcoxon	signed	
rank test.
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KC	play	a	role	 in	HBV	recognition	and	immune	activation	 in	the	early	phase	after	
infection.	Whether	the	HBsAg	acquired	by	intrahepatic	KC	is	the	result	of	a	direct	
interaction	between	HBsAg	as	part	of	the	whole	HBV	virion,	HBsAg	as	circulating	
subviral	particle,	or	the	result	of	the	uptake	of	HBV/HBsAg-containing	hepatocytes	
remains to be elucidated. Although serum HBsAg levels were not determined, we 
did	not	find	a	correlation	between	serum	HBV-DNA	levels	and	HBsAg-positivity	in	
KC	(data	not	shown).	
The	relative	low	percentage	and	staining	intensity	of	the	HBsAg+	KC	in	HBV-infected	
livers compared to the signals obtained from KC-HBsAg interaction in vitro seems 
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Figure 4. HBsAg activates 
macrophage-induced NK cell 
function Healthy donor NK cells 
were cultured with autologous 
monocyte-derived macrophages 
(AB)	 or	 KC	 (CD)	 for	 48	 hours	
with/without pHBsAg. (A)	 CD69	
expression on CD56+ NK cells 
in representative dot-plots and 
expressed as mean±SEM of 
all	 donors	 tested	 (n=7)	 and	 (B)	
mean±SEM	 IFNγ secretion of all 
donors as measured by ELISA 
(n=9)	upon	co-culture	of	peripheral	
blood NK cells and macrophages. 
(C)	 Representative	 dot-plots	 of	
NK cell CD69 expression and (D)	
mean±SEM	 IFNγ secretion of all 
donors as measured by ELISA after 
liver	 NK	 cell-KC	 co-culture	 (n=8).	
*p<0.05,	Wilcoxon	signed	rank	test.
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counter-intuitive,	but	could	have	several	explanations.	First,	HBsAg+ KC detection by 
using	anti-HBsAg	antibody	instead	of	directly	fluorescent	HBsAg	used	in vitro was 
significantly	lower	(data	not	shown).	Additionally,	it	is	tempting	to	speculate	that	the	
longer exposure time of KC to HBsAg in vivo may not further increase the level of 
antigen uptake, but rather impairs HBsAg detection since it is known that HBsAg, 
once	taken	up,	will	be	broken	down	by	macrophages	[24].	Furthermore,	the	higher	
activation status of KC present in these chronically infected livers may negatively 
influence	the	uptake	capacity	of	macrophages	as	has	been	shown	for	dendritic	cells,	
cells	closely	related	to	macrophages	[25,	26].	
The	receptors	involved	in	KC-HBsAg	interaction	will	be	subject	of	future	research,	but	
several candidate receptors exist. CD14 has been demonstrated as an interesting 
candidate receptor on monocytes. Recently, Gehring et al. demonstrated HBsAg-
positivity in CD14+	 monocytes	 of	 chronic	 HBV	 patients,	 using	 a	 very	 sensitive	
Tissuefax	 system	due	 to	 the	 low	quantity	of	HBsAg	 in	 these	cells	 [27].	Due	 to	a	
possible less sensitive detection method as discussed above, we cannot rule out the 
presence of HBsAg+ monocytes and therefore also the role of CD14 in HBsAg binding 
cannot be excluded. Another possible receptor involved in HBsAg-KC interaction 
not expressed by monocytes is the macrophage mannose receptor, known to be 
involved	in	HBsAg	interaction	with	dendritic	cells	[34].	Altogether,	it	seems	plausible	
to conclude that KC contain higher levels of HBsAg than circulating monocytes, 
which could be explained by cell-intrinsic properties of macrophages and/or higher 
levels	of	HBV/HBsAg	in	the	intrahepatic	compartment.	
The	absence	of	HBsAg-induced	upregulation	of	co-stimulatory	and	MHC	molecules	
on KC in vitro suggests that indirect activation is responsible for the activated 
phenotype	 of	 KC	 in	 HBV-infected	 livers.	 However,	 since	 HBsAg	 exposure	 of	 in 
vitro-generated monocyte-derived macrophages induced an activated phenotype, 
an alternative explanation could be that the activated phenotype observed is the 
result	 of	 activated	 infiltrating	monocyte-derived	macrophages	 since	 an	 increased	
differentiation	of	monocytes	into	macrophages	is	likely	to	occur	during	inflammatory	
responses	[28-30].	As	monocytes,	monocyte-derived	macrophages	and	KC	share	
many surface markers it is hard to discern between these cell populations.
Although HBsAg did not directly affect KC phenotype in vitro, HBsAg induced 
production	of	high	levels	of	pro-inflammatory	cytokines	by	these	cells.	The	HBsAg-
induced	production	of	 IL-6,	TNF	and	CXCL8	by	KC	 is	comparable	with	 the	HBV-
induced production of these cytokines by non-parenchymal liver cells, presumably 
KC,	reported	by	Hösel	et al.	These	cytokines	are	possibly	beneficial	for	the	early	viral	
containment,	since	cytokines	like	IL-6	and	TNF	directly	inhibit	HBV	replication	[20,	
31],	and	could	provide	the	first	signals	towards	the	initiation	of	HBV-specific	immunity	
in	the	early	phase	after	HBV	infection	by	attracting	and	activating	other	immune	cells.	
The	IFNγ production by NK cells upon co-culture with HBsAg-activated macrophages 
is	likely	mediated	by	KC-derived	cytokines	such	as	IL-12	and	IL-15	[10].	Interestingly,	
also	in	WHV,	intrahepatic	IFNγ and IL-12 expression were found in the early phase 
after	 infection,	and	also	the	chimpanzee	model	of	HBV	demonstrated	intrahepatic	
IFNγ	 levels	prior	 to	clear	onset	of	 the	adaptive	T	cell	 response	[32,	33].	Although	
we	cannot	completely	rule	out	a	contribution	of	T	cell-derived	IFNγ in these animal 
models,	 elevated	NK	cell	 frequencies	 have	been	 reported	 in	 acute	HBV	patients	
[34].	Together	with	 the	cytokines	produced	by	 the	KC	themselves,	 these	NK	cell-
derived factors may further control viral replication and will support the induction of 
virus-specific	immunity	[35].	And	although	KC	were	recently	described	to	restrict	liver	
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damage	[36],	these	cytokines	could	also	be	harmful	contributing	to	liver	inflammation	
and	liver	fibrosis	[37,	38].
In conclusion, the present study shows a direct interaction between KC and HBsAg, 
in vivo and in vitro.	HBsAg-induced	KC	function	and	subsequent	NK	cell	activation,	
could	be	an	early	event	 in	the	inhibition	of	HBV	replication	and	induction	of	HBV-
specific	immunity	during	the	early	phase	after	HBV	infection,	but	may	also	contribute	
to liver damage during the chronic phase.
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Supplementary Figure 1. Kupffer cells display an activated phenotype in chronic HBV. The	phe-
notype	of	KC	present	in	healthy	control	liver	tissue	(HC;	n=14)	and	chronic	HBV	patients	(n=7).	(A)	Rep-
resentative pseudo-colour density plots of liver biopsy cells stained for CD45 and CD14 demonstrates 
the	KC	gating	strategy	used	to	perform	flow	cytometric	analysis,	which	is	based	on	CD45-positivity,	FFS/
SSC-gating to identify liver mononuclear cells and high CD14 expression. (BC)	Representative	histo-
grams	demonstrating	the	surface	expression	of	different	molecules	on	KC	as	assessed	by	flow	cytometry	
as	described	in	A.	Shown	are	overlays	of	specific	(black)	and	background	staining	(grey).
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Supplementary Figure 2. Perfusate-derived KC phenotype and expression of co-stimulatory mol-
ecules and cytokines after HBsAg exposure. (A)	Perfusate-derived	KC	were	isolated	and	assessed	
by	flow	cytometry	to	determine	their	phenotype.	Representative	histograms	are	shown	(n=6).	(B)	Isolated	
perfusate-derived KC were cultured with pHBsAg. After 48h, KC were assessed for their activation status 
by	flow	cytometry	of	which	representative	overlays	are	shown	(n=6)	(C)	Isolated	perfusate-derived	KC	
were	cultured	with	rHBsAg.	After	48h,	KC	were	assessed	for	cytokine	production	(mean±SEM)	as	as-
sessed	by	ELISA	(n=3).
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Supplementrary figure 3. In vitro-generated macrophage phenotype, and expression of co-stimu-
latory molecule expression after HBsAg exposure. In vitro-generated macrophages were assessed 
by	flow	cytometry	to	determine	their	phenotype.	(A)	Representative	histograms	demonstrating	the	pheno-
type	of	monocyte-derived	macrophages	(n=10).	(B)	Comparison	of	isolated	liver	graft	perfusate-derived	
KC	(n=5)	and	 in vitro-generated	macrophages	(n=10)	phenotypes.	Shown	are	box	and	whiskers	plots,	
whiskers representing smallest and largest value, line in the middle representing median (C)	Monocyte-
derived	macrophages	were	cultured	with/without	pHBsAg	and	assessed	for	their	activation	status	by	flow	
cytometry. Histograms demonstrated are representative for 9 independent experiments with different 
donors.
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Introduction
Chronic	 HBV	 infection	 research	 was	 and	 still	 is	 focused	mainly	 on	 the	 adaptive	
immune system, albeit the last ten years there has been a steady but slow increase 
in papers on antigen-presenting cells. As discussed by Bertoletti et al., coordinate 
activation	 of	 innate	 and	 adaptive	 response	 is	 necessary	 for	 HBV	 control	 [1].	
Without	a	proper	immune	reaction	by	innate	immune	cells	like	DC,	monocytes	and	
macrophages,	the	ensuing	adaptive	immune	response	will	be	severely	hampered	[2,	
3].	In	this	thesis	we	explored	two	aspects	of	the	role	of	APC	in	HBV	infection:	firstly,	
we	looked	into	effects	of	IFN	on	the	function	and	phenotype	of	APC	(chapter	3	and	
4);	secondly,	we	looked	at	the	interaction	of	APC	and	viral	proteins,	most	importantly	
HBsAg	 (chapters	5	and	6).	Although,	per	chapter	experiments	and	findings	have	
been	 reviewed	 in	 each	 chapter’s	 own	 discussion,	 some	 remaining	 topics	 will	 be	
discussed	below.	Ultimately,	the	consequences	of	some	of	the	findings	in	this	thesis	
and	the	future	perspectives	for	this	part	of	the	field	will	be	addressed.
Part I: Effect of in vivo and in vitro IFN on antigen-presenting cells
The mode of action of ribavirin
IFN	 until	 recently	 have	 been	 the	 mainstay	 of	 chronic	 hepatitis	 B	 treatment	 and	
hepatitis C treatment. Likewise, ribavirin has been a critical component of the 
standard	of	care	combination	therapy	of	IFN	and	ribavirin	in	the	treatment	of	chronic	
hepatitis C infection for almost 20 years. Despite the extensive use of ribavirin in the 
treatment	of	HCV,	the	mechanism	by	which	it	executes	its	antiviral	function	remains	
unknown. Several mechanisms have been proposed, some of which we discussed 
in	chapter	3.	However,	none	convincingly	accounts	for	the	boost	that	it	gives	to	IFN-
based	 therapy	as	 reviewed	 in	 [4].	 Indeed,	one	would	expect	mechanisms	 like	 (1)	
the	 inhibition	 of	 inosine	 5’-monophosphate	 dehydrogenase	 (IMPDH),	 an	 enzyme	
important	 in	 the	 de	 novo	 synthesis	 of	 guanosine	 [4],	 to	 affect	 a	 broad	 spectrum	
of	 especially	 RNA	 viruses.	 However,	 since	 GTP	 is	 a	 necessary	 component	 of	
viral	RNA	synthesis	and	HBV	replicates	via	an	RNA	 intermediate,	 ribavirin	would	
be	expected	to	inhibit	HBV	replication	also.	The	lack	of	clinical	efficacy	of	ribavirin	
monotherapy	in	HCV	[5]	and	of	the	addition	of	ribavirin	to	IFN	monotherapy	in	HBV	
[6]	suggests	that	mechanisms	like	(1)	inhibition	of	IMPDH,	(2)	the	induction	of	lethal	
viral	mutagenesis,	(3)	impairment	of	translation	via	eIF4E,	and	(4)	direct	inhibition	of	
viral RNA-dependent RNA-polymerases, are not important mechanisms employed 
by	ribavirin	in	this	case	[4].	Even	though	the	latter	mechanism	is	HCV-specific	and	
ribavirin	might	have	different	direct	effects	on	HBV.	Because	ribavirin	showed	a	lack	
of	clinical	effect	in	chronic	HBV	patients,	we	were	able	to	research	immunological	
effects	of	adding	ribavirin	independently	of	a	simultaneous	decrease	in	HBV-DNA,	
assessing	 some	 of	 the	 other	 proposed	modes	 of	 action	 of	 ribavirin.	 Another	 (5)	
mechanism	 proposed	 for	 ribavirin	 is	 the	 modulation	 of	 the	 TH1/TH2 lymphocyte 
balance	[4],	which	does	not	 take	place	 in	 the	 treatment	group	containing	ribavirin	
in	our	study,	as	addressed	 in	chapter	3.	Additionally,	 IFN-based	 therapy	 led	 to	a	
strong	decline	of	 IFNγ-producing	TH1 cells. In accordance with these data, it has 
been	suggested	that	it	is	unlikely	that	restoration	of	T	cell	responses	is	causal	to	an	
early	response	or	SVR	to	therapy	[7].	A	different	possible	immune-modulatory	effect	
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of	ribavirin	is	(6)	the	modulation	of	the	ISG	expression.	One	of	the	ways	that	ribavirin,	
as a purine analogue, can exert such modulation was already discussed in chapter 
3:	direct	activation	of	TLR7	and/or	TLR9,	or	potentiation	of	 the	response	to	TLR7	
and/or	TLR9	did	not	occur	in	our	study.	However,	another	way	of	modulating	the	ISG	
expression	is	by	improving	the	IFN	signalling	cascade.	Especially	when	ribavirin	was	
used	in	conjunction	with	IFNα,	induction	of	specific	ISG	was	synergistic	as	compared	
to	 IFN	 or	 ribavirin	monotherapy	 [8].	How	exactly	 this	 takes	 place,	 remains	 to	 be	
resolved. An interesting recent addition to this mechanism suggests that ribavirin 
seems	 to	 potentiate	 the	 susceptibility	 for	 IFN	 signalling	 by	 lowering	 the	 baseline	
expression	of	some	ISG	[9].	Since	in	our	study	we	did	not	focus	on	this	mechanism	
of ribavirin action, it is hard to draw conclusions or even speculate based on the data 
presented	in	chapter	2.	The	ribavirin-induced	increase	of	co-stimulatory	molecules	
suggests	 that	 ribavirin	 enhances	 IFN	 effects	 since	 IFN	 is	 known	 to	 increase	 the	
expression	 of	 CD40,	 CD80	 and	 CD86	 [10,	 11].	 However,	 if	 ribavirin	 potentiates	
IFN	action	by	augmenting	ISG	induction,	one	might	not	expect	that	this	effect	also	
improves	clinical	efficacy	 in	chronic	HBV	infection.	A	possible	explanation	 for	 this	
could	be	that	ribavirin	amplifies	the	expression	of	specific	ISG	important	in	anti-HCV	
immunity,	but	unimportant	in	anti-HBV	immunity.	Another	explanation	could	be	that	
IFN	signalling	in	HBV	is	more	impaired	than	that	in	HCV,	resulting	in	differential	IFN	
effects,	 with	 or	 without	 ribavirin.	 Since	 the	 IFN-induced	 effects	 on	 co-stimulatory	
molecules,	and	perhaps	also	other	IFN-induced	factors,	are	limited	in	our	study,	it	is	
not surprising that a ribavirin-induced enhancement is minimal.
Importantly, the type of cell in which certain ISG are upregulated seem to be 
pivotal for treatment response. In the case of ISG15, non-responders mainly show 
an upregulation of this ISG in hepatocytes, while upregulation of the same ISG is 
found	primarily	 in	KC	of	responders	[12].	This	shows	us	two	important	 things:	(A)	
modulation of the innate immunity by ribavirin may well be as important, if not more 
important,	 in	 resolving	HCV	 infections	 than	 its	 effect	 on	 the	 intracellular	 immune	
response;	and	(B)	the	importance	of	cell	type-specific	induction	of	ISG,	which	will	be	
addressed	further	in	the	type	III	IFN	paragraph.	Concerning	the	modulation	of	the	
innate immunity: in our study we showed an increase in the basal activation status 
of peripheral DC upon ribavirin addition. An increase in the activation status of DC 
may mean that these DC are functionally altered. Although not apparent in our study, 
changes in activation markers on pDC have been correlated to clinical outcome in 
HCV	treatment	[13].	Furthermore,	the	induction	of	DC-mediated	T-cell	proliferation	
and	 IFNγ	production,	and	pDC-derived	 IFNα production was not increased in our 
study,	there	are	other	functionalities	like	the	induction	of	T-cell	or	NK	cell	cytotoxicity	
that we have not looked at. Perhaps more importantly, in our study we looked at the 
effects of ribavirin on peripheral leukocytes, and we can therefore not exclude that 
the effects on DC and other immune cells like KC and NK cells migrating to or found 
in	 the	 liver	may	be	more	 potent.	Additional	 questions	 remaining	 are	whether	 the	
differences	induced	by	ribavirin	are	specific	for	HBV	infection	and	whether	the	same	
takes	place	in	for	instance	HCV	infection.
The effect of type I IFN on antigen-presenting cells
When	observing	 the	 IFN-based	 therapy	 in	 our	 study	 in	 chapter	 3	 one	will	 notice	
that the most profound therapy-induced effects found were not caused by ribavirin, 
but	by	peginterferon.	Despite	that	the	activity	of	type	I	IFN	was	originally	described	
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close	to	60	years	ago	[14],	and	the	use	of	IFN	as	antivirals	in	hepatitis	B	infection	
stems	 from	around	40	 years	ago	 [15],	we	 still	 have	only	 a	 limited	understanding	
of	 their	 effects	 in	 antiviral	 immunity.	 IFN	 treatment	 is	 known	 to	 cause	decreased	
blood	counts	in	a	dose-dependent	fashion	[16].	Indeed,	in	our	study	peginterferon	
treatment	of	chronic	HBV	patients	induced	a	strong	decrease	in	absolute	leukocyte	
numbers.	 These	 haematological	 changes	 are	 mostly	 considered	 side-effects,	 of	
which anaemia, thrombocytopenia and leukopenia are the most prominent and can 
be	attributed	to	a	direct	effect	of	IFNα	on	bone	marrow	[16].	The	role	that	IFN	play	
in	 inducing	an	antiviral	 state	 can	 roughly	be	divided	 into	 (a)	 the	 induction	of	 IFN	
response	genes	and	(b)	the	modulation	of	immune	cells.	In	our	study	in	chapter	3,	
also the relative numbers decreased for mDC (both BDCA-1+ and BDCA-3+)	and	
monocytes,	which	may	be	due	to	the	immune	modulatory	effects	of	IFN.	It	was	noted	
earlier that the fact that leukocyte numbers decline shortly after starting treatment 
and recover within days to baseline levels after stopping treatment, suggests that 
a redistribution of leukocytes takes place from the peripheral circulation to other 
compartments	 like	 tissues	 [16].	 In	 our	 study	 the	 decline	 in	 cell	 numbers	 starts	
within 12 weeks, possibly much earlier, while cell numbers return to baseline after 
discontinuing treatment. Although we did not see changes in adhesion markers 
on	DC	upon	treatment	of	chronic	HBV	patients,	there	were	changes	in	chemokine	
receptors.	This	suggests	a	different	migration	pattern	that	may	cause	a	redistribution	
of these leukocytes. Moreover, it could be that the sub-populations of leukocytes 
that	actually	migrated	to	the	liver	show	an	even	more	changed	phenotypical	profile.	
Namely,	a	profile	that	leads	to	actual	migration	and	perhaps	also	functional	change.	
In	agreement	with	this	data,	earlier	reports	show	that	IFNα in vitro and in vivo alters 
chemokine	receptor	expression	[17,	18].	Further	immune	modulatory	effects	of	type	
I	 IFN	 therapy	are	on	proliferation,	differentiation,	activation	and	maturation	of	not	
only DC, but also various other leukocyte populations like monocytes, macrophages 
and	 lymphocytes	 [19].	 Monocytes	 and	 mDC	 incubated	 with	 IFNα obtained an 
increased	 maturation	 status	 [20].	 We	 were	 able	 to	 show	 a	 similar	 IFN	 therapy-
induced increase in maturation status of DC and monocytes measured by markers 
like	CD40,	CD80,	CD86.	Specifically	the	CD14+ CD16- monocytes and not the CD14- 
CD16+	monocytes	showed	 this	 increased	maturation	 (data	not	 shown).	However,	
we could not show that these cells were endowed with higher functional potential, 
leading	for	instance	to	a	higher	capacity	to	induce	T	cell	activation	[19].	Since	we	
performed	T-cell	stimulatory	assays	with	total	PBMC,	the	relative	decrease	of	mDC	
–	the	most	potent	of	antigen-presenters	–	may	be	to	blame	for	this.	In	addition	to	
what we reported in our paper, that focuses mostly on DC, in our study we also 
found	IFN	effects	on	other	immune	cells:	the	numbers	of	peripheral	NK	cells	strongly	
increased, caused primarily by an increase in CD56bright NK cells. Increased CD56bright 
NK	cell	 numbers	 during	 peginterferon	 treatment	 of	 chronic	HBeAg-negative	HBV	
patients were reported to be accompanied by a concomitant enhanced expression 
of	 activation	markers,	 activating	 receptor	NKp46,	TRAIL	and	 IFNγ	 [21].	A	 similar	
effect	was	found	in	the	treatment	of	chronic	HCV	patients	with	IFN-based	therapy.	
This	led	to	an	increased	frequency	of	CD56bright NK cells, while not only the CD56dim 
NK	cell	 frequency	decreased	but	also	perforin	and	CD16	 levels	strongly	dropped	
[22].	It	has	been	suggested	that	this	shift	in	NK	cell	subsets	may	result	in	more	NK	
cells	 able	 to	 produce	 IFNγ while these cells demonstrate less cytotoxic capacity 
possibly	 resulting	 in	 less	 liver	 damage	 [22].	 However,	 since	 these	 studies	 were	
performed on peripheral cells, the effects of these peripheral cells on the intrahepatic 
immune system are unsure. Moreover, it could be that the CD56dim to CD56bright shift 
took place because of migration of NK cells to the liver. As with ribavirin, perhaps 
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more	 interesting	would	 be	 the	 effect	 of	 IFN	on	 intrahepatic	 immune	 cells.	 It	was	
reported	that	during	IFN	treatment	intralobular	CD68	expression	(denoting	KC)	was	
stable. However, intrahepatic CD14 expression was increased, likely representing 
monocytes/infiltrating	macrophages	[23],	while	also	NK	cell	numbers	were	increased	
in	 the	portal	areas	 [24].	Together	 these	cells	presumably	 reflect	an	 IFNα-induced 
enhancement of the antiviral immune response. CD1a and CD83 expression was 
unaltered	by	IFN	therapy,	while	there	are	contrasting	reports	on	HLA-DR	expression	
[23,	24].	At	the	same	time,	T-cell	infiltration	was	reduced,	mostly	caused	by	a	decrease	
in CD8+	T	cell	numbers	[23].	Further	assessment	of	IFN-induced	changes	and	what	
functional	consequences	such	changes	would	have	remain	to	be	performed.
Ultimately,	the	goal	of	IFN	therapy	is	helping	the	patient,	who	did	not	spontaneously	
clear the virus, to get rid of the virus after all. In our study only 4 out of 14 patients 
presented a combined virological and biochemical response, while the majority 
failed	 to	 do	 so	 despite	 the	 immunological	 changes	 induced	by	 IFN	and	 ribavirin.	
None of these changes in phenotype or function correlated with response to therapy, 
suggesting that these changes found in peripheral immune cells do not aid or harm 
anti-viral	immunity.	Which	immunological	changes,	peripheral	but	also	intrahepatic,	
during treatment are of importance for clinical outcome remains to be assessed 
further. Not only for prediction purposes, like pre-treatment CXCL9 and CXCL10 
can	predict	 peginterferon	 treatment	 outcome	 [25,	 26],	 but	 also	 for	 immunological	
understanding.
The effect of type III IFN on antigen-presenting cells
As	mentioned	in	the	 introduction	of	 this	thesis,	 IFNλ	 is	a	type	III	 IFN	that	 induces	
ISG	expression	 largely	overlapping	with	that	 induced	by	IFNα. However, because 
of	a	more	 restricted	expression	pattern	of	 its	 receptor	 compared	 to	 that	 of	 IFNα, 
IFNλ	induces	ISG	only	in	specific	cell	types.	RNA	expression	for	IL-28Rα has been 
shown	in	blood	and	in	most	tissues,	among	which	was	liver	[27,	28].	But	as	stated,	
only	few	cell	types	react	to	IFNλ.	Peripheral	blood	monocytes,	B	cells,	T	cells	and	
NK	cells	have	been	reported	not	to	react	to	IFNλ	[28],	although	on	NK	cells	there	are	
studies	that	conflict	with	this	notion	[29-31]	as	discussed	in	chapter	4.	Within	blood,	
only	pDC	have	convincingly	been	shown	to	express	the	IFNλR	and	react	 to	 IFNλ 
[32],	as	have	the	in vitro-cultured	macrophages	that	we	look	at	in	chapter	4	[33].	In	
our	study	we	wanted	to	assess	whether	IFNλ can affect cells other than those that 
become infected, like hepatocytes in the viral hepatitis setting. Due to the lack of 
expression	of	the	IFNλR1	subunit	and	the	lack	of	reaction	to	IFNλ by NK cells, an 
interesting	and	important	cell	to	combat	HBV	infection,	we	focused	on	IFNλ effects 
on	macrophages.	Functional	interactions	between	NK	cells	and	other	innate	immune	
cells	 like	DC	and	macrophages	are	well	 described	 [34-38].	We	 then	 reported	an	
indirect	effect	of	 IFNλ	on	NK	cells,	via	macrophages	 (Figure	1A),	a	cell	 type	 that	
expressed	 the	 IFNλR	and	 functionally	 reacted	 to	 IFNλ exposure. But monocytes, 
the precursor of our in vitro-generated	macrophages,	were	negative	for	the	IFNλR1 
subunit.	Exposing	monocytes	to	GM-CSF	over	time	caused	upregulation	of	IFNλR1, 
showing the effect of environmental factors on the expression of this receptor. 
Since the liver has a cytokine milieu different from peripheral blood in steady state 
conditions,	but	also	 in	 inflammatory	conditions	 like	during	HBV	 infection,	 it	would	
be	interesting	to	see	what	the	expression	of	the	IFNλR on immune cells in the liver 
is. Interestingly, in vitro, murine peritoneal and bone marrow-derived macrophages 
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were	shown	not	to	react	to	IFNλ,	suggesting	a	lack	of	functional	IFNλ receptor on 
tissue and another type of in vitro-generated	macrophages	[39,	40].	Moreover,	KC	
from	healthy	human	liver	showed	no	IFNλR1 expression and cytokine production did 
not	change	upon	exposure	to	IFNλ	(data	not	shown).	The	cause	of	this	discrepancy	
in	 IFNλR expression between KC and monocyte-derived macrophages may be in 
the liver environment, but could also be explained by possible differences in origin 
[41].	Phenotypically,	M1-like	macrophages	like	the	monocyte-derived	macrophages	
that	 we	 cultured	 differ	 from	 KC	 (data	 not	 shown),	 which	 is	 likely	 caused	 by	 the	
liver	 environment.	 It	 remains	 to	 be	 seen	 whether	 infiltrating	 macrophages	 also	
express	IFNλR	within	the	liver.	If	they	do,	this	suggests	that	infiltrating	monocytes/
macrophages	 are	 the	 cells	 that	 react	 to	 IFNλ, not KC, producing cytokines that 
induce	NK	cell	 function,	but	perhaps	also	adaptive	immunity.	Whether	this	 indeed	
takes place during hepatitis B infection, in an altered hepatic cytokine milieu and in 
the	presence	of	HBV	and	its	proteins	that	on	the	one	hand	inhibit	IFN	signalling,	but	
on	the	other	hand	induce	cytokine	production	by	macrophages	(Figure	1B),	remains	
to	be	investigated	(see	Figure	1C).
Taken	together,	based	on	literature	and	our	data	in	chapter	3,	it	seems	most	likely	
that	 ribavirin	 enhances	 the	 IFN	 response	 instead	 of	 employing	 any	 of	 the	 other	
described	 methods.	 Since	 IFN	 in	 our	 study	 induced	 a	 proper	 clinical	 response	
in	 only	 a	minority	 of	 patients	 despite	 the	 IFN-induced	 immunological	 changes,	 it	
is	 tempting	 to	 conclude	 that	 the	 antiviral	 capacity	 of	 IFN	 is	 mostly	 targeted	 at	
hepatocytes.	However,	although	HBV	inhibits	IFN	signalling	in	human	hepatocytes	
[42],	 during	 acute	HBV	 infection	 of	 chimpanzees	 no	 IFN	 signalling	was	 found	 in	
liver	tissue	as	a	whole,	including	immune	cells	[43].	Additional	factors	like	increased	
bile	acid	concentrations	during	HBV	 infection	are	able	 to	disturb	 IFN	signalling	 in	
not	only	hepatocytes	but	also	 immune	cells	 [44].	Therefore,	we	can	certainly	not	
exclude	 that	 the	 therapeutic	 effect	 of	 IFN	 is	 accomplished	 via	 not	 only	 a	 direct	
effect on hepatocytes but also an immune-modulatory effect making use of APC. 
Furthermore,	since	KC	and	peripheral	immune	cells,	except	pDC,	lack	the	functional	
IFNλR	it	is	hard	to	determine	the	importance	of	IFNλ in the local immune response. 
It	seems	unlikely	that	IFNλ, inducing an ISG pattern largely overlapping with that of 
IFNα,	would	perform	better	than	IFNα	as	a	therapeutic	in	HBV	infection,	except	for	
an	improved	tolerability.	However,	based	on	the	observation	that	IFNλ induces an 
ISG	response	that	 is	more	sustained	than	that	 induced	by	IFNα,	 IFNλ	may	fit	 the	
requirements	for	a	therapy	that	provides	a	long-lasting	protective	immune	response	
[45,	46].	Additionally,	the	mechanisms	inducing	the	expression	of	type	I	and	type	III	
IFN	are	not	identical	[47,	48],	suggesting	differential	actions	and/or	similar	actions	
differentially induced, perhaps as a resistance mechanism to viral evasion strategies. 
Moreover,	due	to	its	restricted	receptor	expression	IFNλ	may	exert	biological	efficacy	
on	other	cell	types	than	IFNα	does,	limiting	its	actions	to	certain	cells.	Therefore,	until	
important	questions	like	intrahepatic	receptor	expression,	importance	of	 infiltrating	
macrophages in the anti-viral immune response, possible unfavourable pro-viral 
IFNα	 effects	 that	 IFNλ	might	not	 induce	and	most	 importantly,	 clinical	 efficacy	of	
IFNλ,	have	been	addressed	IFNλ	will	remain	a	promising	therapeutic	option	for	HBV	
infection worth exploring.
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Figure 1. KC and monocyte-derived macrophages induce NK cell function. (A)	Addition	of	 IFNλ 
activates LPS-induced monocyte-derived macrophages to produce IL-12p40 and IL-23, and to induce 
(IL-12-dependent)	IFNγ production by NK cells. (B)	HBsAg-induced	monocyte-derived	macrophages	and	
KC	produce	IL-6,	TNF	and	IL-10,	and	induce	IFNγ production by and activation of NK cells. (C)	Will	ad-
dition	of	IFNλ	to	HBsAg-induced	monocyte-derived	macrophages	further	induce	IFNγ production by and 
activation of NK cells? KC, Kupffer cells; MoMΦ, monocyte-derived macrophages.
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Part II Effect of HBsAg on function of antigen-presenting cells
The recognition of HBV
Even	though	recently	an	HBV	receptor	has	been	identified	on	hepatocytes	[49],	 it	
remains	to	be	resolved	how	immune	cells	recognize	HBV	and	what	the	functional	
consequences	of	this	interaction	are.	It	has	been	stated	that	HBV	is	a	stealth	virus	
since,	 in	 contrast	 to	HCV	 and	 other	 viruses,	 HBV	 does	 not	 seem	 to	 induce	 any	
type	 I	 IFN	and	 ISG	during	 the	 early	 stages	 of	 infection	 [43,	 50].	 And	 although	 it	
is	 difficult	 to	 assess	 such	 early	 events	 in	 acute	HBV	 infection	 in	 humans,	 it	was	
recently	 shown	 that	 type	 I	 IFN	 responses	are	also	absent	 in	acute	HBV	patients	
[51].	Moreover,	 it	was	shown	 that	pDC,	 immune	cells	 specifically	 known	 for	 their	
ability	 to	produce	copious	amounts	of	 IFNα upon recognizing viruses, display no 
IFNα	response	to	HBV	exposure	[38].	However,	despite	not	inducing	the	type	I	IFN	
response normally seen upon viral infection, over 90% of infected adult patients 
clear	 the	virus	spontaneously	 [52].	This	 indicates	 that	a	proper	antiviral	 response	
is	mounted	nonetheless,	meaning	 that	HBV	does	not	stay	under	 the	 radar	but	 is	
recognized,	 in	which	APC	an	 important	 role.	By	 recognizing	HBV,	APC	can	start	
and from there on regulate the antiviral immune response. It was already shown that 
non-parenchymal	cells,	presumably	KC,	react	to	HBV	by	secreting	pro-inflammatory	
cytokines IL-1β,	 IL-6,	 TNF	 and	 CXCL8	 [50].	 Liver	 macrophages	 (CD68+)	 and	 a	
CD11c+	 intrahepatic	population	 (either	macrophages	or	mDC)	also	produce	 IL-23	
during	HBV	infection	[53].	Monocytes	produce	TNF	and	IL-10	upon	HBsAg	exposure	
[54],	 while	 monocyte-derived	 DC	 produced	 IL-12	 [55].	 In	 a	 different	 study	 both	
HBsAg and HBcAg induce IL-23 production in monocyte-derived DC, but little IL-12 
production	[53].	However,	besides	stimulatory	capabilities,	it	has	also	been	reported	
that	HBV	and	 its	components	are	 inhibitory,	being	able	 to	suppress	TLR-induced	
cytokine	production	in	various	cell	types	[38,	56-61].	
In chapter 5 and 6, we show that patient-derived HBsAg induces cytokine production 
in not only monocytes, but also in KC and monocyte-derived macrophages; cells 
that are found at the place of infection, i.e. the liver. Although we could not show the 
presence	of	HBsAg	on	or	in	monocytes,	there	are	several	findings	that	corroborate	
our	HBsAg-induced	monocyte	 data	 [54,	 62,	 63].	 This	would	 indicate	 not	 only	 an	
interaction but also the capacity to recognize HBsAg and act on it. Likewise, there 
has	been	circumstantial	evidence	suggesting	the	interaction	of	KC	with	HBV	[50].	
Although we show that both monocytes and KC interact with and react to HBsAg in 
vitro by producing cytokines, whether the latter takes place in vivo is unsure. In our 
study in chapter 5 we speculate that cytokine production by peripheral monocytes in 
chronic	HBV	patients	is	likely	regulated.	Also	cytokine	production	in	the	liver	might	
well	be	regulated,	since	the	liver	is	known	for	its	tolerogenic	environment.	If	HBV	and	
its proteins turn out to induce KC and monocytes in vivo, it is likely that KC, and not 
monocytes, are the cells that initiate an antiviral response since KC are already at 
the place where it is needed: in the liver. KC can produce chemokines and cytokines 
to attract and activate other immune cells. Monocytes can add to this response 
by	removing	viral	proteins	from	the	periphery	and	producing	cytokines	 influencing	
peripheral	 immune	 cells.	Monocytes	 can	also	 infiltrate	 the	 liver	 and	 reinforce	 the	
antiviral	 inflammatory	 response	 by	 differentiating	 to	 macrophages.	 Due	 to	 the	
lack	of	distinctive	markers	further	analysis	of	the	role	of	KC	versus	liver-infiltrating	
macrophages is hampered. How either of these cells contributes to viral immunity 
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and disease pathogenesis should be assessed in future efforts.
As both monocytes and macrophages interact with HBsAg, an interesting and more 
often	proposed	putative	receptor	for	HBV	is	CD14	[63].	CD14	was	put	forward	as	a	
possible receptor on peripheral monocytes for recombinant HBsAg, in combination 
with	LPS-binding	protein	(LBP).	However,	the	same	paper	showed	that	HBV	patient	
plasma-derived	 HBsAg	 (pHBsAg)	 was	 not	 endowed	 with	 the	 capacity	 to	 bind	 to	
CD14	via	LBP	[63],	although	we	show	that	pHBsAg	is	able	to	activate	monocytes	
and therefore likely to bind to them. Since CD14 is only expressed by a limited 
number	of	cell	types,	suggesting	it	as	a	possible	receptor	for	HBV/HBsAg	imposes	a	
restriction	on	the	number	of	cells	able	to	bind	HBV/HBsAg.	This	theoretically	either	
excludes	CD14-negative	cells	being	able	to	interact	with	HBV	or	makes	it	necessary	
to introduce an additional putative receptor to do so. Since it has been shown that 
CD14-negative cells like BDCA-1+ mDC and monocyte-derived DC interact with 
HBsAg	(Shi	2007,	Op	den	Brouw	2008	Immunology),	the	former	of	the	two	options	
seems unwarranted. However, as shown for LPS triggering, CD14-negative cells like 
DC, but also endothelial, epithelial and smooth muscle cells, are not CD14 negative in 
an	absolute	sense.	Besides	as	a	membrane-bound	form	(bound	via	its	GPI-anchor),	
CD14	also	exists	 in	a	soluble	form	(sCD14)	either	as	a	shedded	molecule	(48-49	
kDa)	or	a	secreted	molecule	(55-56	kDa).	Although	the	biological	difference	between	
these forms of different size for now remains unknown, it is clear that sCD14 plays 
an important role in the LPS-mediated activation of aforementioned CD14-negative 
cells	[64].	The	same	may	hold	true	for	HBsAg.	Indeed,	rHBsAg	bound	sCD14	as	it	
did	mCD14	[63].	Since	sCD14	(and	LBP)	are	found	in	serum	in vivo, but also in in 
vitro-used serum-containing media, HBsAg may bind to sCD14. sCD14 then can 
bind CD14-negative cells like DC, but also CD14-positive cells, via its GPI-anchor 
and hereby activate the cell. Since the interaction between sCD14, LPS and LBP is 
fundamentally	different	from	that	between	mCD14,	LPS	and	LBP	[64],	it	could	well	
be that the resulting signalling induced by sCD14 and HBsAg likewise differs from 
that induced by mCD14 and HBsAg, resulting in a different cellular reaction pattern 
depending on the receptor used and the cell the receptor binds to or is bound to.
Another possible receptor for HBsAg put forward is the mannose receptor (MR; 
CD206),	expressed	by	DC	[65]	and	KC	[66],	and	to	a	lesser	extent	by	monocytes	
[67].	mDC	were	shown	to	bind	HBsAg	via	 the	MR.	HBsAg+ mDC were especially 
found within the liver. Interestingly, mDC MR expression and HBsAg are positivity 
correlated, suggesting that the MR-mediated interaction between mDC and 
HBsAg	mostly	 takes	 place	 at	 the	 site	 of	 inflammation,	 i.e.	 the	 liver.	 Additionally,	
HBsAg-induced IL-23 production by monocyte-derived DC and monocyte-derived 
Mf (MoMΦ)	was	shown	to	be	dependent	on	the	binding	of	HBsAg	to	the	MR	and	
subsequent	 endocytosis	 [53].	 Interestingly,	 on	 cells	 that	 express	 both	CD14	 and	
CD206, co-ligation of these receptors can lead to a different response than ligation 
of	 the	separate	receptors	 [68].	This	would	 indicate	 that	also	the	balance	of	CD14	
and CD206 expression levels may attune the reaction to their ligands per cell type. 
Accordingly,	MR	can	 induce	production	of	cytokines	 like	 IL-10,	 IL-17,	TNF,	CCL2	
and CXCL8 in response to some fungal pathogens, but paradoxically also inhibit the 
production	of	cytokines	such	as	IL-12	and	TNF	in	response	to	other	fungal	pathogens	
[53].	This	adds	another	variable	to	the	various	reaction	patterns	of	the	different	APC	
to HBsAg. 
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Consequence of APC interacting with HBV, and their role in the HBV-induced 
immune response
A. Self-limiting hepatitis B infection 
As stated in the introduction, a coordinate activation of innate and adaptive immunity 
is key in controlling hepatitis B infection, with a central role for antigen-presenting 
cells.	 By	 recognizing	 HBV	 and	 its	 components,	 and	 subsequently	 secreting	 pro-
inflammatory	cytokines,	KC	are	able	to	contribute	to	the	immune	activation	and	antiviral	
immunity	upon	HBV	infection,	as	described	in	chapter	2.	By	secreting	chemokines	
and	cytokines,	KC	will	not	only	attract	and	activate	HBV-specific	immune	cells	like	
CD8+	T	cells.	Also	non-specific	immune	cells	like	monocytes,	DC	and	NK	cells	will	
be	attracted.	Monocytes,	like	we	show	in	chapter	5,	in	turn	can	react	to	HBV	and/
or its components by producing cytokines. Moreover, monocytes can differentiate 
into	macrophages	upon	entering	 the	 liver,	 becoming	 infiltrating	monocyte-derived	
macrophages. In chapter 6 we showed that monocyte-derived macrophages can 
bind	 HBsAg,	 subsequently	 becoming	 activated	 and	 producing	 pro-inflammatory	
cytokines.	 We	 showed	 that	 both	 HBsAg-induced	 KC	 and	 monocyte-derived	
macrophages	were	able	to	induce	NK	cells	to	produce	IFNγ production. Additionally, 
monocyte-derived DC derived from HBsAg+ monocytes from the peripheral blood of 
chronic	HBV	patients	were	shown	to	cross-present	intracellularly	stored	viral	antigen	
to	autologous	HBV-specific	T	cells,	inducing	IFNγ	secretion	[62].	Among	the	APC,	
DC	are	 known	 to	 be	 excellent	 cytokine	 producers	 and	 the	most	 efficient	 antigen	
presenters, and therefore are thought to play a central role in viral infections like 
HBV	infection	[3,	69].	Despite	that	DC	have	been	shown	to	be	functionally	impaired	
in	chronic	HBV	patients	 [58,	70-72],	 there	 is	a	direct	 interaction	between	DC	and	
HBV	[65].	 In	acute	HBV	infection	there	may	hence	still	be	a	pivotal	 role	 for	 these	
cells.
Together,	 APC	 will	 be	 able	 to	 regulate	 antiviral	 immunity,	 bridging	 innate	 and	
adaptive responses, leading to a self-limiting infection in most cases among adults.
B. Chronic hepatitis B infection
The	abundant	cytokine	production	by	monocytes	 from	healthy	 individuals	upon	 in 
vitro exposure to HBsAg suggests that in vivo a constant production of cytokines 
takes place, since peripheral blood monocytes are constantly exposed to high levels 
of HBsAg. However, chronic hepatitis B patients have not been reported to have 
exceedingly high levels of cytokines in their blood, suggesting that some regulatory 
mechanism	 is	 in	 place	 that	 restrains	 the	monocytes’	 reaction	 to	 viral	 proteins.	 A	
mechanism like sensitization, due to continuous exposure to a certain stimulus, 
seemed	a	logical	explanation	given	the	high	levels	of	viral	particles	in	patients’	blood.	
However,	based	on	the	unaffected	cytokine	production	upon	TLR	ligand	exposure,	
the	variable	concentrations	of	HBV	DNA,	HBeAg	and	HBsAg	did	not	affect	the	ex	
vivo	functional	inducibility	of	monocytes.	What	determines	the	differential	effects	that	
have	been	reported	for	viral	proteins,	being	either	inhibitory	[38,	56,	58,	60,	73-77]	or	
activatory	[50,	53-55]	and	[this	thesis]	remains	to	be	assessed.	As	put	forward	in	our	
study,	regulatory	cytokines	like	IL-10	and	TGFβ	[51,	78-81],	are	molecules	that	have	
inhibitory effects on cytokine production in vivo.	We	showed	that	both	molecules	are	
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able to abrogate HBsAg-induced cytokine production in vitro. An additional factor 
in the regulation of the monocyte response to HBsAg may be sCD14, based on 
a similar function this molecule has in LPS-induced activation of monocytes and 
clearance	of	 apoptotic	 bodies	 [64,	 82].	 sCD14	binds	and	 clears	apoptotic	 bodies	
without	cellular	activation	and	pro-inflammatory	cytokine	secretion	[64,	82].	Besides	
enabling CD14-negative cells to react to LPS or HBsAg, sCD14 may also inhibit the 
reaction	of	mCD14-positive	cells	by	competition	 for	 the	binding	of	 the	 ligand	[64].	
Indeed, adding sCD14 to monocyte cultures strongly decreased binding of HBsAg 
to	the	monocytes	[63].	After	stimulation,	monocytes	secrete	sCD14	[83].	In	chronic	
hepatitis B patients, blood sCD14 levels were higher than those in acute hepatitis 
B patients and healthy controls. Moreover, sCD14 levels inversely correlated with 
the	HBsAg	levels	in	chronic	HBV	patients,	but	not	with	HBV-DNA	levels	[82].	This	
suggests	that	HBsAg	influences	sCD14	levels,	either	by	decreasing	secretion	or	by	
increasing removal from the circulation. Since we performed our monocyte studies 
in	X-VIVO	medium,	without	any	serum	and	thus	sCD14,	it	is	interesting	to	see	what	
the addition of serum and/or sCD14 does to the monocyte-HBsAg interaction in our 
cultures, and what exactly takes place mechanistically. 
Especially	cirrhotic	chronic	HBV	patients	showed	high	sCD14	levels	[82].	Since	also	
hepatocytes	are	known	to	express	and	secrete	CD14	[64],	it	would	be	interesting	to	
see how sCD14 levels are in the liver, and what the effect of these levels would be 
on intrahepatic immune cells like KC.
Although the cytokines that monocytes and KC produce upon HBsAg exposure 
separately	have	been	shown	to	inhibit	HBV	replication	[50,	84],	in	combination	with	
each other, with additional cytokines and with other soluble molecules the effect 
becomes more complex as we discussed in chapter 2 and describe below. Recently, 
it has been shown that the sodium/bile acid co-transporter Na+-taurocholate 
cotransporting	polypeptide	(NTCP),	expressed	mainly	by	hepatocytes,	is	a	receptor	
for	HBV.	This	receptor	interacts	with	the	pre-S1	of	HBsAg	L.	Using	siRNA	to	reduce	
NTCP	expression,	 it	was	possible	to	inhibit	HBV	infection	in	the	HepaRG	cell	 line	
[49].	 NTCP	 expression	 is	 reduced	 by	 LPS	 via	 the	 reduction	 of	 the	 RXRα/RARα 
heterodimer. IL-1β turns out to play a major role in this, causing the export of RXR 
from	the	nucleus.	Further	reduction	of	NTCP	is	caused	by	a	reduction	of	transcription	
factors	like	HNF1α. Besides IL-1β,	also	IL-6	and	TNF	decrease	NTCP	expression	
[85].	IL-6	has	been	shown	to	inhibit	NTCP	expression	via	the	reduction	of	HNF1α 
[86].	Additionally,	IL-6-induced	inhibition	of	HNF1α, a transcription factor essential 
for	HBV	gene	 expression	 and	 replication,	 led	 to	 the	 inhibition	 of	HBV.	Since	KC	
are in the proximity of hepatocytes, we hypothesised that cytokines produced by 
HBsAg-activated KC, especially IL-1β,	IL-6,	and	TNF,	separately	but	also	together	
would	inhibit	HBV	replication.	To	test	this	we	set	up	experiments	using	the	HepaRG	
cell	line.	We	differentiated	these	cells	and	infected	them	with	HBV,	in	the	absence	
or presence of single cytokines or conditioned medium containing KC supernatants. 
We	harvested	the	hepatocytes	and	measured	the	HBV	total	RNA	and	HBV	3.5	kb	
RNA	for	HBV	pre-C	and	pregenome	RNA	(pgRNA)	by	PCR.	Following	infection	of	
differentiated	HepaRG	cells	with	HBV	we	were	able	to	measure	HBV	3.5	kb	RNA	
(Figure	2A)	and	HBV	total	RNA	(data	not	shown),	indicating	active	HBV	replication.	
In	 the	 same	 figure	 we	 show	 that	 undifferentiated	 HepaRG	 did	 not	 support	 HBV	
infection.	In	accordance	with	literature,	adding	IL-6	or	IFNγ to the culture inhibited 
HBV	replication.	However,	the	addition	of	IL-1β	and	TNF	increased	HBV	replication	
(Figure	2A).	Besides	single	cytokines,	we	also	cultured	 infected	HepaRG	cells	 in	
conditioned	medium,	as	shown	 in	Figure	2B.	This	conditioned	medium	contained	
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supernatant	 of	 unstimulated	 (medium	 condition)	 or	 HBsAg-stimulated	 (HBsAg	
condition)	KC.	Interestingly,	when	incubating	infected	HepaRG	cells	with	conditioned	
medium	 HBV	 replication	 is	 increased,	 as	 indicated	 by	 an	 increase	 of	 HBV	 3.5	
kb	RNA	 (Figure	 2B)	 and	HBV	 total	RNA	 (data	 not	 shown).	Conditioned	medium	
containing	unstimulated	supernatant	induced	an	increase	of	HBV	replication	similar	
to that induced by IL-1β	 or	 TNF,	 while	 conditioned	 medium	 containing	 HBsAg-
stimulated	supernatant	 induced	HBV	replication	even	2	 to	4	 times	more	potently.	
These	 data	 show	 that	 KC	 do	 not	 necessarily	 have	 an	 inhibitory	 effect	 on	 HBV,	
despite	producing	cytokines	that	are	known	to	inhibit	HBV	replication	(Figure	3A).	
Apparently, combinations of cytokines that we measured and/or other cytokines and 
soluble	molecules	in	this	case	induce	HBV	replication	in	an	infected	HepaRG	cell	
line	(Figure	3B).	Moreover,	the	notion	that	unstimulated	KC,	albeit	to	a	lesser	extent	
than	stimulated	KC,	induce	HBV	replication	suggest	that	KC	constitutively	produce	
pro-viral factors that increase when they are activated. It remains to be investigated 
what	factors	play	a	role	in	increasing	KC-induced	HBV	replication.	In	addition	to	the	
example above, in chapter 2 we described that KC can play not only an important 
role	in	building	up	anti-viral	immunity	against	HBV,	but	also	in	tissue	damage	and	
development of viral persistence.
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Figure 2. HBsAg-induced KC supernatants enhance HBV replication. HepaRG cells were incubated 
with	medium	or	HBV	for	16	hours	in	the	presence	or	absence	of	cytokines	(A)	or	KC	supernatant	(B).	
Subsequently	HepaRG	cells	were	washed	and	cultured	further	for	10	days	in	the	presence	or	absence	of	
the	same	cytokines	(A)	or	KC	supernatant	(B),	partly	refreshing	medium,	cytokines	and/or	supernatants	
every	2	days.	10	days	after	 infection	 relative	expression	of	HBV	3.5	kb	RNA	was	measured	by	PCR.	
Undiff, undifferentiated.
Together,	APC	play	a	role	in	chronic	HBV	infection:	on	the	one	hand	failing	to	build	up	
an effective innate and adaptive immune response, and on the other hand causing 
tissue	damage	and	aiding	in	the	development	of	fibrosis,	cirrhosis	and	HCC.
Concluding remarks
This	thesis	focused	on	the	role	of	APC	in	HBV	infection,	both	in	the	peripheral	blood	
and	 in	 the	 liver.	DC,	monocytes	and	KC	all	 interact	with	HBV	and	 its	proteins.	 In	
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chapter 6 we showed a direct interaction between KC and HBsAg, in vivo and in 
vitro. Chapters 5 and 6 combined clearly show that in vitro HBsAg strongly induces 
monocytes,	monocyte-derived	macrophages	and	KC	 to	produce	pro-inflammatory	
cytokines.	HBsAg-activated	KC	and	monocyte-derived	macrophages	subsequently	
induced	 NK	 cell	 activation	 and	 IFNγ	 production.	 Cytokines	 like	 IL-6	 and	 IFNγ 
have	 been	 shown	 to	 have	 direct	 antiviral	 effect.	 Together,	 this	 suggests	 that	
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Figure 3. HBsAg-induced KC cytokines enhance HBV replication. (A)	While	chronic	in vivo exposure 
of peripheral monocytes to HBsAg does not lead to high cytokine levels, possibly due to regulation by 
molecules	like	IL-10	and	TGFβ, in vitro exposure of monocytes, KC and monocyte-derived macrophages 
leads	to	high	expression	of	cytokines	like	IL-6,	TNF	and	IL-10.	IL-6	and	TNF	have	been	shown	in	literature	
to	be	able	to	inhibit	replication	of	HBV.	(B)	Supernatants	of	medium-induced	(not	shown)	and	HBsAg-
induced	KC,	including	the	cytokines	IL-6,	TNF	and	IL-10,	in	our	experiment	did	not	lead	to	inhibition	of	
HBV	replication,	but	enhancement	of	HBV	replication.
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KC,	but	perhaps	 later	also	 inflammatory	monocytes	play	an	 important	 role	 in	 the	
initiation of the antiviral immune response. Additionally, in chapter 4 we showed 
that	 IFNλ,	 a	 possible	 future	 HBV	 therapeutic	 option,	 potentiates	 IL-12	 secretion	
by monocyte-derived macrophages enhancing their NK-cell stimulatory capacity. 
Since	we	showed	 that	KC	do	not	express	 the	 IFNλR, this might signify a role for 
liver-infiltrating	monocyte-derived	macrophages	in	IFNλ-induced antiviral immunity, 
enhancing their IL-12 family cytokine production that can activate NK cells but has 
also	been	shown	to	be	important	for	T	cells.	Another	IFN,	IFNα,	one	of	the	first-line	
therapeutics	in	HBV	infection	was	shown	to	directly	activate	NK	cells.	The	ability	of	
these	IFN	to	activate	NK	cells	seems	redundant,	but	it	may	also	signify	a	difference	
in	antiviral	mechanism	where	IFNα induces a short, strong antiviral reaction, while 
IFNλ	induces	a	slow	and	long-lasting	protective	immune	response.	Furthermore,	as	
shown	in	chapter	3,	IFNα also induced an increase in activation status in mDC and 
pDC, an effect that was slightly enhanced by the addition of ribavirin. Although in our 
study these immunological changes did not lead to an improved clinical outcome, 
they may improve the induction of antiviral immunity and/or correlate with clinical 
outcome.	Possibly,	by	improving	the	IFN	response	in	HBV	patients,	immunological	
changes	might	be	more	profound	and	be	able	to	tip	the	balance	towards	an	efficient	
antiviral immune response.
In contrast to activatory effects, in chapter 6 HBsAg was also able to induce IL-
10 secretion by KC and monocyte-derived macrophages, suggesting an additional 
immune	regulatory	role	for	these	cells.	Also,	despite	the	induction	of	pro-inflammatory	
cytokines in monocytes in vitro, constant exposure to serum viral components in vivo 
did not alter monocyte function, suggesting that also here regulatory mechanisms 
may	 be	 at	 play.	 Furthermore,	 as	 shown	 in	 chapter	 7,	 when	 incubating	 infected	
hepatocyte cell lines with supernatants from KC, either unactivated or activated by 
HBsAg,	HBV	 replication	was	promoted,	despite	 the	presence	of	TNF	and	 IL-6	 in	
these supernatants. As discussed in chapter 2, these are not the only deleterious 
effects APC may have.
Together,	this	shows	that	APC	can	have	opposing	roles.	On	the	one	hand	they	may	
play	a	pivotal	role	in	initiating	the	immune	response	against	HBV.	On	the	other	hand	
they	can	also	disturb	the	immune	response	and	support	viral	replication.	Factors	like	
the	dual	effects	(inhibitory/activatory)	that	HBV	proteins	can	have,	but	also	the	dual	
effects	(antiviral/virus-promoting)	that	antiviral	cytokines	can	have	will	contribute	to	
this.	What	determines	what	exact	effects	 these	cytokines	and	viral	proteins	have	
on	APC,	on	HBV,	on	the	liver	remains	to	be	determined,	especially	when	they	are	
combined.
Future	 HBV	 research	 will	 require	 a	 systematic	 analysis,	 intrahepatically	 and	
peripherally,	of	the	role	of	specific	types	and	subsets	of	APC	involved	in	hepatitis	B	
infection.	Not	only	in	chronic	HBV,	but	also	in	acute	HBV,	in	order	to	define	which	
APC features like phagocytosis, cytokine production or NK cell activation determine 
resolution of the infection, be it spontaneously or therapy-induced, and what APC 
features determine advancement towards chronicity despite therapy. 
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Algemene introductie
In het kort: Wat is hepatitis, wat zijn de spelers in de immuunafweer en waar is mijn 
onderzoek op gericht?
Hepatitis B virus
Hepatitis	B	virus	(HBV)	is	een	virus	dat	specifiek	de	lever	infecteert.	Deze	infectie	
resulteert in acute en daaropvolgend mogelijk chronische leverinfectie, ofwel hepatitis. 
HBV	wordt	overgedragen	van	moeder	op	kind	tijdens	de	geboorte,	via	bloed-bloed	
contact, bijvoorbeeld via een wond in de huid of een naald, of via onbeschermd 
seksueel	contact.	Infectie	met	HBV	vindt	vaak	zonder	ziekteverschijnselen	plaats.	
Als	 die	er	 toch	 zijn	 dan	 is	 de	patiënt	 vaak	geel	 (huid,	 oogwit),	moe,	misselijk	 en	
plast bijvoorbeeld donkere urine. Het risico op het ontwikkelen van een chronische 
infectie hangt af van de leeftijd van de patiënt, maar ook van de infectieroute en de 
dosis	(hoeveelheid	virus	die	binnendringt).	Tot	wel	90%	van	de	HBV-geïnfecteerde	
pasgeborenen ontwikkelt chronische hepatitis. Het merendeel van de geïnfecteerde 
volwassenen daarentegen klaart het virus uit zichzelf, terwijl slechts een klein deel dit 
niet lukt en een chronische vorm van hepatitis ontwikkelt. Momenteel zijn meer dan 
240	miljoen	mensen	wereldwijd	chronisch	geïnfecteerd	met	HBV.	Dit	kan	leiden	tot	
voortschrijdende leverschade waardoor de patiënt een verhoogd risico heeft op het 
ontwikkelen	van	levercirrose	(verlittekening	van	de	lever),	leverfalen	en	leverkanker.	
De	gevolgen	van	HBV	infectie	leiden	tot	de	dood	van	ongeveer	600.000	mensen	per	
jaar. Het is kortom een belangrijk wereldwijd gezondheidsprobleem. 
Het	virusdeeltje	ziet	er	in	het	kort	als	volgt	uit	(zie	figuur	2	in	hoofdstuk	1):	het	DNA	
van	 het	 virus	 (viraal	 DNA)	 wordt	 omgeven	 door	 een	 kapsel.	 Dit	 kapsel	 bestaat	
uit	een	grote	hoeveelheid	exemplaren	van	een	eiwit	dat	we	HBV	kapsel	antigeen	
(“HBV	core	 antigen”,	HBcAg)	 noemen.	Om	het	 kapsel	 heen	 zit	 een	 envelop,	 die	
weer	uit	een	grote	hoeveelheid	exemplaren	van	het	eiwit	HBV	oppervlak	antigeen	
(“HBV	surface	antigen”,	HBsAg)	bestaat.	 In	een	geïnfecteerde	cel	wordt	het	DNA	
gebruikt	om	HBcAg,	HBsAg	en	andere	eiwitten	 te	maken,	maar	ook	nieuwe	HBV	
DNA.	Vervolgens	wordt	het	virusdeeltje	opgebouwd.	Virusdeeltjes	en	onder	andere	
HBsAg worden in grote getalen aangemaakt en kunnen beide in het bloed van 
patiënten gemeten worden.
Immuunrespons
Wanneer	 het	 lichaam	 blootgesteld	 wordt	 aan	 een	 virus	 vormt	 het	 zogenaamde	
aangeboren	 (“innate”)	 immuunsysteem	de	eerste	barrière	 tegen	binnendringende	
ziekteverwekkers, ook wel pathogenen genoemd. Het aangeboren immuunsysteem 
bestaat	 uit	 verschillende	 onderdelen,	 waaronder	 fysieke	 en	 chemische	 barrières	
zoals de huid en slijmvliezen, maar ook immuuncellen waarvan een aantal in dit 
proefschrift	 besproken	 worden.	 Voorbeelden	 van	 ‘innate’	 immuuncellen	 zijn	 NK	
(“natural	killer”)	cellen	en	de	groep	cellen	die	we	fagocyten	noemen.	Dit	zijn	cellen	
die gespecialiseerd zijn in het opeten van onder meer schadelijke deeltjes, bacteriën 
en	virussen.	Fagocyten	zoals	monocyten,	macrofagen	en	dendritische	cellen	(DC)	
struinen de omgeving af op zoek naar virus om op te eten en vervolgens te vernietigen, 
waardoor ze de hoeveelheid virus in het lichaam verminderen. In plaats van het 
Chapter 8 | 142
virus	te	vernietigen	kunnen	ze	het	ook	verwerken	tot	kleine	stukjes	virus	(antigeen)	
die	ze	aan	andere	cellen	van	het	aangeleerde	(“adaptive”)	immuunsysteem	kunnen	
laten	 zien;	 dit	 noemen	 we	 antigeenpresentatie.	 Vanwege	 deze	 functie	 worden	
monocyten, macrofagen en vooral DC professionele antigeen-presenterende cellen 
(APC)	genoemd.	De	cellen	van	het	aangeleerde	 immuunsysteem,	B	en	T	cellen,	
worden hierdoor geactiveerd zodat ze het virus en virus-geïnfecteerde cellen kunnen 
aanvallen.	Zie	figuur	1	in	hoofdstuk	1	voor	een	schematische	weergave	van	de	rol	
van APC in de antivirale immuunrespons.
Interferonen
Belangrijke spelers in het starten en reguleren van de respons tegen virussen in 
het	 algemeen,	 de	 zogenaamde	antivirale	 response,	 zijn	 interferonen	 (IFN).	Deze	
moleculen hebben niet alleen een directe antivirale werking door allerlei mechanismes 
aan te zetten in geïnfecteerde cellen en hun buurcellen, maar hebben ook indirect 
effect op virussen door immuuncellen te reguleren.
In dit proefschrift kijken we naar twee types interferonen: de type I en de type III 
interferonen.	 De	 twee	 type	 I	 interferonen,	 IFNα	 en	 IFNβ, worden tijdens een 
virusinfectie gemaakt door allerlei cellen (bijvoorbeeld geïnfecteerde cellen maar 
ook	 immuuncellen).	 Vooral	 bepaalde	 DC,	 de	 plasmacytoide	 DC	 (pDC),	 staan	
bekend	om	hun	grote	vermogen	om	type	I	IFN	te	maken.	De	meeste	cellen	reageren	
op	type	I	IFN,	omdat	ze	op	hun	oppervlak	een	receptor	voor	IFN	dragen.	Type	I	IFN	
is	uiteindelijk	in	staat	om	virussen,	waaronder	HBV,	direct	te	remmen,	maar	ook	om	
immuuncellen	 te	activeren.	Echter,	 tijdens	HBV	 infectie	wordt	er	geen	 type	 I	 IFN	
gemaakt. Het kan wel van buitenaf gegeven worden, als medicijn, wat kan leiden 
tot	 het	 verminderen	 van	 de	HBV	 infectie,	 in	 een	 deel	 van	 de	 patiënten	 zelfs	 tot	
klaring	van	het	virus	(genezing).	Type	III	interferonen,	de	IFNλ, zijn recent ontdekte 
interferonen.	Ze	worden	door	veel	minder	cellen	geproduceerd,	maar	hebben	ook	op	
veel minder cellen effect omdat veel minder cellen de receptor voor deze interferonen 
dragen. Ook deze interferonen hebben echter de capaciteit om virussen waaronder 
ook	HBV	direct	te	remmen	en	immuuncellen	te	activeren.
Immuuncellen
Het in dit proefschrift beschreven onderzoek is gericht op de hierboven genoemde 
professionele	 antigeen-presenterende	 cellen.	 Vooral	 de	myeloide	DC	 (mDC)	 zijn	
efficiënt	in	het	opnemen,	verwerken	en	presenteren	van	antigeen.	DC	hebben	als	
speciale eigenschap dat ze tijdens een infectie, na het opeten van bijvoorbeeld een 
virus, naar lymfeklieren kunnen gaan om daar de immuunrespons op gang te brengen 
door	T	en	B	cellen	 te	activeren.	Ook	kunnen	zij,	samen	met	pDC,	monocyten	en	
macrofagen, stoffen maken die immuuncellen aantrekken en activeren. Deze stoffen 
noemen we cytokines. Macrofagen staan vooral bekend om hun hoge capaciteit om 
ziektekiemen als virussen op te eten en mogelijk te herkennen. Het is belangrijk om 
niet alleen naar immuuncellen in het bloed te kijken, maar ook naar immuuncellen in 
het weefsel dat geïnfecteerd is, in dit geval de lever. Daarom hebben we macrofagen 
onderzocht	die	 je	specifiek	 in	de	 lever	kunt	 vinden.	Deze	 levermacrofagen	heten	
Kupffer cellen. Daarnaast hebben we gekeken naar macrofagen die we vanuit 
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monocyten gemaakt hebben.
De onderzoeksvragen
In dit proefschrift onderzochten we twee aspecten van de rol van APC tijdens infectie 
met	HBV:	ten	eerste	hebben	we	gekeken	naar	de	effecten	van	IFN	op	de	functie	en	
het	uiterlijk	van	APC	(hoofdstuk	3	en	4);	ten	tweede	hebben	we	gekeken	naar	de	
interactie tussen APC en virale eiwitten, in het bijzonder die tussen APC en HBsAg 
(hoofdstukken	5	en	6).
Dit	 proefschrift	 richt	 zich	 op	 aspecten	 van	 de	 rol	 van	 APC	 bij	 chronische	 HBV-
infectie.	 Verschillende	 studies	 benadrukken	 het	 belang	 van	 APC	 in	 het	 op	 gang	
brengen en reguleren van de antivirale immuunrespons. Daarom gaan we er van 
uit dat APC in het algemeen een centrale rol spelen in de antivirale immuunrespons 
tegen	HBV.	Echter,	wat	de	rol	van	elk	type	APC	is	in	HBV-infectie	dient	nog	nader	
te	worden	gespecificeerd.	IFN	worden	gebruikt	als	antivirale	therapie	bij	chronische	
HBV-infectie,	maar	wat	de	precieze	effecten	van	IFN	op	APC	zijn	en	hoe	dit	invloed	
heeft	op	de	rol	van	APC	tijdens	HBV	infectie	blijft	onduidelijk.	Daarnaast	zijn	APC	
voortdurend blootgesteld aan virale eiwitten, maar de literatuur waarin een duidelijke 
interactie tussen deze virale eiwitten en APC aangetoond wordt is schaars, terwijl 
literatuur over de effecten van virale eiwitten op APC tegenstrijdig en/of onvoldoende 
is.	 Daarom	 is	 ons	 doel	 de	 effecten	 van	 IFN	 en	 virale	 eiwitten	 op	 APC	 tijdens	
chronische	HBV	infectie	te	onderzoeken	en	zo	de	rol	van	APC	tijdens	HBV	infectie	
verder in te kunnen vullen.
Deel I. Effecten van IFN op de functie en fenotype van antigeen presenterende 
cellen
Na hoofdstuk 2, waar we in een literatuuroverzicht de rol beschrijven die KC spelen 
en kunnen spelen bij chronische hepatitis B en C infecties, wordt in deel I (hoofdstuk 
3	en	4)	een	aantal	effecten	van	 in vivo en in vitro	 IFN	op	APC	aangesneden.	 In	
hoofdstuk	3	worden	de	effecten	van	de	behandeling	van	chronische	HBV	patiënten	
met	 IFN	monotherapie	versus	 IFN/ribavirine	combinatietherapie	aan	de	hand	van	
verschillende parameters bestudeerd. In hoofdstuk 4, worden de immunologische 
effecten	van	het	nieuwe	type	III	IFN	in vitro op NK-cellen en macrofagen bestudeerd. 
In het kort de belangrijkste resultaten
In hoofdstuk 3 laten we zien dat het toevoegen van het medicijn ribavirine aan de voor 
HBV	gebruikte	interferon	therapie	leidt	tot	dendritische	cellen	die	meer	geactiveerd	
zijn. Dit zou kunnen leiden tot een betere werking van het immuunsysteem tegen 
HBV	en	daaropvolgend	meer	patiënten	die	het	virus	klaren.	Klinisch	bleek	dit	echter	
niet het geval. Hoe dat komt is voer voor toekomstig onderzoek. In hoofdstuk 4 laten 
we	zien	dat	het	interferon	type	III	IFNλ1,	in	tegenstelling	tot	het	interferon	type	I	IFNα, 
geen	rechtstreeks	effect	op	NK	cellen	heeft.	Via	macrofagen	kan	IFNλ1 alsnog effect 
uitoefenen	op	deze	cellen.	Dit	indirecte	effect	van	IFNλ1 op NK cellen vindt plaats 
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via	 de	 productie	 van	 een	 belangrijk	 pro-inflammatoir	 cytokine	 door	 macrofagen,	
namelijk	IL-12.	Verder	onderzoek	naar	de	antivirale	en	immuunregulatoire	werking	
van	IFNλ1	zijn	van	belang	om	te	begrijpen	hoe	type	III	IFN	vervolgens	werken	om	
bijvoorbeeld te bepalen of en waarom ze geschikt zijn als antivirale medicijnen.
Deel II: Interactie tussen antigeen-presenterende cellen en virale eiwitten, met 
name HBsAg 
In hoofdstuk 5 en 6 onderzoeken we het effect van virale eiwitten op de 
immuunrespons. In hoofdstuk 5 bekijken we de gevolgen van blootstelling van 
monocyten aan virale eiwitten in vivo en HBsAg in vitro. In hoofdstuk 6 onderzoeken 
we	 KC	 van	 patiënten	 die	 chronisch	 geïnfecteerd	 zijn	 met	 HBV.	 We	 meten	 de	
aanwezigheid van HBsAg in deze cellen en hun uiterlijk. Daarnaast bepalen we het 
effect van HBsAg op het uiterlijk van de KC maar ook op dat van macrofagen die we 
vanuit monocyten gemaakt hebben.
In het kort de belangrijkste resultaten
In hoofdstuk 5 tonen we dat blootstelling van monocyten aan HBsAg leidt tot de hoge 
productie van cytokines; monocyten kunnen dus HBsAg binden en herkennen. Omdat 
monocyten	in	het	bloed	van	HBV	patiënten	continu	bloot	staan	aan	virale	eiwitten	
waaronder HBsAg zou je verwachten dat ook in het bloed hoge cytokinewaarden te 
meten zijn. Dit is echter niet het geval, wat suggereert dat in het lichaam regulatie 
plaats vindt van cytokineproductie van aan HBsAg-blootgestelde monocyten, 
bijvoorbeeld	 door	 een	 anti-inflammatoir	 cytokine	 als	 IL-10	 of	 TGFβ. In hoofdstuk 
6 laten we nogmaals zien dat HBsAg witte bloedcellen, in dit geval KC, aanzet tot 
cytokine productie. Maar in dit artikel laten we ook daadwerkelijk de directe interactie 
zien	tussen	KC	en	HBsAg	die	leidt	tot	cytokineproductie.	Verder	laten	we	zien	dat	
HBsAg niet in staat is om NK cellen rechtstreeks te activeren, maar dit wederom kan 
doen via macrofagen, namelijk KC en macrofagen afkomstig van monocyten. De door 
HBsAg uitgelokte cytokineproductie en activatie van immuuncellen als macrofagen 
en NK cellen kan mogelijk een belangrijke eerste stap zijn in het opwekken van een 
immuunrespons	tegen	HBV	na	infectie.	
Afsluitend: conclusies en resterende vragen
Dit	proefschrift	richtte	zich	op	de	rol	van	APC	tijdens	HBV	infectie,	zowel	in	het	bloed	
als in de lever. In hoofdstuk 6 laten we een directe interactie zien tussen KC en HBsAg, 
en gezamenlijk laten hoofdstuk 5 en 6 duidelijk zijn dat monocyten, macrofagen 
afkomstig van monocyten en KC reageren op HBsAg door cytokines te produceren. 
Beide	types	macrofagen	stimuleren	vervolgens	NK	cellen	tot	de	productie	van	IFNγ. 
Dit	 cytokine,	 samen	met	 andere	 cytokines	 als	 IL-6	 en	TNF,	 hebben	 rechtstreeks	
antiviraal	 effect	 op	HBV.	Samen	 lijkt	 dit	 er	 op	 te	wijzen	dat	KC,	en	mogelijk	 ook	
monocyten die naar de lever komen, een belangrijke rol spelen in het opzetten van 
een	 immuunrespons	 tegen	HBV.	 Verder	 laten	we	 in	 hoofdstuk	 4	 zien	 dat	 IFNλ1 
de IL-12 productie van macrofagen verbetert waardoor ze beter NK cellen kunnen 
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activeren.	Mogelijk	kan	 IFNλ op HBsAg-gestimuleerde macrofagen en indirect op 
NK	cellen	eenzelfde	effect	hebben.	IFNα, dat nu al gebruikt wordt als medicijn tegen 
HBV	infectie,	kan	ook	NK	cellen	activeren,	maar	dan	rechtstreeks.	Het	bestaan	van	
IFNα	 en	 IFNλ	 naast	 elkaar	 lijkt	 door	overlappende	mechanismes	overtollig.	 IFNα 
heeft	echter	effect	op	veel	meer	cellen	dan	IFNλ,	en	bovendien	lijkt	IFNα een korter 
durend	 effect	 te	 hebben.	Welke	 effecten	 van	 IFNα	 en	 IFNλ belangrijk zijn bij de 
opbouw van een antivirale respons en welke van de vele effecten niet nodig zijn of 
zelfs	tegenwerken	moet	nog	verder	uitgezocht	worden.	Een	celtype	waar	IFNα ook 
effect op heeft zijn DC zoals we laten zien in hoofdstuk 3. Maar ook patiënten die 
het	virus	niet	klaren	hebben	door	IFN-geactiveerde	DC.	Dit	wijst	er	op	dat	het	IFN	
effect op DC in onze studie onvoldoende is om klinisch het verschil te maken. Door 
de	IFN	respons	verder	te	verbeteren	in	HBV	patiënten	kunnen	er	mogelijk	grotere	
immunologische	veranderingen	teweeg	gebracht	worden	door	IFN	therapie.	Dit	kan	
dan leiden tot het aanzetten van effectieve antivirale immuunrespons.
In hoofdstuk 7 laat ik uiteindelijk enige nieuwe data zien die tonen dat er nog een 
andere kant aan het verhaal kan zijn, namelijk het tegenwerken van de antivirale 
immuunrespons	of	het	helpen	van	het	virus.	We	laten	 in	de	andere	hoofdstukken	
zien dat er cytokines geproduceerd worden waarvan bekend is dat ze antiviraal 
werken. Maar vaak is onbekend wat deze cytokines in combinatie doen. In de data 
in hoofdstuk 7 leek een combinatie van onder andere cytokines niet antiviraal te 
werken, maar eerder het virus te ondersteunen. Ook produceren KC en monocyten 
cytokines die juist de immuunrespons remmen, zoals IL-10, waarvan we in hoofdstuk 
5	 laten	zien	dat	het	ook	de	 reactie	op	HBsAg	kan	 remmen.	Verdere	effecten	die	
bijvoorbeeld KC hebben die de antivirale respons niet helpen hebben we uitgebreid 
besproken in hoofdstuk 2.
Samen laat dit zien dat APC een tweeledige rol kunnen hebben. Aan de ene kant 
kunnen	ze	een	centrale	rol	in	de	immuunrespons	tegen	HBV	spelen.	Aan	de	andere	
kant	kunnen	ze	de	afweer	verstoren	en	het	virus	 juist	ondersteunen.	Zowel	virale	
eiwitten als cytokines beïnvloeden APC, maar wat bepaalt welk precieze effect deze 
hebben	op	APC	en	de	immuunrespons	in	het	algemeen	en	uiteindelijk	op	HBV	moet	
nog nader bepaald worden. Hiervoor is verder onderzoek nodig, zowel in het bloed 
als in de lever, waarbij niet alleen APC in het algemeen, maar ook naar APC types 
en subsets gekeken wordt. De grote vraag blijft: welke eigenschappen leiden tot het 
klaren	van	het	virus,	en	welke	leiden	tot	chroniciteit	(ondanks	medicijnen)?
Dankwoord
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Het is al weer even geleden dat ik deze reis aanving. Hoewel ik in de afgelopen 
jaren veel met de trein gereisd heb, heb ik de langste afstanden toch in mijn hoofd 
afgelegd. En ondanks dat dit werk een afsluiting is van een periode, voelt het slechts 
als een tussenstation, op weg naar een verdere bestemming die voor nu dichter bij 
huis ligt dan voorheen, maar toch ook verder weg. In dit deel van mijn proefschrift wil 
ik graag mijn medereizigers bedanken. Sommigen die net als ik, met weinig ervaring 
instapten en met wie ik een hoop ervaring heb opgedaan. Anderen waren reeds zeer 
bereisd	waardoor	 ik	een	hoop	heb	geleerd	tijdens	mijn	tocht.	Zowel	de	eerste	als	
de laatste groep, en een ieder die tussen deze twee groepen invalt, hebben het in 
meer of mindere mate mogelijk gemaakt deze reis te kunnen maken. Ik hoop dat, in 
welke categorie je ook denkt te vallen, de deelname aan mijn reis ook jullie verder 
heeft gebracht.
Andrea, het begon bij jou toen je me nogmaals belde om te vragen of ik echt wel 
enthousiast was om dit promotieonderzoek aan te gaan. Bedankt voor het vertrouwen 
dat je toen toonde, maar ook in de jaren erna. Het is niet altijd even gemakkelijk 
gegaan	(zowel	voor	jou	als	voor	mij)	in	de	afgelopen	periode,	maar	op	een	gegeven	
moment is het toch goed gekomen, en sluiten we nu mijn promotietraject af. Bedankt 
voor je begeleiding.
André, ook jij was er al vanaf het begin, maar werd pas later betrokken bij mijn 
promotietraject.	 Ook	 jij	 bedankt	 voor	 de	 begeleiding,	 overdag	 en	 ’s	 avonds	 laat,	
vanaf het EMC, je vakantieadres of tijdens een diner. Het leek niet uit te maken.
Van	 jullie	 beiden	 heb	 ik	 veel	 geleerd,	 ondanks	 –	 of	 misschien	 wel	 dankzij	 –	 de	
verschillende stijlen van onderzoek en begeleiding. Aan het eind van het traject 
heb ik niet alleen dit werk afgeleverd maar ook geleerd wat er bij komt kijken om dit 
voor elkaar te krijgen, hoe het wel en hoe het niet moet, en ook het tonen van deze 
resultaten aan de buitenwereld werd steeds beter. Daar zie ik toch duidelijk jullie 
hand(en)	in.
Harry, elke keer kwam ik met knikkende knieën naar het overleg, maar uiteindelijk 
ben ik toch zo ver gekomen om het nu af te ronden. Bedankt voor je vasthoudendheid 
en de mogelijkheid om mijn promotie in jouw lab te doen.
Ook wil ik alle coauteurs bedanken, voor zo ver die niet verder op nog genoemd 
worden; met name Jaap en Luc bedankt voor jullie hulp aangaande het KC paper, 
zowel	qua	materialen	als	inhoudelijk.	
In deze opsomming wilde ik de diagnostiek nog graag apart noemen. Jan, Buddy, 
Martine,	en	Francis,	 de	 interne	klok	van	de	afdeling	en	fijne	mensen	om	mee	 te	
werken. Altijd bereid om een helpende hand te reiken als het nodig was. En Jan kent 
ook echt iedereen in het EMC.
Alle	 overige	 collega’s	 die	 niet	 binnen	 de	 virale	 hepatitis	 groep	 vallen	 of	met	wie	
ik	 niet	 een	 kamer	 heb	 gedeeld.	 Een	 aantal	 bij	 naam:	 Bedankt	 Marieke	 en	 Yin	
voor	 het	 sorten,	 Petra	 en	 Shanta	 voor	 de	 fijne	 samenwerking	 betreffende	 de	
levertransplantaties,	 natuurlijk	 Raymond	 en	 Leonie	 van	 het	 secretariaat.	 Verder,	
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Ron:	eigenlijk	begon	het	bij	jou	-	dank	voor	het	doorsturen	van	mijn	CV	naar	Andrea.	
En	Susanne,	voor	de	nodige	fietstochtjes	van	Utrecht	naar	Rotterdam,	of	andersom.	
En	ook	de	klinische	collega’s	mogen	niet	 vergeten	worden,	de	HBV/HCV	artsen,	
maar ook de onderzoeksverpleegkundigen. En als laatste, Marion, die tijdens het 
promotietraject steeds al aanwezig is maar vooral op het eind onmisbaar wordt. 
Bedankt voor al je hulp!
 
Binnen mijn eigen treinstel: de virale hepatitis groep.
HBV:	Marjolein,	Paula,	Gertine,	Rekha,	Lianne,	Eric,	Aniek,	Evelyn,	Nadine
HCV:	Duygu,	Anthonie,	Dowty,	Mark,	Bi-Sheng,	Rik,	Kim,	Michelle,	Jun,	Thomas
–	waar	te	beginnen?	Marjolein,	mijn	voorgangster	–	bedankt	voor	het	laten	zien	hoe	
het moet. Rekha, hoewel het kort was, bedankt voor je hulp in het PARC project. 
Gertine,	van	wie	ik	me	een	oudere	maar	ook	een	jongere	broer	voelde	–	dat	laatste	
als me weer eens verteld werd hoe het precies zat. Met jou had ik veel meer willen 
samenwerken, maar toch is het er nauwelijks van gekomen. Gelukkig was je er 
wel	altijd!	Lianne,	de	vreemde	eend	in	de	bijt:	moleculaire	biologie!	Van	jou	heb	ik	
veel	geleerd.	Aniek,	Lianne’s	rechterhand,	weinig	mee	samengewerkt,	maar	fijn	om	
samen mee te werken. Eric, de man met mooie vragen over het leven en wat dies 
meer	zij.	En	Evelyn	en	Michelle,	de	jonge	oio’s	–	“hoezo	van	onze	leeftijd?”	zei	Evelyn	
hard	lachend	–	bedankt	voor	de	leuke	tijd	samen	in	het	lab	en	er	buiten.	Anthonie,	
oude brombeer: met jou gingen die projecten toch veel sneller. Bedankt! Mark, altijd 
met	flair.	Dowty,	één	van	mijn	medereizigers	die	het	zelfde	 traject	aanging,	maar	
dan via een andere route. Het was een plezier om met je op te trekken en nu, twee 
uur na aanvang van mijn verdediging is het jouw beurt. Succes! Jun, het gezelschap 
in	het	weekend,	bedankt	voor	je	werk	aan	het	IFN-lambda	artikel.	En	Thomas,	voor	
het eerst echt gesproken op de liver retreat, bedankt voor het redigeren van het 
klinische gedeelte van de tekst.
En dan uiteindelijk deel je ook een coupé, soms eerste klas, soms tweede klas: mijn 
kamergenoten. 
Kamer	1:	Angela,	Elvira,	Wendy,	Willem
Kamer	2:	Bisheng,	Colin,	Gwenny,	Nadine,	Rik,	Wouter
Hoe het ook ging met de promotie, het was nooit een straf om naar Rotterdam te 
komen om met jullie de kamer te delen. In tegendeel. Angela, bedankt voor alle 
leuke	 gesprekken.	 Zelfs	 nu	 ik	 in	 het	WKZ	 zit	 laat	 je	weten	 als	 je	 toevallig	 in	 de	
buurt	 bent.	 Bisheng,	 de	 slapende	 Chinees.	 Van	monocyten	 via	 Chinese	 politiek	
tot je belastingformulieren. Onnavolgbaar. Goed je te kennen. De postdocs Colin, 
Gwenny	en	Nadine.	Van	jullie	heb	ik	ontzettend	veel	geleerd.	Colin,	het	was	fijn	om	
je	weer	tegen	te	komen	in	het	WKZ,	een	bekend	gezicht	in	een	toch	al	vriendelijke	
omgeving. Gwenny, buitengewoon getalenteerd of het nou moleculaire biologie of 
gitaar betrof, het maakt niet uit. Bedankt voor de lessen. Rik, een beetje Americuh 
op	het	eind	van	mijn	promotietraject,	zowel	in	het	lab	als	op	de	klimmuur.	Thanks	
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mate.	En	Wouter,	de	rust	zelve,	ook	jij	bedankt.
En naast werk heb ik met een hoop van bovengenoemde mensen ook lange 
gesprekken en discussies gevoerd op onze kamers, cake gegeten met de cake 
van de week, bier gedronken in het algemeen maar ook met bier van de maand, 
nachtclubs en concerten bezocht, en gekampeerd en gebarbecued op de camping 
in Elp. U begrijpt, op een dergelijke lange reis kan de boog niet altijd gespannen zijn.
Daarom	wil	 ik	ook	graag	mijn	vrienden	bedanken	voor	de	nodige	afleiding:	op	de	
fiets,	bij	een	kop	thee,	achter	of	bij	de	draaitafels,	in	de	keuken	of	aan	de	eettafel,	op	
skype of in het echt. Jullie weten wel wie je bent.
Ter	voorkoming	dat	ik	tijdens	mijn	verdediging	in	elkaar	geslagen	wordt	of	om	het	
over te nemen bij een black-out van ondergetekende heb ik twee paranimfen mee 
genomen. Paula, de alfa en de omega voor mijn tijd hier. Met jou heb ik menig dag 
doorgebracht in het lab, maar ook buiten het lab was er nog tijd. Bedankt voor alles 
en dat je naast me komt staan bij mijn verdediging. Nadine, in jouw geval is het meer 
omikron en omega, aangezien je pas later aansloot bij de groep. Maar ik ben blij dat 
je	er	bij	kwam.	Ook	jij	bedankt	voor	alles,	het	werk,	de	lange	discussies	op	de	fiets	
en dat ook jij naast me komt staan tijdens mijn verdediging. 
.
Tenslotte,	mijn	familie.	
Familie	Boltjes	en	Dreijerink/Kremers	bedankt	voor	alles	de	afgelopen	jaren.	
Geertje, jij in het bijzonder bedankt voor de voorkant van mijn boekwerk.
Heit	&	Mem,	betankt	foar	alles	dat	jimme	mij	leart	hawwe	en	de	steun	oer	de	ôfrûne	
jierren.	Sûnder	jim	wie’k	sa	fier	noait	kommen.
Thieme,	lytse	pjut.	Tanke	foar	datst	heit	syn	libben	noch	wat	drokker	makke	hast,	
mar	ek	o	sa	protte	riker.	In	noflik	tebektinken	dat	der	ek	noch	wat	oars	dan	wurk	is.
En Lieke. Bedankt voor je geduld, je hulp, dat je er elke keer weer was/bent, of het 
me nou meezit of tegenzit. X.
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Name PhD student:  Arjan Boltjes
Erasmus MC Department: Gastroenterology and Hepatology
Research School:  Erasmus Postgraduate school Molecular Medicine 
PhD	period:	 	 	 October	2008	–	September	2014
Promotor:   Prof.dr. H.L.A. Janssen
Supervisors:   Dr. André Boonstra
	 	 	 	 Dr.	Andrea	M.	Woltman
PhD training
General academic and research skills
2008	 Course	 “Stralingshygiëne,	 deskundigheidsniveau	 5B”,	 Erasmus	 MC	
zorgacademie, Erasmus MC University Medical Center
2009 Course Molecular Immunology, Erasmus Postgraduate school Molecular 
Medicine, Erasmus University, Rotterdam
2009 Sensing and signaling by the immune system, Dutch Society for Immunology, 
Lunteren.
2010 Guiding the action of the immune system: Interactions between the immune 
system and non-immune tissues, Dutch Society for Immunology, Lunteren.
2011	 Course	Scientific	English	Writing,	 Erasmus	Postgraduate	 school	Molecular	
Medicine, Erasmus University, Rotterdam
2012	 Course	Virology,	Erasmus	Postgraduate	school	Molecular	Medicine,	Erasmus	
University, Rotterdam
2012 APCs revisited: the function of antigen presenting cells in health and disease, 
Dutch Society for Immunology, Lunteren.
Presentations – international conferences
2010	 European	Macrophage	and	Dendritic	Cell	Society	(EMDS)	Conference,	
Edinburgh, UK. 
Hepatitis B surface antigen activates human Kupffer cells. Poster.
2011	 Joint	Meeting	of	the	International	Cytokine	Society	(ICS)	and	the	
International	Society	for	Interferon	and	Cytokine	Research	(ISICR),	
Florence,	Italy. 
Peginterferon therapy of chronic viral hepatitis patients differentially 
regulates	plasmacytoid	dendritic	cell	TLR7	and	TLR9	function.	Poster.
2012	 European	Association	for	the	Study	of	the	Liver	(EASL)	Conference:	Immune	
Mediated Liver Injury, Stratford upon Avon, UK. 
Hepatitis B virus infection activates Kupffer cells. Poster.
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Presentations – domestic conferences
2009	 Dutch	Society	for	Immunology	(NVVI)	Annual	meeting,	Noordwijkerhout. 
Ribavirin	improves	PEG-IFN-induced	DC	modulation	in	chronic	hepatitis	B.	
Poster.
2010	 Dutch	Society	of	Hepatology	(NVH)	meeting,	Veldhoven. 
Ribavirin improves Pegylated-interferon-α 2a induced dendritic cell 
modulation in chronic hepatitis B. Poster.
2010	 Dutch	Society	for	Immunology	(NVVI)	Annual	meeting,	Noordwijkerhout 
Hepatitis B surface antigen activates Kupffer cells. Poster.
2011	 Dutch	Society	of	Hepatology	(NVH)	meeting,	Veldhoven. 
The	interaction	between	Hepatitis	B	virus	and	Kupffer	cells	leads	to	immune	
activation. Poster.
2011	 Dutch	Society	for	Gastroenterology	(NVGE)	and	the	Dutch	Society	of	
Hepatology	(NVH):	Dutch	Liver	Retreat,	Spier. 
Hepatitis B virus infection activates Kupffer cells. Oral.
2011	 Dutch	Society	for	Immunology	(NVVI)	Annual	meeting,	Noordwijkerhout. 
IFNα	therapy	of	chronic	viral	hepatitis	patients	differentially	regulates	TLR7	
and	TLR9	activity	by	plasmacytoid	dendritic	cells.	Poster.
2012	 Dutch	Society	for	Immunology	(NVVI)	Annual	meeting,	Noordwijkerhout 
Hepatitis	B	virus-induced	activation	of	Kupffer	cells	as	first	step	towards	
virus-specific	immunity?	Poster.
2013	 Dutch	Society	of	Hepatology	(NVH)	meeting,	Veldhoven. 
Hepatitis	B	virus-induced	activation	of	Kupffer	cells	as	first	step	towards	
virus-specific	immunity?	Poster.
Attendance – domestic conferences
2008 Erasmus Liver Day, Erasmus MC University Medical Center Rotterdam, 
Rotterdam.
2010	 Mini-symposium:	Virus-Host	Interactions	and	the	Regulation	of	Viral	
Immunity, Erasmus MC University Medical Center Rotterdam, Rotterdam.
Scientific awards and grants
2010	 Travel	grant:	Dutch	Society	for	Immunology
2011	 Travel	grant:	Erasmus	Trustfonds
2012	 European	Association	for	the	Study	of	the	Liver	(EASL)	Bursary.
2013	 Dutch	 Society	 for	 Hepatology,	 section	 Basic	 Hepatology	 (2013)	 DEGH	
poster prize for best poster + presentation.
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Arjan Boltjes, de auteur van dit proefschrift, werd geboren op 20 oktober 1978 te 
Leeuwarden. Hij groeide op in Marrum, Stiens en kortstondig in Heerenveen. In 
1997 behaalde hij zijn middelbare schooldiploma aan het Christelijk Gymnasium 
Beyers Naudé te Leeuwarden.
Na uitgeloot te zijn voor de studie geneeskunde begon hij de studie biologie, die 
hij met veel plezier doorliep tot en met het derde jaar. Na bij de vierde maal loten 
eindelijk ingeloot te zijn ving hij in 2000 alsnog de studie Geneeskunde aan. In 2004 
besloot hij dat, in plaats van coschappen te lopen voor geneeskunde, hij de voorkeur 
gaf aan onderzoekstages om zijn studie biologie af te ronden.
In 2004 deed hij een onderzoeksstage in het tumor immunologie laboratorium van 
het	 universitair	 medisch	 centrum	 Groningen	 onder	 begeleiding	 van	 dr.	 Wijnand	
Helfrich.	Dit	onderzoek	betrof	de	relatie	tussen	eigenschappen	van	EBV-specifieke	
CD8+	T	cellen	enerzijds	en	EBV	DNA	load	anderzijds	in	longtransplantatie	patiënten.
In 2005 volgde hierop een onderzoeksstage in het laboratorium van professor Bjarne 
Bogen onder begeleiding van dr. Alexandre Corthay in het instituut voor immunologie 
in het Rikshospitalet en aan de Universiteit van Oslo, in Oslo, Noorwegen. Deze 
onderzoeksstage betrof het onderzoeken van mogelijke mechanismes waarmee 
idiotype-specifieke	T	cellen	de	groei	van	de	multipele	myeloma	cellijn	MOPC-315	
kunnen remmen.
In april en mei 2006 ontving hij een doctorandustitel voor zowel medische biologie 
als geneeskunde.
Na	 enige	 uitstapjes	 in	 het	 bancaire	 (Rabobank)	 en	 publieke	 (Rijkswaterstaat)	
wezen besloot hij alsnog in Nederland te beginnen aan een promotieonderzoek. 
Dit promotieonderzoek is beschreven in dit proefschrift en vond plaats in het 
laboratorium van professor Harry Janssen, tevens promotor, onder begeleiding van 
dr.	Andrea	Woltman	en	dr.	André	Boonstra.	Laatstgenoemden	zijn	beide	copromotor	
voor deze promotie.
Sinds 1 mei 2013 is hij aangesteld als wetenschappelijk onderzoeker in de 
onderzoeksgroep	 van	 dr.	 Femke	 van	 Wijk	 en	 professor	 Berent	 Prakken	 op	 de	
afdeling kinderimmunologie van het universitair medisch centrum Utrecht. Hier doet 
hij onderzoek naar de rol van antigen-presenterende cellen in jeugdreuma.
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